![]() |
![]() |
![]() |
![]() |
LBP-001 | HCV and HBV prevalence and associated risk factors among people who inject drugs in Kenya | Matthew Akiyama | ![]() |
![]() |
|||
LBP-002 | Using FIB-4s parameters an explainable black-box machine learning model outperforms FIB-4 index on the diagnosis of advanced fibrosis of non alcohol related fatty liver disease patients in three cohorts from China, Malaysia and India | Athanasios Angelakis | ![]() |
![]() |
|||
LBP-003 | Safety and efficacy of continuous infusion terlipressin (BIV201) in patients with decompensated cirrhosis and refractory ascites: a phase 2, randomized, controlled, open-label study | Abigail Kent | ![]() |
![]() |
|||
LBP-004 | Long-term trends of circulating hepatitis B virus RNA and hepatitis B core-related antigen levels in persons with HIV and functional hepatitis B cure during tenofovir therapy | Lorin Begré | ![]() |
![]() |
|||
LBP-5 | Dramatic reductions in hepatic steatosis accompanied by improved HbA1c following a 4-week treatment of obese/diabetic/NAFLD patients with DD01, a novel long-acting GLP-1/glucagon receptor agonist | Adam Bell | ![]() |
![]() |
|||
LBP-6 | Preventing liver disease with policy measures to tackle alcohol consumption and obesity: a microsimulation study - Hepahealth II | Maria Buti | ![]() |
![]() |
|||
LBP-007 | Validation of the R3-AFP model for risk prediction of HCC recurrence after liver transplantation in the SiLVER clinical trial | Charlotte Costentin | ![]() |
![]() |
|||
LBP-008 | High prevalence of short telomeres in patients with idiopathic porto-sinusoidal vascular disorder | Alexander Coukos | ![]() |
![]() |
|||
LBP-9 | Further decompensation as a new prognostic stage in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements | Gennaro DAmico | ![]() |
![]() |
|||
LBP-010 | Prospective direct comparisons of four widespread noninvasive fibrosis tests (NITs) in outpatients with type-2 diabetes (T2D) using EPoS histological staging as reference | Valentina Peta | ![]() |
![]() |
|||
LBP-011 | Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D) | Elisabetta Degasperi | ![]() |
![]() |
|||
LBP-012 | Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease | Katja Deterding | ![]() |
![]() |
|||
LBP-013 | Safety, pharmacokinetics and antiviral efficacy of freethiadine, a novel capsid assembly modulator, in healthy volunteers and patients with chronic hepatitis B virus infection | Yanhua Ding | ![]() |
![]() |
|||
LBP-014 | Evaluation of 8 non-invasive models in predicting NAFLD severity and progression in a one-year prospective study based on MRI-PDFF | Yanhua Ding | ![]() |
![]() |
|||
LBP-015 | Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report | Robert Elston | ![]() |
![]() |
|||
LBP-016 | Hepatocellular carcinoma surveillance improves early detection and curative treatment in chronic hepatitis C patients treated with direct acting antivirals | cassia leal | ![]() |
![]() |
|||
LBP-017 | Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH a phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo | Stephen Harrison | ![]() |
![]() |
|||
LBP-018 | ALG-000184, a capsid assembly modulator, dosed with entecavir for up to 28 weeks is well tolerated and resulted in substantial declines in surface antigen levels in untreated Hepatitis B e antigen positive subjects with chronic hepatitis B | Matthew McClure | ![]() |
![]() |
|||
LBP-019 | Assessing progress towards achieving regional hepatitis B control goal nationwide serosurvey among children, Uzbekistan, 2022 | Nino Khetsuriani | ![]() |
![]() |
|||
LBP-20 | Continued treatment of early nonresponder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses | Pietro Lampertico | ![]() |
![]() |
|||
LBP-021 | A global research priority agenda to advance public health responses to fatty liver disease | Jeffrey Lazarus | ![]() |
![]() |
|||
LBP-022 | Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial | Allyson Taylor | ![]() |
![]() |
|||
LBP-023 | Improving hepatitis B screening and linkage to care rates via the electronic medical record, provider engagement, and patient navigation in a large, urban health system | Anna Mageras | ![]() |
![]() |
|||
LBP-024 | Safety and efficacy of anti-pre-S1 domain monoclonal antibody (HH-003) treatment in patients with co-infection of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV): a single center, open-label, phase 2 trial | Junqi Niu | ![]() |
![]() |
|||
LBP-025 | Concurrent nivolumab and external beam radiation therapy for patients with advanced hepatocellular carcinoma with vascular invasion: a phase 2, single-arm NEXTRAH trial | Bo Hyun Kim | ![]() |
![]() |
|||
LBP-026 | Evaluation of noninvasive tests to identify pre-cirrhotic fibrosis due to NASH in patients screened for the phase 3 REGENERATE and REVERSE studies of obeticholic acid | Mary Rinella | ![]() |
![]() |
|||
LBP-027 | Evaluation of the hepatitis B virus liver reservoir with fine needle aspirates | Armando Andres Roca Suarez | ![]() |
![]() |
|||
LBP-028 | Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study | Agnes Costello | ![]() |
![]() |
|||
LBP-029 | Predictors of long-term mortality after HCV eradication among PLWH | Alessia Siribelli | ![]() |
![]() |
|||
LBP-030 | A new risk model outperforms FIB-4 when predicting incident cirrhosis in the general population: a cohort study of 504,000 persons | Rickard Strandberg | ![]() |
![]() |
|||
LBP-033 | Investigating the potential of the primary cilium as an immunomodulatory organelle in intrahepatic cholangiocarcinoma | Sara Teles | ![]() |
![]() |
|||
LBP-034 | Modelling intrahepatic bile duct morphogenesis in vitro using synthetic hydrogels | Iona Thelwall | ![]() |
![]() |
|||
LBP-035 | Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): data from the MARCH-ON study | Richard Thompson | ![]() |
![]() |
|||
TOP-036 | Liver cell-type specific molecular signatures marking transition from advanced fibrosis to cirrhosis in human non-alcoholic steatohepatitis | Martin Madsen | ![]() |
![]() |
|||
LBP-036 | Oral vancomycin induces remission in PSC-IBD, which is associated with a reduction in bile salt hydrolase and colonic amine oxidase activity | Palak Trivedi | ![]() |
![]() |
|||
LBP-037 | Intestinal bacterial vesicles cause fibrosis progression and serum albumin levels reduction in cirrhosis | Atsunori Tsuchiya | ![]() |
![]() |
|||
TOP-037 | Does sex influence the development of sarcopenia in liver fibrosis? | Katia Sayaf | ![]() |
![]() |
|||
LBP-038 | Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection | Karen Sims | ![]() |
![]() |
|||
TOP-38 | Gut viral and bacterial alterations modulate the presence and dynamics of minimal hepatic encephalopathy at baseline and longitudinally | Jasmohan Bajaj | ![]() |
![]() |
|||
TOP-039 | Tissue resident NK NTCP- transplanted to immunosuppressed mice exhibiting liver fibrosis and fed with high fat diet (HFD) alleviate intestinal fibrosis | Johnny Amer | ![]() |
![]() |
|||
TOP-040 | Evaluation of albumin and midodrine versus albumin alone in the outcome of refractory ascites in patients with decompensated cirrhosis: a randomized controlled trial (NCT04816240) | Priti Jain | ![]() |
![]() |
|||
TOP-41 | Randomised controlled trial of intravenous versus oral iron in treatment of iron deficiency anaemia after variceal bleeding in patients with cirrhosis | Tabish Mohammad | ![]() |
![]() |
|||
TOP-042 | Yaq-001, a non-absorbable, engineered carbon beads of controlled porosity impacts on gut dysbiosis, gut permeability, organ function and reduces mortality in rodent models of cirrhosis and ACLF | Jinxia Liu | ![]() |
![]() |
|||
TOP-043 | Natural history of patients with NAFLD-associated compensated advanced chronic liver disease stratified according to severity of portal hypertension | Rafael Paternostro | ![]() |
![]() |
|||
TOP-044 | Nutritional therapy improves minimal hepatic encephalopathy in cirrhosis by improvement in sarcopenia, proinflammatory cytokines and myostatin: a double blind randomized controlled trial | Sudhir Maharshi | ![]() |
![]() |
|||
TOP-045 | The effect of precipitating factors for hepatorenal syndrome on response to terlipressin treatment: a subgroup analysis of a pooled North American database | Vanessa Borkhoche | ![]() |
![]() |
|||
TOP-46 | The role of Toll-like receptor 4 in ammonia metabolism and as a therapeutic target for hyperammonemia | Annarein Kerbert | ![]() |
![]() |
|||
TOP-048 | Predictors and management of post-banding ulcer bleeding in cirrhosis: a systematic review and meta-analysis | Annalisa Berzigotti | ![]() |
![]() |
|||
TOP-049 | Increased level of presepsin in patients with acutely decompensated cirrhosis predicts development of acute-on-chronic liver failure | Alberto Zanetto | ![]() |
![]() |
|||
TOP-050 | Swarm hunting of virus-specific CD8 T cells together with auto-aggressive CD8 T cells to achieve efficient killing of virus-infected hepatocytes | Ariane Eceiza Tenreiro | ![]() |
![]() |
|||
TOP-051 | Neoadjuvant PD-1 blockade with Pembrolizumab combined with Lenvatinib therapy in patients with hepatocellular carcinoma beyond Milan criteria before liver transplantation (PLENTY): a single-site pilot randomized controlled trial | Zijie ZHANG | ![]() |
![]() |
|||
TOP-052 | Graft steatosis and donor diabetes mellitus additively increase the risk of retransplantation and death in adult liver transplantation - data from the Eurotransplant registry | Milan Sonneveld | ![]() |
![]() |
|||
TOP-053 | Rheostat function of liver sinusoidal endothelial cells and macrophages limiting antiviral CD8 T cell immunity in the liver | Anna Fürst | ![]() |
![]() |
|||
TOP-054 | Health-related quality of life in a population at-risk of steatotic liver disease | Helle Lindholm Schnefeld | ![]() |
![]() |
|||
TOP-055 | Clinical features of portal hypertension and their prognostic implication in patients with Wilsons disease | Lukas Burghart | ![]() |
![]() |
|||
TOP-057 | Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results with 96 weeks or more of treatment | Ekkehard Sturm | ![]() |
![]() |
|||
TOP-058 | Metabolomic profiles facilitate differential diagnosis of porto-sinusoidal vascular disorder versus liver cirrhosis | Bernhard Scheiner | ![]() |
![]() |
|||
TOP-059 | Two-year follow-up of liver grafts from COVID-19 donors | Margherita Saracco | ![]() |
![]() |
|||
TOP-060 | Bacteriophage therapy against pathological Klebsiella pneumoniae that determine the clinical course of primary sclerosing cholangitis | Masataka Ichikawa | ![]() |
![]() |
|||
TOP-061 | Long-term prospective follow-up of a primary biliary cholangitis (PBC) multicenter cohort treated with Obeticholic Acid (OCA). Interaction effect of triple therapy with fibrates | Conrado Fernandez-Rodriguez | ![]() |
![]() |
|||
TOP-062 | Change in serum bile acids correlates with improvement in itch in patients with primary biliary cholangitis receiving linerixibat | Sam Leeves | ![]() |
![]() |
|||
TOP-063 | Seladelpar treatment resulted in correlated decreases in serum IL-31 and pruritus in patients with primary biliary cholangitis (PBC): post-hoc results from the phase 3 randomized, placebo-controlled ENHANCE study | Andreas E Kremer | ![]() |
![]() |
|||
TOP-064 | Development of an in vitro bile-duct-on-a-chip-platform using patient-derived cholangiocytes | Anna Katharina Frank | ![]() |
![]() |
|||
TOP-065 | Multidimensional genomic analysis of cell-free DNA for early detection of hepatocellular carcinoma | Ju Dong Yang | ![]() |
![]() |
|||
TOP-066 | PD1-negative CD45RA effector-memory CD8 T-cells are essential for response to checkpoint inhibition in advanced hepatocellular carcinoma | Sarah Cappuyns | ![]() |
![]() |
|||
TOP-067 | A simple characterization of dynamic changes in circulating CD8PD1 lymphocytes early predicts response to atezolizumab-bevacizumab in hepatocellular carcinoma | Catia Giovannini | ![]() |
![]() |
|||
TOP-068 | Deep learning-based model in pre-operative computed tomography for prediction of hepatocellular carcinoma recurrence after curative surgery | Rex Wan-Hin Hui | ![]() |
![]() |
|||
TOP-069 | Interleukin 10-mediated signaling dampens antitumor immunity and promotes liver metastasis | Tao Zhang | ![]() |
![]() |
|||
TOP-070 | Constitutive signaling from an engineered IL-21 receptor programs long-lived effector TCR-T cells for HCC therapy | Wei Zhu | ![]() |
![]() |
|||
TOP-072 | Antitumoral activity of the G9a inhibitor EZM8266 in hepatocellular carcinoma: potential for combination with immune checkpoint inhibitors | MAITE G FERNANDEZ-BARRENA | ![]() |
![]() |
|||
TOP-073 | AKR1B10 as a novel molecular driver of alcohol-associated hepatitis | Maria Hernandez-Tejero | ![]() |
![]() |
|||
TOP-074 | Significant dose-dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis | Rohit Loomba | ![]() |
![]() |
|||
TOP-075 | Validation and expansion of the American gastroenterological association clinical care pathway for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes | Veeral Ajmera | ![]() |
![]() |
|||
TOP-076 | A deep exploration of bridging fibrosis evolution and individual septa parameters in NASH using quantitative second harmonic generation imaging reveals fibrosis changes in natural history and treatment-induced not seen with conventional histology | Nikolai Naoumov | ![]() |
![]() |
|||
TOP-077 | Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem) in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH) | Noelia Gordillo | ![]() |
![]() |
|||
TOP-079 | Risk of bacterial infections in non-alcoholic fatty liver disease: a nationwide population-based cohort study | Axel Wester | ![]() |
![]() |
|||
TOP-080 | A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes | Eduardo Vilar Gomez | ![]() |
![]() |
|||
TOP-081 | The growing global burden of non-alcoholic fatty liver disease (NAFLD) among teenagers | Carey Escheik | ![]() |
![]() |
|||
TOP-082 | Identification of a new gene signature that accurately predicts the risk of hepatic decompensation in non-alcoholic fatty liver disease | Maria Jimenez Ramos | ![]() |
![]() |
|||
TOP-083 | Utility of serum phosphatidylethanol in differentiating NAFLD from alcohol-associated liver disease among individuals with overweight and obesity: the San Diego liver study | Monica Tincopa | ![]() |
![]() |
|||
TOP-084 | Absence of Caspase 8 reverses progression of NASH after hepatocyte-specific JNK deletion | Ines Volkert | ![]() |
![]() |
|||
TOP-085 | Long-term liver-related outcomes in 1,260 patients with non-cirrhotic NAFLD | Ying Shang | ![]() |
![]() |
|||
TOP-086 | Novel role of macrophage Foxo1-mediated YAP-Notch axis in NASH progression | Bibo Ke | ![]() |
![]() |
|||
TOP-087 | Epigenetic modifications implicated in idiosyncratic drug-induced liver injury | Marina Villanueva | ![]() |
![]() |
|||
TOP-088 | Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease | Roberta Forlano | ![]() |
![]() |
|||
TOP-089 | NAFLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance | Thomas Marjot | ![]() |
![]() |
|||
TOP-090 | Single-cell RNA sequencing in DIAMOND mice reveals differentially regulated pathways specifically associated with the transition from simple steatosis towards NASH | Rocío Gallego-Durán | ![]() |
![]() |
|||
TOP-091 | Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2-F3 NASH patients: secondary analysis of Ph2b HARMONY study | Jörn Schattenberg | ![]() |
![]() |
|||
TOP-092 | Distinctive cytokine profiles in checkpoint inhibitor-induced liver injury, idiosyncratic drug-induced liver injury and autoimmune hepatitis: a potential mechanistic biomarker panel | Edmond Atallah | ![]() |
![]() |
|||
TOP-093 | Soluble and monocyte surface CD206 is a promising indicator of sepsis in patients with acute liver failure | Anna Cavazza | ![]() |
![]() |
|||
TOP-094 | Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019 | Chi Zhang | ![]() |
![]() |
|||
TOP-95 | A systematic review of interventions for alcohol use disorder in patients with cirrhosis or alcohol-related hepatitis | Christopher Oldroyd | ![]() |
![]() |
|||
TOP-096 | Trends in hepatitis B and hepatitis C related hepatocellular carcinoma, 2015 to 2030 | Devin Razavi-Shearer | ![]() |
![]() |
|||
TOP-097 | Engagement of patients with viral hepatitis diagnosed by opt-out universal emergency department testing | Amy Teague | ![]() |
![]() |
|||
TOP-098 | Socioeconomic disparities and survival in patients with primary liver cancer by subtype: a french population-based study | Thi Thu Nga Nguyen | ![]() |
![]() |
|||
TOP-99 | Higher ultra-processed food intake positively associated with non-alcoholic fatty liver disease in both adolescents and adults | Xuehong Zhang | ![]() |
![]() |
|||
TOP-100 | Long-term outcome of hepatitis delta in different regions world-wide: results of the hepatitis delta international network (HDIN) | Anika Wranke | ![]() |
![]() |
|||
TOP-101 | Identification of liver-associated gene signatures from serum exosomes in patients with chronic hepatitis B | Mario Cortese | ![]() |
![]() |
|||
SUN-101 | Test Poster | Philipp Schwabl | ![]() |
![]() |
|||
TOP-102 | Proteomics analysis of HBV cccDNA-bound proteins for therapeutic targeting in liver biopsies from hepatitis B patients | Purnima Tyagi | ![]() |
![]() |
|||
TOP-103 | HDV full genome sequencing and sensitive HBV genotyping from a large cohort of HBV/HDV co-infected patients | Savrina Manhas | ![]() |
![]() |
|||
TOP-104 | The TLR8 agonist Selgantolimod modulates Kupffer cell differentiation status and indirectly impairs HBV entry into hepatocytes via an IL-6-dependent mechanism | Armando Andres Roca Suarez | ![]() |
![]() |
|||
TOP-106 | The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir | Romina Salpini | ![]() |
![]() |
|||
TOP-107 | Intrahepatic CD8 T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse model | Hildegund Ertl | ![]() |
![]() |
|||
TOP-108 | HBsAg induces mild activation, but not suppression, of intrahepatic immune cells as shown by single-cell RNA sequencing of fine-needle aspirates in chronic HBV patients | Zgjim Osmani | ![]() |
![]() |
|||
TOP-109 | VIR-2218 and VIR-3434 Therapy Is Efficacious in Preclinical Models of Hepatitis Delta Virus Infection | Kaman Nalbandian | ![]() |
![]() |
|||
TOP-110 | Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial | Florian van Bömmel | ![]() |
![]() |
|||
TOP-111 | The distinct spatiotemporal evolutionary landscape of HBV and HDV largely determines their unique epidemic features globally. | Wenshi Wang | ![]() |
![]() |
|||
TOP-112 | Programmed cell death protein 1/ligand 1 inhibitor versus tyrosine kinase inhibitor in the efficacy of HBsAg reduction in chronic hepatitis B patients with hepatocellular carcinoma | TE-WEI TSENG | ![]() |
![]() |
|||
FRI-113 | Estimating the economic value allocation of the social surplus generated by the utilization of all-oral direct-acting antivirals for hepatitis C in the United States, 2015-2019 | Jens Grueger | ![]() |
![]() |
|||
WED-113 | The performance of the cobas HBV RNA assay for use on the cobas 5800/6800/8800 Systems (RUO) against genomic variants and transcript heterogeneity | Thomas Meister | ![]() |
![]() |
|||
THU-113 | Prediction for gastrointestinal bleeding in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma | Kanghee Park | ![]() |
![]() |
|||
WED-114 | Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors | Jane Kovalevich | ![]() |
![]() |
|||
THU-114 | Quality of life in patients with unresectable hepatocellular carcinoma treated with ive internal radiation therapy (SIRT) and Nivolumab: a sub-analysis of the NASIR-HCC trial | Manuel de la Torre Aláez | ![]() |
![]() |
|||
FRI-114 | Late diagnosis of hepatitis C in Quebec, Canada, 1990-2018: a population-based study | Ana Maria Passos-Castilho | ![]() |
![]() |
|||
THU-115 | Impact of baseline liver function on overall survival (OS) and safety in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study | Masatoshi Kudo | ![]() |
![]() |
|||
SAT-115 | Healthcare resource use and costs among patients with primary sclerosing cholangitis in Sweden - a retrospective population-based cohort study | Hannes Hagström | ![]() |
![]() |
|||
FRI-115 | An international coalition to eliminate hepatitis B virus (ICE-HBV) survey confirms inadequate HBV/ HDV screening and diagnosis diminishing elimination targets in resource limited settings | Daryl Lau | ![]() |
![]() |
|||
SAT-116 | Health economics of the enhanced liver fibrosis test in the detection of advanced liver fibrosis in patients with non-alcoholic fatty liver disease in the UK | Carey Escheik | ![]() |
![]() |
|||
WED-116 | A retrospective observational cohort study of liver-related events among individuals with hepatitis B virus infection with and without hepatitis delta virus infection | Laura Telep | ![]() |
![]() |
|||
FRI-116 | Population adjusted prevalence of hepatitis delta virus in 21 countries and territories | Devin Razavi-Shearer | ![]() |
![]() |
|||
THU-116 | The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab | Antonio DAlessio | ![]() |
![]() |
|||
FRI-117 | Prevalence and incidence of delta hepatitis in HIV-HBV coinfected patients in the DatAIDS cohort | Dulce Alfaiate | ![]() |
![]() |
|||
THU-117 | Dipeptidyl-peptidase 4 inhibitors improve survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy | Dorothy Cheuk-Yan Yiu | ![]() |
![]() |
|||
WED-117 | Novel serum biomarkers for risk stratification in chronic hepatitis B - what do they bring to the table? | Louise Downs | ![]() |
![]() |
|||
SAT-117 | Influence of the COVID-19 pandemic on liver cancer-related mortality in the United States | Zhu Zhan | ![]() |
![]() |
|||
WED-118 | Long-term outcomes of untreated chronic hepatitis B patients with persistent HBsAg 100 IU/mL | Rachel Wen-Juei Jeng | ![]() |
![]() |
|||
THU-118 | Application of deep learning auto-segmentation and unsupervised machine learning in developing a radiomic prognostic score to predict disease recurrence post radiofrequency ablation for hepatocellular carcinoma | Mathew Vithayathil | ![]() |
![]() |
|||
FRI-118 | Patients with persistently abnormal liver biochemistry are under-investigated and can be rapidly identified using a novel case-finding database | Almuthana Mohamed | ![]() |
![]() |
|||
SAT-118 | Acceptability and feasibility of a multimodal early detection pilot study for liver disease in high risk groups: Alright My Liver? | Ann Archer | ![]() |
![]() |
|||
FRI-119 | Care cascade for children with hepatitis C virus exposure in the United States and implications of early ribonucleic acid testing | Megan Rose Curtis | ![]() |
![]() |
|||
WED-119 | HBcrAg-based risk score predicts HCC better than HBV DNA-based risk scores in HBeAg-negative grey zone patients | Tai-Chung Tseng | ![]() |
![]() |
|||
SAT-119 | Lifestyle-related population-attributable risk for non-alcoholic fatty liver disease in adolescents and youth | Vanessa Garcia Larsen | ![]() |
![]() |
|||
THU-119 | Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study | ELIA Gigante | ![]() |
![]() |
|||
THU-120 | Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002-2022) | Sabrina Sidali | ![]() |
![]() |
|||
WED-120 | Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: a nationwide cohort study | Moon Haeng Hur | ![]() |
![]() |
|||
FRI-120 | Opt-out testing of Hepatitis B and C in a London Emergency Department | Jingwei Zeng | ![]() |
![]() |
|||
WED-121 | Prediction of hepatocellular carcinoma in chronic hepatitis B patients following HBsAg seroclearance: Lage score | Jonggi Choi | ![]() |
![]() |
|||
THU-121 | Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib | Sun Young Yim | ![]() |
![]() |
|||
FRI-121 | Estimation of prevalence of chronic HCV infection in EU/EEA countries using multiparameter evidence synthesis | Georgios Nikolopoulos | ![]() |
![]() |
|||
SAT-121 | Identify, screen and treat via electronic pathway (I-STEP): An innovative approach to rapid assessment and management of a long waiting list. | Eliza Flanagan | ![]() |
![]() |
|||
THU-122 | Efficacy and safety of atezolizumab plus bevacizumab in Child Pugh B patients with advanced hepatocellular carcinomaa french italian real life study | Leonardo Stella | ![]() |
![]() |
|||
SAT-122 | Socio-economic disparities drive the prevalence of non-alcoholic Fatty Liver Disease (NAFLD) among teenagers in the United States | Zobair Younossi | ![]() |
![]() |
|||
FRI-122 | One step closer to the goal: mobile InfoHep centre offering detection, protection, prevention and treatment / linkage-to care services in Croatian penalty institutions | Tatjana Reic | ![]() |
![]() |
|||
WED-123 | HBsAg seroclearance decreases risk of hepatocellular carcinoma but not hepatic decompensation in nucleos(t)ide analogue-treated cirrhotic patients with complete hepatitis B virus suppression: a territory-wide cohort study | Terry Cheuk-Fung Yip | ![]() |
![]() |
|||
THU-123 | Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile | Louisa Stern | ![]() |
![]() |
|||
FRI-123 | Late presentation of chronic hepatitis C for care in Georgia: data from the national hepatitis C elimination program, 2016-2021 | Tengiz Tsertsvadze | ![]() |
![]() |
|||
SAT-123 | Non-alcoholic fatty liver disease prevalence has increased in Australia, particularly amongst women | Karl Vaz | ![]() |
![]() |
|||
SAT-124 | Multiple vitamin co-exposure and mortality risk in metabolic dysfunction-associated fatty liver disease | Wang Zilong | ![]() |
![]() |
|||
WED-124 | Influence of viral load and fibrotic burden on hepatocellular carcinoma risk at phase change to immune-active phase in chronic hepatitis B | Ho Soo Chun | ![]() |
![]() |
|||
THU-124 | Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
FRI-124 | The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: descriptive results from a cross-sectional study across Italy, Germany, Spain and the US | Pietro Lampertico | ![]() |
![]() |
|||
SAT-125 | Prevalence and predictors of clinically significant pruritus in patients with non-alcoholic fatty liver disease (NAFLD): data from the global NASH registry (GNR) | Carey Escheik | ![]() |
![]() |
|||
THU-125 | Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study | Tim Meyer | ![]() |
![]() |
|||
WED-125 | IP10 and anti-HBc can predict virological relapase and HBsAg loss for chronic hepatitis B patients after nucleos(t)ide analogue discontinuation | Yandi Xie | ![]() |
![]() |
|||
FRI-125 | The impact of Covid-19 on hepatocellular carcinoma screening in British Columbia | Makuza Jean Damascene | ![]() |
![]() |
|||
WED-126 | Off-therapy events in hepatitis B e antigen-negative patients with sustained HBV surface antigen 100 and 50 IU/mL | Yen-Chun Liu | ![]() |
![]() |
|||
SAT-126 | Relationships between education and non-alcoholic fatty liver disease | Florian Koutny | ![]() |
![]() |
|||
FRI-126 | HCV screening automation at hospitals level based on extrahepatic manifestations and risk profile. Preliminary results from the Hospitals without_ C programme (hospitales sin C) | Marinela Mendez | ![]() |
![]() |
|||
THU-126 | Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study | Xingzhi Li | ![]() |
![]() |
|||
SAT-127 | A pilot study to improve the uptake of hepatocellular carcinoma surveillance | Maria Qurashi | ![]() |
![]() |
|||
FRI-127 | Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers | Lindsey Hiebert | ![]() |
![]() |
|||
WED-127 | Improved prediction for liver fibrosis of Fibrosis-4 using machine learning in patients with chronic hepatitis B | Zhiyi Zhang | ![]() |
![]() |
|||
WED-128 | Passive transfer of hepatitis B core antibody after intravenous immunoglobulin administration in adult patients: a retrospective review | Sital Shah | ![]() |
![]() |
|||
THU-128 | Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study | Vincent Jörg | ![]() |
![]() |
|||
SAT-128 | Non-alcoholic fatty liver disease awareness, misperception, and their association with healthcare access in Korean general population: a nationally representative survey | Sang Bong Ahn | ![]() |
![]() |
|||
FRI-128 | Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona | Anna Pocurull | ![]() |
![]() |
|||
SAT-129 | Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma | Luis Antonio Diaz | ![]() |
![]() |
|||
FRI-129 | Health outcomes of hepatitis C direct-acting antivirals: beyond real life sustained viral response data | Carmen Alonso Martin | ![]() |
![]() |
|||
THU-129 | Survival outcomes of hepatocellular carcinoma after yttrium-90 ive internal radiation therapy in an Asian population stratified by tumour volume and distribution | Kaina Chen | ![]() |
![]() |
|||
WED-129 | Secular trends of newly diagnosed chronic hepatitis B in 2000-2022 a territory-wide study | Grace Wong | ![]() |
![]() |
|||
WED-130 | Patients with chronic hepatitis delta virus coinfections have higher risk of disease progression than chronic hepatitis B virus monoinfection results from a Spanish national hospital database | Chong Kim | ![]() |
![]() |
|||
SAT-130 | Exploring attitudes towards non-invasive liver fibrosis tests in secondary care pathways: comparing national surveys between 2014 and 2021 | Kushala Abeysekera | ![]() |
![]() |
|||
FRI-130 | Low HBV treatment uptake among Rwandan people with HIV and HCV co-infections: a cohort study from 2016-2019 | Jean Damascene Makuza | ![]() |
![]() |
|||
THU-130 | Salvage hepatectomy for recurrent hepatocellular carcinoma after radiofrequency ablation | Jai Young Cho | ![]() |
![]() |
|||
THU-131 | Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib | Eleonora Alimenti | ![]() |
![]() |
|||
SAT-131 | Evidence suggests significant alcohol-associated mortality in a large population cohort in Uganda | Cori Campbell | ![]() |
![]() |
|||
FRI-131 | Prevalence of chronic hepatitis C on the Swiss organ transplantation list from 2009-2019 | Philip Bruggmann | ![]() |
![]() |
|||
WED-131 | Dynamic monitoring of HBsAg-specific B cells in CHB patients and its clinical significance in predicting interferon therapy efficacy | Yu Geng | ![]() |
![]() |
|||
THU-132 | Risk stratification for early recurrence after resection in patients with intermediate stage hepatocellular carcinoma | Han Ah Lee | ![]() |
![]() |
|||
SAT-132 | Detection of potential subjects at risk of liver fibrosis in general population in Spain | María Del Barrio Azaceta | ![]() |
![]() |
|||
FRI-132 | The impact of removing all hepatitis B virus (HBV) testing and treatment restrictions | Homie Razavi | ![]() |
![]() |
|||
WED-132 | Association of TLR7 polymorphisms in Caucasians with disease stages and HBsAg loss in hepatitis virus B infections | Janett Fischer | ![]() |
![]() |
|||
SAT-133 | Comparison of the opt in vs opt out policy and its impact on the donation rate of liver transplantation in the Colombian healthcare system | Andres Gomez Aldana | ![]() |
![]() |
|||
THU-133 | Impact of radiological response and pattern of progression on overall survival in patients with hepatocellular carcinoma treated by atezolizumab-bevacizumab | Claudia Campani | ![]() |
![]() |
|||
WED-133 | Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage | Leonardo Duca | ![]() |
![]() |
|||
FRI-133 | Spontaneous clearance of hepatitis C virus infection in the country of Georgia, 2015-2021 | George Kamkamidze | ![]() |
![]() |
|||
FRI-134 | Automation of hepatitis C screening through electronic health record algorithm | Vítor Magno Pereira | ![]() |
![]() |
|||
WED-134 | Hepatitis delta treatment utilization in the United States: an analysis of commercially insured adults with hepatitis delta virus infection | Chong Kim | ![]() |
![]() |
|||
THU-134 | Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction | Claudia AM Fulgenzi | ![]() |
![]() |
|||
WED-135 | Comparison of HCC incidence between entecavir and tenofovir in a chronic hepatitis B cohort with balanced censoring | Janghan Jung | ![]() |
![]() |
|||
SAT-135 | Impact of coronavirus disease pandemic on hospitalizations due to chronic liver disease in Belgrade, Serbia | Ivana Pantic | ![]() |
![]() |
|||
THU-135 | Clinical profile and outcomes of hepatocellular carcinoma in primary budd chiari syndrome | Ankit Agarwal | ![]() |
![]() |
|||
FRI-135 | Hepatitis C seroconversion rates among individuals with repeated testing Georgia, 2017-2021 | Davit Baliashvili | ![]() |
![]() |
|||
WED-136 | Serum CXCL16 serves as the predictor for liver inflammation functioning through a NKT cell-depend way in chronic hepatitis B patients | Yawen Wan | ![]() |
![]() |
|||
SAT-136 | SIRIUS project: sensing probe exploring liver fibrosis in Slovakia | Lubomir Skladany | ![]() |
![]() |
|||
FRI-136 | Characterization of recent HCV infections and re-infections among the high-risk population from Georgia using global hepatitis outbreak and surveillance technology | Adam Kotorashvili | ![]() |
![]() |
|||
THU-136 | Surgical resection of hepatocellular carcinoma has high feasibility, safety and survival in non-cirrhotic liver: a prospective Spanish multicentre study | MARTA ROMERO-GUTIÉRREZ | ![]() |
![]() |
|||
WED-137 | Distinct virologic trajectories in chronic hepatitis B patients identify heterogeneity in response to nucleotide analogue therapy | Tingyan Wang | ![]() |
![]() |
|||
THU-137 | Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma | Jeong Heo | ![]() |
![]() |
|||
SAT-137 | Anti-hepatitis B surface antigen negativity can be a risk factor for SARS-CoV-2 infection in SARS-CoV-2 vaccinated healthcare workers | Tomohide Kurahashi | ![]() |
![]() |
|||
FRI-137 | Zero-HCV before end stage renal disease (ESRD): a collaborative treat-all approach to eliminate HCV in chronic kidney disease population in Taiwan | Tsung-Hui Hu | ![]() |
![]() |
|||
WED-138 | Utilizing machine learning-based predictive models to identify early virological recurrence in Chinese chronic hepatitis B patients following entecavir withdrawal | Xiaoke Li | ![]() |
![]() |
|||
THU-138 | Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: focusing on hepatic safety and viral kinetics | San-Chi Chen | ![]() |
![]() |
|||
FRI-138 | Low coverage of hepatitis D virus testing in individuals with HIV and HBV in the Netherlands: a retrospective, cross-sectional and longitudinal study | Anders Boyd | ![]() |
![]() |
|||
FRI-139 | Retrospective study of hepatitis C virus antibodies and active viral replication in at-risk population with dual diagnosis in a Spanish university hospital | Cristina Del Rio-Cubilledo | ![]() |
![]() |
|||
THU-139 | Portal-hypertension parameters are associated with survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy | Heloďse Giudicelli-Lett | ![]() |
![]() |
|||
THU-140 | Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B | Ji Won Yang | ![]() |
![]() |
|||
WED-140 | Association of liver fibrosis and hypophosphatemia in treatment-naďve patients with chronic hepatitis B | Jian Wang | ![]() |
![]() |
|||
FRI-140 | Acceptance and feasibility of hepatitis C screening by assisted self-testing in high-risk and general population: a randomized clinical trial | Federica Benítez Zafra | ![]() |
![]() |
|||
SAT-141 | Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: a nationwide population study, 1998-2020 | Paul Wasuwanich | ![]() |
![]() |
|||
WED-141 | Treatment eligibility and initiation among chronic hepatitis B patients in a real-world setting in the United States | Mark Schmidt | ![]() |
![]() |
|||
FRI-141 | Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States | Robert Blissett | ![]() |
![]() |
|||
THU-141 | Downstaging hepatocellular carcinoma with checkpoint inhibitor therapy safely improves access to curative liver transplantation: a case series | Margaret Liu | ![]() |
![]() |
|||
FRI-142 | Consider schistosomiasis screening in hepatitis B patients from endemic regions: a hepatic comorbidity that should not be neglected | Oriane PALAPRAT | ![]() |
![]() |
|||
THU-142 | Clinical outcomes of surgical resection vs yttrium 90 radioembolization (Y90) in hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI) | Zhaozhen Zou | ![]() |
![]() |
|||
WED-142 | Effects of tenofovir alafenamide fumarate on serum lipids in patients with chronic hepatitis B | Chao Wu | ![]() |
![]() |
|||
WED-143 | Novel serum markers of cccDNA transcriptional activity HBcrAg and pre-genomic RNA and CXCL10 pro-inflammatory chemokine levels can reduce uncertainty of HBeAg-negative chronic hepatitis B phases | Ivana Carey | ![]() |
![]() |
|||
SAT-143 | Hepatitis E virus infection before and after liver transplantation | Petra Dinjar Kujundic | ![]() |
![]() |
|||
FRI-143 | Micro-elimination of Hepatitis C virus infection in mountainous and remote areas of Taiwan a multi-center collaborative care model | Ching-Chu Lo | ![]() |
![]() |
|||
WED-144 | HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes | Ivana Carey | ![]() |
![]() |
|||
THU-144 | Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis | Ciro Celsa | ![]() |
![]() |
|||
FRI-144 | Impact of the anti-HDV reflex testing on the reduction of hepatitis D burden in Spain | Maria Buti | ![]() |
![]() |
|||
SAT-144 | Predictors of Baveno VII criteria for recompensation in patients with hepatitis B-related decompensated cirrhosis | Vicki Wing-Ki Hui | ![]() |
![]() |
|||
WED-145 | Systematic screening for hepatitis B at emergency department and linkage to care in Barcelona, Spain | Juan Carlos Ruiz-Cobo | ![]() |
![]() |
|||
THU-145 | Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments | Mara Persano | ![]() |
![]() |
|||
FRI-145 | Final results of a hepatitis C micro-elimination campaign in a highly endemic, well-defined demographic area of peri-urban Karachi, Pakistan | Saeed Hamid | ![]() |
![]() |
|||
SAT-145 | Utility of partial cure as an endpoint after nucleos(t)ide analogue withdrawal among chronic hepatitis B patients (RETRACT-B study) | Grishma Hirode | ![]() |
![]() |
|||
FRI-146 | Evaluation of hepatitis B core-related antigen rapid test (HBcrAg-RDT) to identify HBV-infected women eligible for peripartum antiviral prophylaxis in resource-limited countries | Jeanne Perpétue Vincent | ![]() |
![]() |
|||
SAT-146 | Effects of tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B : a nationwide claims study | Eunju Kim | ![]() |
![]() |
|||
WED-146 | Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort | Loreta A. Kondili | ![]() |
![]() |
|||
SAT-147 | Effects of interferon-based therapies in functional cure and hepatocellular carcinoma risk reduction in patients with chronic hepatitis B: real-world evidence from 2-year data of OASIS project | Qiran Zhang | ![]() |
![]() |
|||
WED-147 | Effect of Tenofovir and Entecavir on occurrence of hepatocellular carcinoma depends on duration of antiviral treatment and hierarchical PAGE-B risk score | Yi-Hsiang Huang | ![]() |
![]() |
|||
THU-147 | Sequential systemic treatment in patients with hepatocellular carcinoma: real-world data in the era of immune checkpoint inhibition | Jana Pauly | ![]() |
![]() |
|||
FRI-147 | Implementing hepatitis C self-testing (HCVST) among the general population in Georgia: preliminary results | Ketevan Stvilia | ![]() |
![]() |
|||
THU-148 | Comparison of Clinical Outcome between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Advanced Hepatocellular Carcinoma | Jae Seung Lee | ![]() |
![]() |
|||
FRI-148 | Retrospective study of hepatitis C virus antibodies and active viral replication in patients with severe mental illness in a Spanish university hospital | Cristina Del Rio-Cubilledo | ![]() |
![]() |
|||
WED-148 | Significant disparities in risk of cirrhosis and hepatocellular carcinoma among non-cirrhotic, treatment naďve, e-antigen negative hepatitis B patients with low levels of serum alanine aminotransferase | Robert Wong | ![]() |
![]() |
|||
SAT-148 | Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy | Milan Sonneveld | ![]() |
![]() |
|||
WED-149 | aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in virologically suppressed CHB patients | Jinlin Hou | ![]() |
![]() |
|||
SAT-149 | NTCP genetic variants may influence early virological response to bulevirtide monotherapy in patients with HDV related cirrhosis | Elisabetta Degasperi | ![]() |
![]() |
|||
FRI-149 | Tailored message intervention by nudge theory increases the number of the viral hepatitis screening for Japanese workers and consultation behavior of positive patients - Consideration of 1.7 million general check-up participants | Masaaki Korenaga | ![]() |
![]() |
|||
THU-149 | Efficacy of Atezolizumab/Bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression and liver disease severity | Spyridon Pantzios | ![]() |
![]() |
|||
SAT-150 | Stopping bulevirtide in long-term HDV-RNA suppressed patients seems safe and may enable long treatment-free intervals | Mathias Jachs | ![]() |
![]() |
|||
FRI-150 | Metabolicassociated fatty liver disease in socio-economic vulnerable population with chronic hepatitis B and C | Speranta Iacob | ![]() |
![]() |
|||
WED-150 | Systematic review and meta-analysis: the proportion of chronic hepatitis B patients with different alanine transaminase upper limits and significant hepatic histology | Yuhao Yao | ![]() |
![]() |
|||
THU-150 | Changing treatment landscape associated with improved survival in patients with hepatocellular carcinoma: a nationwide, population-based study | Najib Ben Khaled | ![]() |
![]() |
|||
SAT-151 | Switching to Besifovir in chronic hepatitis B patients receiving Tenofovir Disoproxil Fumarate: 96 weeks results of phase 4 trial | Hyung Joon YIM | ![]() |
![]() |
|||
WED-151 | Self-stigma in chronic hepatitis B: content and psychometric validation of a new patient-reported outcome instrument | Krishna Patel | ![]() |
![]() |
|||
FRI-151 | Strategies to eliminate hepatitis C virus infection in the Americas | Luis Antonio Diaz | ![]() |
![]() |
|||
THU-151 | Efficacy and tolerability of stereotactic body radiation therapy in patients with hepatocellular carcinoma: a retrospective cohort study | Dorothy Liu | ![]() |
![]() |
|||
WED-152 | Hepatitis flare appeared to be more severe with poorer outcome in chronic hepatitis B patients with recent COVID vaccination during the COVID pandemic | Jennifer Tai | ![]() |
![]() |
|||
SAT-152 | Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D | Heiner Wedemeyer | ![]() |
![]() |
|||
FRI-152 | Qualitative interviews to assess the impact of chronic hepatitis delta virus infection on health-related quality of life in untreated patients from the US, Italy, Spain, and Germany | Pietro Lampertico | ![]() |
![]() |
|||
FRI-153 | Microbiological analysis of acute hepatitis of unknown aetiology in children in Spain | Ana Avellón | ![]() |
![]() |
|||
WED-153 | Increased baseline comorbidity burden among commercially insured patients with hepatitis delta virus infection vs hepatitis B virus monoinfection in the United States | Chong Kim | ![]() |
![]() |
|||
SAT-153 | Long-term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 Phase 3 studies | Young-Suk Lim | ![]() |
![]() |
|||
FRI-154 | Emergency department contribution to hepatitis C elimination through opportunistic screening in Cascais, Portugal | Diogo Medina | ![]() |
![]() |
|||
SAT-154 | Association of post-treatment virologic relapse and biochemical flares with HBV serum biomarkers in long-term virologically suppressed HBeAg-negative patients stopping NA treatment: Exploratory analyses from the control arm of the REEF-2 study | Krishna Patel | ![]() |
![]() |
|||
THU-154 | Improved identification of good candidates for the treatment of intermediate/advanced hepatocellular carcinoma by Yttrium-90 transarterial radioembolization | Carole Vitellius | ![]() |
![]() |
|||
WED-154 | Can we better characterize HBeAg-negative chronically infected hepatitis B patients using novel biomarkers? | Thais Leonel | ![]() |
![]() |
|||
THU-155 | Clinical impact of relative dose intensity over the first four weeks in cabozantinib therapy for unresectable hepatocellular carcinoma | Kaoru Tsuchiya | ![]() |
![]() |
|||
SAT-155 | Comparable risk of cardiovascular events in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide | Hyeyeon Hong | ![]() |
![]() |
|||
FRI-155 | Implementation of anti-HDV reflex testing among HBsAg-positive in a tertiary center in South Italy | Valentina Cossiga | ![]() |
![]() |
|||
SAT-156 | Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response | Katja Deterding | ![]() |
![]() |
|||
THU-156 | Tolerability of first line systemic therapy in elderly patients with advanced hepatocellular carcinoma | Giulia Francesca Manfredi | ![]() |
![]() |
|||
FRI-156 | Effectiveness of a direct care action strategy at the drug addiction center (test and treat in point of care) for the detection and treatment of hepatitis C in drug users on opioid agonist substitution therapy | Inés Sáenz De Miera | ![]() |
![]() |
|||
WED-156 | Hepatitis D screening in HBsAg positive individuals in Germany: insufficient implementation results in a large number of undiagnosed cases | Toni Herta | ![]() |
![]() |
|||
THU-157 | Incidence and risk factors of post-transarterial chemoembolization complications in patients with hepatocellular carcinoma: a single center retrospective cohort analysis in a large tertiary hospital | Melissa April Pajinag | ![]() |
![]() |
|||
SAT-157 | Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switchingto tenofovir alafenamide in chronic hepatitis B patients | Pin-Nan Cheng | ![]() |
![]() |
|||
FRI-157 | Comparison of HCVRNA results using plasma separation card with gold standard veni-puncture | Huma Qureshi | ![]() |
![]() |
|||
SAT-158 | Model-based meta-analysis of pegylated IFN-alpha induced HBsAg loss at end of treatment and 24 weeks post treatment in chronic hepatitis B virus infection | Vera Gielen | ![]() |
![]() |
|||
FRI-158 | Patients with hepatitis B and D are more often linked to medical care than patients with hepatitis C | Elena Vargas Accarino | ![]() |
![]() |
|||
WED-158 | Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D | Soo Aleman | ![]() |
![]() |
|||
WED-159 | B cell phenotype, Toll-Like receptor 9 expression and proinflammatory cytokines profile in patients with chronic hepatitis B with HBsAg loss or persistent | Nour Nasser | ![]() |
![]() |
|||
SAT-159 | Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response | Stefano DAnna | ![]() |
![]() |
|||
FRI-159 | The impact of hepatitis B and C serologies on the outcomes of non-liver solid organ transplantation | Carey Escheik | ![]() |
![]() |
|||
SAT-160 | Comparison of kidney function decline between chronic hepatitis B patients with versus without antiviral therapy | Jae Seung Lee | ![]() |
![]() |
|||
WED-160 | Healthcare resource use and costs associated with hepatitis delta virus infection compared to hepatitis B virus monoinfection among commercially insured patients in the US | Chong Kim | ![]() |
![]() |
|||
FRI-160 | Development of a rapid workflow for detecting HCV RNA from whole blood | Matthew Pauly | ![]() |
![]() |
|||
SAT-161 | Effect of first-line nucleot(s)ide analogues on blood lipids in patients with chronic hepatitis B: a network meta-analysis | kexin tong | ![]() |
![]() |
|||
WED-161 | Clinical characteristics and phase transition of chronic hepatitis B patients with HBeAg and anti-HBe coexistence | Ruifei Xue | ![]() |
![]() |
|||
FRI-161 | Hepatitis D infection in a HBsAg cohorts referred from specialist liver clinics vs. reflex community referred patients in South East London | Ivana Carey | ![]() |
![]() |
|||
FRI-162 | Screening, confirmation, and treatment rates of hepatitis C virus infections in patients undergoing surgery in a single tertiary academic centre | Jae Seung Lee | ![]() |
![]() |
|||
THU-162 | External validation of models to predict hepatocellular carcinoma (HCC) in HCV SVR F3-F4 patients | Marina Berenguer | ![]() |
![]() |
|||
WED-162 | Lower HBV DNA levels is associated more severe liver fibrosis in chronic hepatitis B with serological immune-tolerant phase | Jian Wang | ![]() |
![]() |
|||
THU-163 | Impact of direct-acting antiviral therapy on tumor progression and survival in intermediate to advanced hepatocellular carcinoma patient with HCV infection | Chen-Ta Chi | ![]() |
![]() |
|||
FRI-163 | Impact of hepatitis B family screening, counselling and education program on active case detection: a step towards elimination through preventive hepatology clinic in India | Ajeet Singh Bhadoria | ![]() |
![]() |
|||
SAT-163 | Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Tenofovir Following Incomplete Response to Prior Antivirals | Hyunjae Shin | ![]() |
![]() |
|||
WED-163 | Clinical evaluation of highly sensitive iTACT hepatitis B core-related antigen and hepatitis B surface antigen assays in the management of HBV reactivation | Takako Inoue | ![]() |
![]() |
|||
WED-164 | Serum thrombospondin-2 for predicting liver fibrosis in patients with chronic hepatitis B virus infection | Chao Wu | ![]() |
![]() |
|||
THU-164 | The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure | Veronika Pitova | ![]() |
![]() |
|||
FRI-164 | HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network | Massimo Puoti | ![]() |
![]() |
|||
SAT-164 | Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection, a systematic review | Vera Gielen | ![]() |
![]() |
|||
SAT-165 | The efficacy of peginterferon alpha in Chinese inactive chronic hepatitis B virus carriers and nucleoside analogs-experienced patients: a real world research | Chaojing Wen | ![]() |
![]() |
|||
WED-165 | Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis | Yu Jun Wong | ![]() |
![]() |
|||
FRI-165 | A modelling study of the impact of scaling up of HCV case finding and treatment for people who inject drugs in English region of Bristol and Severn | Zoe Ward | ![]() |
![]() |
|||
THU-165 | MAFLD (metabolic associated fatty liver disease) outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents | Serena Pelusi | ![]() |
![]() |
|||
SAT-166 | Similarly low risk of chronic kidney disease (CKD) progression in chronic hepatitis B patients with Stage 2 CKD on tenofovir alafenamide versus entecavir | Yan Liang | ![]() |
![]() |
|||
WED-166 | Characterizing chronic hepatitis delta in Spain and the gaps in its management | Sergio Rodríguez-Tajes | ![]() |
![]() |
|||
THU-166 | Most vulnerable HCV patient groups treated with direct acting antivirals achieve high response rates and gain quality of life data from the German hepatitis C-registry (DHC-R) | Yvonne Serfert | ![]() |
![]() |
|||
SAT-167 | Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - a long term follow-up study | Che To Lai | ![]() |
![]() |
|||
THU-167 | The impact of 5 years of testing for hepatitis C in prisons in the north east of England | Amy Johnson | ![]() |
![]() |
|||
FRI-167 | Who is missing? Analysis of the 2021 Georgian seroprevalence survey to identify the population left to be screened for hepatitis C | Sophia Surguladze | ![]() |
![]() |
|||
WED-167 | Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan | Osama Mohamed | ![]() |
![]() |
|||
SAT-168 | Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: preliminary results from a randomized, blinded, Phase 1b study | Jane Kovalevich | ![]() |
![]() |
|||
FRI-168 | Are primary healthcare facilities ready to provide hepatitis delta services in Mongolia: service availability and readiness assessment findings | Enkhjargal Altangerel | ![]() |
![]() |
|||
WED-168 | In patients with chronic hepatitis D, the decline of &8805;2log HDV-RNA levels that remain detectable is associated with better clinical outcomes | Adriana Palom | ![]() |
![]() |
|||
THU-168 | Results of the hepatitis B and C screening within the Check-Up35 in the German primary care setting one year after implementation by the federal joint committee | Johannes Wiegand | ![]() |
![]() |
|||
SAT-169 | Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg | Marc Bourliere | ![]() |
![]() |
|||
THU-169 | Clinical outcomes after therapy with direct acting antiviral in patients with HCV-related B-cell Non-Hodgkin lymphomas and/or mixed cryoglobulinemia | Marco Tizzani | ![]() |
![]() |
|||
WED-169 | Neglible 10-year risk of liver-related events in chronic hepatitis B patients with low liver stiffness | Lesley Patmore | ![]() |
![]() |
|||
FRI-169 | Cascade of care among people with hepatitis B in New South Wales, Australia | Syed Hassan Bin Usman Shah | ![]() |
![]() |
|||
THU-170 | Analysis of mortality rate in the patients after hepatitis C virus elimination using direct acting antivirals and comparison with the general population | Satoshi Miuma | ![]() |
![]() |
|||
WED-170 | Steadily decline of HBV DNA load under NAs in lymphoma patients and higher level of qAnti-HBc predict HBV reactivation | Yi-Qi Liu | ![]() |
![]() |
|||
SAT-170 | The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients | Asgeir Johannessen | ![]() |
![]() |
|||
FRI-170 | Reimplementation of a revamped cost-effective national elimination strategy is the only way Brazil moves towards eliminating HCV | Alexis Voeller | ![]() |
![]() |
|||
WED-171 | Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection | Lisa Sandmann | ![]() |
![]() |
|||
SAT-171 | Deep learning cluster analysis reveals subtypes in response to antisense oligonucleotide therapy in chronic hepatitis B | Caroline Weis | ![]() |
![]() |
|||
THU-171 | Impact of direct-acting antiviral therapy on survival in patients with liver cirrhosis and ascites. Data from the hepa-C registry | Alvaro Hidalgo Romero | ![]() |
![]() |
|||
FRI-171 | The evaluation of people suspected of sexually transmitted diseases requires tools for the comprehensive diagnosis of viral hepatitis and HIV | Joaquin Cabezas | ![]() |
![]() |
|||
WED-172 | Distribution of the natural history stages of pregnant women with chronic hepatitis B virus infection and its association with pregnancy complications and adverse pregnancy outcomes | Xuelian Zhang | ![]() |
![]() |
|||
THU-172 | HCV elimination: reengagement of previously diagnosed but unlinked patients with chronic hepatitis C to initiate treatment | Maria Fernanda Guerra Veloz | ![]() |
![]() |
|||
SAT-172 | Safety and antiviral activity of RBD1016, a RNAi therapeutic, in chinese subjects with chronic hepatitis B virus (HBV) infection | Guoliang Chen | ![]() |
![]() |
|||
FRI-172 | The impact of hepatitis C and socio-demographic variables on Health-related quality of life among patients in Pakistan | Siwaporn Niyomsri | ![]() |
![]() |
|||
THU-173 | HCV screening rates in reproductive age women after universal screening guidelines | Roshni Singh | ![]() |
![]() |
|||
SAT-173 | AHB-137, a novel hepatitis B virus antisense oligonucleotide with substantially enhanced in vitro and in vivo antiviral activity | Xiaoli Wu | ![]() |
![]() |
|||
FRI-173 | Hepatitis C screening program in Lithuania: first results and scenarios for virus elimination | Limas Kupcinskas | ![]() |
![]() |
|||
WED-173 | Comparison of hepatitis B reactivation in patients with resolved hepatitis B infection receiving rituximab or non-rituximab based immunosuppressive therapy: does presence of hepatitis b surface antibody reduce the risk of reactivation? | Wei-Lun Liou | ![]() |
![]() |
|||
WED-174 | Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naďve for antiretrovirals) cohort | Massimo Puoti | ![]() |
![]() |
|||
SAT-174 | Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China | Jane Kovalevich | ![]() |
![]() |
|||
FRI-174 | Challenges and strategies to improve linkage to care and treatment for hepatitis C in pregnancy: perspectives from a global community of practice | Neil Gupta | ![]() |
![]() |
|||
THU-174 | The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry | Chung-Feng Huang | ![]() |
![]() |
|||
WED-175 | Detection of hepatitis delta virus in seminal fluid and female genital tract | Naranjargal Dashdorj | ![]() |
![]() |
|||
FRI-175 | New and easy strategy for mass screening for hepatitis C in leisure spaces | Sonia Albertos Rubio | ![]() |
![]() |
|||
THU-175 | Predicting vertical transmission of hepatitis C in pregnant women using a composite score: a multicenter study | Paul Wasuwanich | ![]() |
![]() |
|||
SAT-175 | Significant improvement of non-invasive fibrosis tests in HDV compensated cirrhotic patients with clinically significant portal hypertension treated with BLV monotherapy un to 96 weeks | Elisabetta Degasperi | ![]() |
![]() |
|||
FRI-176 | Burden of hepatitis C in pregnant women and children in the United States | Paul Wasuwanich | ![]() |
![]() |
|||
THU-176 | Achieving hepatitis C micro-eliminating in 4 female prisons through a nurse led test and treat approach of pathway optimisation and whole prison testing | Andy Jones | ![]() |
![]() |
|||
WED-176 | Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression | Romina Salpini | ![]() |
![]() |
|||
SAT-176 | Analysis of HBV genotype association to bepirovirsen treatment response in patients with chronic HBV infection (Phase 2b B-Clear study) | Jerome Bouquet | ![]() |
![]() |
|||
THU-177 | Post-treatment liver function, but not baseline liver function, predicts survival in hepatitis C virus patients with decompensated cirrhosis after direct-acting antiviral treatment | Yuki Tahata | ![]() |
![]() |
|||
SAT-177 | Single dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection | Phylea Anderson | ![]() |
![]() |
|||
WED-177 | Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C | Javier García-Samaniego | ![]() |
![]() |
|||
FRI-177 | Micro-elimination of chronic hepatitis C virus in patients with psychiatric disorders: a multidisciplinary strategy in the outpatient mental health center | Inés Sáenz De Miera | ![]() |
![]() |
|||
FRI-178 | Simple treatment eligibility score for chronic HBV infection at peripheral health facilities in sub-Saharan Africa | Yusuke Shimakawa | ![]() |
![]() |
|||
WED-178 | Long-term outcomes of a population-based cohort of chronic hepatitis B (CHB) patients in West Africa | Gibril Ndow | ![]() |
![]() |
|||
SAT-178 | AHB-137, a novel and potent hepatitis B virus antisense oligonucleotide with a favorable preclinical pharmacokinetics and safety profile | Tingting Lu | ![]() |
![]() |
|||
THU-178 | Network transmission of hepatitis C genotype 2c and 4d in men who have sex with men in Cape Town, South Africa | Mark Sonderup | ![]() |
![]() |
|||
THU-179 | Direct-acting antivirals reduce disease burden in patients with chronic hepatitis C: a Korean nationwide, multicentre, retrospective cohort study | Won Sohn | ![]() |
![]() |
|||
SAT-179 | Consolidation treatment with Tiaogan-Buxu-Jiedu granule (Traditional Chinese Medicine compound) plus entecavir reduces virological relapse following entecavir withdrawal in Chinese patients with chronic hepatitis B: a randomized, controlled trial | Xiaoke Li | ![]() |
![]() |
|||
FRI-179 | A nationwide study on the core indicators related to elimination of viral hepatitis B and C in Korea | In Hee Kim | ![]() |
![]() |
|||
FRI-180 | Hepatitis C seroprevalence screening and linkage to care of unknown infected patients admitted to a tertiary care emergency departement: on the road to achieve the WHO 2030 virus elimination target | Roberta Lasco | ![]() |
![]() |
|||
SAT-180 | Positive impact of reflex testing in performing hepatitis delta serology in HBsAg patients | Régine TRUCHI | ![]() |
![]() |
|||
THU-180 | Hepatitis C micro-elimination program in Zhuhai: a concerted citywide effort to eliminate hepatitis C by 2030 | Xinchun Zheng | ![]() |
![]() |
|||
WED-180 | Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naďve chronic hepatitis B in the immune tolerant phase | Robert Wong | ![]() |
![]() |
|||
FRI-181 | D-Mongolia: screening and linkage-to-care for Hepatitis D in Mongolian nationals living in Spain | Adriana Palom | ![]() |
![]() |
|||
THU-181 | Real-world data on long-term quality of life after Glecaprevir/Pibrentasvir therapy: data from the German hepatitis C registry (DHC-R) | Beth Stapleton | ![]() |
![]() |
|||
SAT-181 | Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks | Elisabetta Degasperi | ![]() |
![]() |
|||
WED-181 | Contrasting immune fingerprints of chronic hepatitis B Virus infection in adults from South Africa and the United Kingdom | Marion Delphin | ![]() |
![]() |
|||
SAT-182 | Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B | Kosh Agarwal | ![]() |
![]() |
|||
THU-182 | What is the impact of a Hepatitis C test and trace pilot using peer workers? | Stuart McPherson | ![]() |
![]() |
|||
FRI-182 | Improving blood borne virus screening in immigration removal centres in the UK | Katie Abraham | ![]() |
![]() |
|||
WED-183 | The role of PAGE-B score in predicting the development of hepatocelular cancer in patients with chronic delta hepatitis | Cihan Yurdaydin | ![]() |
![]() |
|||
SAT-183 | Safety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosis | Christiane Stern | ![]() |
![]() |
|||
FRI-183 | Exploring the impacts of the COVID-19 pandemic on access to HCV-related care and support: findings from a survey of people with lived experience of incarceration and/or substance use in British Columbia, Canada | Dahn Jeong | ![]() |
![]() |
|||
THU-183 | Evaluation of the follow-up in patients with advanced fibrosis after achieve sustained viral response with direct-acting antivirals. Screening and risk of hepatocellular carcinoma | Vanesa Bernal Monterde | ![]() |
![]() |
|||
THU-184 | Hepatitis C virus (HCV) infection and neurocognitive impairment in subjects with mild liver disease: the role of neuropsychological and cognitive provoked P300 tests | Carlos Eduardo Brandăo Mello | ![]() |
![]() |
|||
FRI-184 | Tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of hepatitis B virus: a cost-effectiveness analysis | Pisit Tangkijvanich | ![]() |
![]() |
|||
WED-184 | Identification and external validation of the optimal ALT thresholds for ruling in significant histologic disease in chronic hepatitis B | Zhiyi Zhang | ![]() |
![]() |
|||
SAT-184 | Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program | Victor de Ledinghen | ![]() |
![]() |
|||
FRI-185 | A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: the 1969-1989 birth-cohort | Roberta DAmbrosio | ![]() |
![]() |
|||
SAT-185 | Treatment with Bulevirtide, with or without PEG-interferon, in HIV-HBV/HDV co-infected patients in a real-life setting | Victor de Ledinghen | ![]() |
![]() |
|||
THU-185 | A prospective, pragmatic post-authorisation safety study of early recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after direct-acting antiviral (DAA) therapy: DAA-PASS | Amit Singal | ![]() |
![]() |
|||
WED-185 | Predominance of genotype 5 hepatitis delta virus infection in a portuguese centre | Mariana Cardoso | ![]() |
![]() |
|||
SAT-186 | The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers | Jane Kovalevich | ![]() |
![]() |
|||
FRI-186 | Cascade of care and HCV treatment of inner city populations engaged in care through community pop-up clinics (CPCs) | Brian Conway | ![]() |
![]() |
|||
THU-186 | Clinical outcomes after hepatitis C treatment in patients with advanced chronic liver disease | Fabio Correia | ![]() |
![]() |
|||
WED-186 | Long-term outcomes of patients with chronic HBsAg positive/HBe-negative infection: differences and transition between inactive carriers and low viremic carriers | Gabriele Rancatore | ![]() |
![]() |
|||
WED-187 | HBV infected pregnant woman received antiviral treatment and discontinued it postpartum can benefit from retreatment | Qiao Tang | ![]() |
![]() |
|||
SAT-187 | Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (Phase 2b B-Clear study) | Jerome Bouquet | ![]() |
![]() |
|||
THU-187 | Mortality risk following HCV cure among people with HIV coinfection | Naveed Janjua | ![]() |
![]() |
|||
FRI-187 | Incidence of hepatitis C virus antibody seroconversion among people who inject drugs in Tbilisi, Georgia | Tengiz Tsertsvadze | ![]() |
![]() |
|||
SAT-188 | Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B | Megan Fitzgerald | ![]() |
![]() |
|||
WED-188 | Higher risk of disease progression in the gray zone relative to hepatitis B e antigen negative chronic hepatitis B infection | Yunling Xue | ![]() |
![]() |
|||
FRI-188 | Survey to evaluate the implementation of the recommendations on the comprehensive diagnosis of viral hepatitis in a single extraction: where are we? | Joaquin Cabezas | ![]() |
![]() |
|||
WED-189 | Analysis of disease progression in patients with chronic hepatitis B using a large nationwide database | Nobuharu Tamaki | ![]() |
![]() |
|||
SAT-189 | Efficacy and safety of celecoxib add on nucleos(t)ide analogues on the hepatitis B surface antigen of virally suppressed patients with chronic hepatitis B - interim analysis | Feng Xue | ![]() |
![]() |
|||
THU-189 | Hospitalisation - missing an opportunity to link to hepatitis C care: a retrospective study at a regional Australian health service | Christine Roder | ![]() |
![]() |
|||
WED-190 | Prognosis of HDV infections in Belgium | Arno Furquim dAlmeida | ![]() |
![]() |
|||
THU-190 | Hepatitis C virus infection follow-up of people who use drugs in the Balearic Islands, Spain | Andrea Herranz Mochales | ![]() |
![]() |
|||
SAT-190 | Quantification of serum HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0 and Eurobioplex | Maria Paola Anolli | ![]() |
![]() |
|||
FRI-190 | Hepatitis E virus seroprevalence in immunosuppressed patients in Belgium: a prospective study | Marie Philippart | ![]() |
![]() |
|||
SAT-191 | A monoclonal antibody 4G2 exhibits anti-viral activity in mouse models of chronic hepatitis B | Aditi Deshpande | ![]() |
![]() |
|||
THU-191 | Serum myostatin decreased after direct acting antivirals for cirrhotic patients | Tomoyuki Suehiro | ![]() |
![]() |
|||
FRI-191 | What is the most effective strategy to identify HBV-infected pregnant women eligible for antiviral prophylaxis in Burkina Faso? | Andréa GOSSET | ![]() |
![]() |
|||
WED-191 | Assessment of clinical and patient reported outcome measures in individuals with chronic hepatitis B who clear HBsAg, followed by the Canadian hepatitis B network | Carla Coffin | ![]() |
![]() |
|||
THU-192 | HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care | Maria Torner Simó | ![]() |
![]() |
|||
FRI-192 | Results from a community-based intervention to increase viral hepatitis screening among at-risk African migrants in Catalonia, Spain (2020-2022) | Jeffrey Lazarus | ![]() |
![]() |
|||
THU-193 | The influence of direct acting antiviral treatment in chronic hepatitis C virus infection on arterial stiffness | Mircea Istrate | ![]() |
![]() |
|||
FRI-193 | Innovation linkage model to re-engage lost-to-follow-up individuals in the national hepatitis C elimination program in Georgia | Vladimer Getia | ![]() |
![]() |
|||
WED-193 | Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions | Valerie Ohlendorf | ![]() |
![]() |
|||
SAT-193 | Efficacy and prediction analysis of pegylated interferon alpha-2b in treatment-naive HBeAg negative chronic hepatitis B patients with normal ALT: a multicenter real-world study (Ice-breakting Project in China) - Interim analysis | Chong Zhang | ![]() |
![]() |
|||
SAT-194 | The safety and efficacy of hepalatide (L47) treatment combined with pegylated interferon-alpha 2a in patients with chronic hepatitis B: the preliminary data from a double-blind, RCT phase II trial | Xiaolu Tang | ![]() |
![]() |
|||
FRI-194 | Hepatocellular carcinoma associated with chronic hepatitis C: a case for an annual mortality and morbidity review | Neil McInnes | ![]() |
![]() |
|||
WED-194 | Barriers to hepatitis B treatment from the patients perspectives: survey study by the canadian hepatitis B network | Hin Hin Ko | ![]() |
![]() |
|||
THU-195 | Long term normalization of systemic inflammation and endothelial activation after hepatitis C virus (HCV) eradication in HIV/HCV coinfected, HCV monoinfected patients and HCV-infected liver transplant recipients | Laura Benitez Gutierrez | ![]() |
![]() |
|||
WED-195 | Driving improvements in hepatitis B care in Africa: profile of the hepatitis B in Africa collaborative network (HEPSANET) | Asgeir Johannessen | ![]() |
![]() |
|||
SAT-195 | A novel class of orally-available small molecules potently inhibiting hepatitis B and D virus entry | Jane Kovalevich | ![]() |
![]() |
|||
FRI-195 | Prevalence of hepatitis B and C viral infections among transgenders and men who have sex with men in Pakistan | Hassan Mahmood | ![]() |
![]() |
|||
SAT-196 | Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: Examples from the B-Clear study | Jenn Singh | ![]() |
![]() |
|||
THU-196 | Differences in baseline characteristics of direct acting antiviral (DAA)- treated Greek HCV patients according to source of infection | Spyridon Siakavellas | ![]() |
![]() |
|||
FRI-196 | Multidisciplinary Approaches to Increase Hepatitis C Screening Rates in a New York City Primary Care Clinic | Carolina Villarroel | ![]() |
![]() |
|||
WED-196 | Risk factors for viral reactivation in patients with overt or occult HepatitisB Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis | Ciro Celsa | ![]() |
![]() |
|||
FRI-197 | Effectiveness of birth-dose vaccine in preventing mother-to-child transmission of hepatitis B virus in Ethiopia | Mebrihit Arefaine | ![]() |
![]() |
|||
THU-197 | Incidence and associations of HCV reinfection in the era of direct acting antivirals | Spyridon Siakavellas | ![]() |
![]() |
|||
WED-197 | T-cell responses to PreS1 and PreS2 are correlated to anti-HBs antibody titres, which are higher and persist longer in volunteers vaccinated with 3-antigen than with 1-antigen hepatitis B vaccine in the PROTECT Study:3.5 year follow up | Francisco Diaz-Mitoma | ![]() |
![]() |
|||
SAT-197 | Therapeutic vaccine candidate CLB-3000 (CLB-405 and CLB-505 adjuvanted with Alhydrogel): a Good Laboratory Practice (GLP)-compliant 15-week intramuscular toxicity study in rabbits with a 4-week recovery | Aileen Rubio | ![]() |
![]() |
|||
SAT-198 | Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV immunotherapy (VTP-300) combined with low-dose nivolumab (LDN) in virally suppressed patients with CHB on nucleos(t)ide analogues | Henrik Sorensen | ![]() |
![]() |
|||
FRI-198 | Complete and maintained elimination of hepatitis C in patients in methadone substitution program | Esther Rodríguez Candelaria | ![]() |
![]() |
|||
THU-198 | Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong | Victor Yung Sin Chow | ![]() |
![]() |
|||
SAT-199 | Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study | Elisabetta Degasperi | ![]() |
![]() |
|||
THU-199 | The prevelance of hepatitis C virus infection in high-risk patients with high normal alanine aminotransferase (ALT) in Israel: a bio bank analysis | Amir Shlomai | ![]() |
![]() |
|||
WED-199 | Epidemiological landscape and clinical spectrum of chronic hepatitis B in East Africa | Abate Shewaye | ![]() |
![]() |
|||
WED-200 | Significantly higher clinical and economic burden following diagnosis of hepatitis delta virus infection among commercially insured adults with chronic hepatitis B in the United States | Chong Kim | ![]() |
![]() |
|||
FRI-200 | Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial part 2 | Brian Conway | ![]() |
![]() |
|||
THU-200 | HCV screening: shortening read time of point-of-care rapid diagnostic test does not effect detection rates of antibodies against hepatitis C virus | Auj Chaudhry | ![]() |
![]() |
|||
SAT-200 | Modeling-based response-guided therapy with bulevirtide monotherapy for chronic hepatitis D to identify patients for finite treatment duration | Harel Dahari | ![]() |
![]() |
|||
FRI-201 | Screening for hepatitis C virus using rapid diagnostic test (RDT) coupled with mammography in women aged from 50 to 74 years in Montpellier (France). (MammOC NCT05067374) | Magdalena Meszaros | ![]() |
![]() |
|||
SAT-201 | A phase 2 study of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir(ETV) in chronic hepatitis B patients with 12-week treatment | Mingfei Ge | ![]() |
![]() |
|||
WED-201 | Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis | Mi Na Kim | ![]() |
![]() |
|||
THU-201 | Digital pathology quantification of cirrhosis severity continuum in human HCV liver biopsies and its correspondence with Laennec and Beijing stages | Louis Petitjean | ![]() |
![]() |
|||
THU-202 | Prognostic factors of post-sustained virological response outcome in patients with chronic hepatitis C treated with direct-acting antivirals | Won Sohn | ![]() |
![]() |
|||
FRI-202 | Hepatitis B, C and D infections among nine high-risk populations in Burkina Faso, West Africa | Armel Moumouni Sanou | ![]() |
![]() |
|||
SAT-202 | Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836 | Christine L. Espiritu | ![]() |
![]() |
|||
WED-202 | High prevalence of hepatic steatosis in adults living with hepatitis B, with and without HIV co-infection, in London, UK | Claire Mullender | ![]() |
![]() |
|||
WED-203 | Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli | Lorenzo Piermatteo | ![]() |
![]() |
|||
FRI-203 | Factors associated with HCV reinfection among treated people who inject drugs in the HCV elimination program in Georgia | Lasha Gulbiani | ![]() |
![]() |
|||
THU-203 | Utilising peer support workers in hepatitis C screening in emergency departments: a pilot study | Fiona Gordon | ![]() |
![]() |
|||
THU-204 | A large-scale, centralized viral hepatitis screening model in Hainan province of China during the COVID-19 pandemic | Tao Wu | ![]() |
![]() |
|||
WED-204 | Ten years follow-up of patients with chronic hepatitis B and hepatitis D infection | Andreea Dobroaia | ![]() |
![]() |
|||
FRI-204 | HCV screening before endoscopy in hepatogastroenterology outpatient clinic: results of DEPISTC-ENDO study | André-Jean Remy | ![]() |
![]() |
|||
THU-205 | Usefulness of serum CCL20 as a post sustained viral response biomarker for HCV-associated liver fibrosis | Atsumasa Komori | ![]() |
![]() |
|||
WED-205 | Overcoming barriers to care for Delta infected patients | Marina Berenguer | ![]() |
![]() |
|||
FRI-205 | Progress in hepatitis C screening as part of the hepatitis C elimination program in Georgia | Maia Tsereteli | ![]() |
![]() |
|||
WED-206 | Clinical phenotypes of hepatocellular carcinoma in patients with chronic hepatitis D compared to patients with chronic hepatitis B | Christoph Schramm | ![]() |
![]() |
|||
THU-206 | Hepatitis C and monoclonal gammopathy of undetermined significance: clinical and hematological outcome after eradication with direct acting antivirals | Rosa Claudia Stasio | ![]() |
![]() |
|||
FRI-206 | New hepatitis C diagnoses in 2022. Who and where. Referral efficiency | Cristina Suárez Montesdeoca | ![]() |
![]() |
|||
THU-207 | Ethnic disparity in mortality related to extrahepatic manifestations among people with chronic HCV infection: a large, linked administrative population-based study in British Columbia, Canada | Dahn Jeong | ![]() |
![]() |
|||
WED-207 | Risk stratification for hepatocellular carcinoma in patients with chronic hepatitis D | Christoph Schramm | ![]() |
![]() |
|||
FRI-207 | Hepatitis C screening and elimination strategy: implementation of the FOCUS program in Almería, Spain | Marta Casado | ![]() |
![]() |
|||
THU-208 | Hepatitis C virus (HCV) infection and neurocognitive impairment in subjects with mild liver disease | Marcia Maria Amendola Pires | ![]() |
![]() |
|||
FRI-208 | Low prevalence found in HCV micro-elimination program among HIV-negative MSM and TW in a community center in Spain | Angel Rivero Calaf | ![]() |
![]() |
|||
WED-208 | Current status of hepatitis delta in Andalusia: multicenter study | Marta Casado | ![]() |
![]() |
|||
THU-209 | Chronic hepatitis C and aging: search for cognitive changes | Carlos Eduardo Brandăo Mello | ![]() |
![]() |
|||
WED-209 | Treatment experience and acceptability in a UK HBV cohort why personalised regimens may be necessary in chronic hepatitis B | Jane Abbott | ![]() |
![]() |
|||
FRI-209 | Late presentation for hepatitis C treatment; prevalence and risk factors in the Swiss hepatitis C cohort | Nathalie Brunner | ![]() |
![]() |
|||
WED-210 | Eliminating viral hepatitis one island at a time the Hainan experience | Biao Wu | ![]() |
![]() |
|||
THU-210 | Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series | Alison Boyle | ![]() |
![]() |
|||
FRI-210 | Characterizing individuals who remain to be screened and those lost to follow-up from Georgias HCV elimination program | Sophia Surguladze | ![]() |
![]() |
|||
WED-211 | Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV) | George Papatheodoridis | ![]() |
![]() |
|||
FRI-211 | Cantabria on the way to HCV elimination. Differential prevalence of hepatitis C in Cantabria: @CohorteCantabria vs ETHON cohort | Joaquin Cabezas | ![]() |
![]() |
|||
SAT-211 | Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC | Beatrice Foglia | ![]() |
![]() |
|||
WED-212 | A novel nomogram for predicting HBeAg clearance in HBeAg-positive chronic hepatitis B patients after nucleos(t)ide analogues treatment | Chao Wu | ![]() |
![]() |
|||
THU-212 | Sustained virologic response outcomes in patient with hemodialysis - hepatitis c receiving treatment with direct-acting antivirals agents | Fardhah Akil | ![]() |
![]() |
|||
FRI-212 | Risk of developing cancer - comparison of HBV, HCV and smoking | Homie Razavi | ![]() |
![]() |
|||
SAT-212 | Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms | Irene Olaizola | ![]() |
![]() |
|||
SAT-213 | Metabolomic liquid biopsy dynamics predict early onset of human hepatocarcinogenesis | Johann von Felden | ![]() |
![]() |
|||
THU-213 | Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis | Devan Pooja | ![]() |
![]() |
|||
FRI-213 | Pandemic preparedness and viral hepatitis - Global survey of hepatitis program managers and healthcare providers | Nida Ali | ![]() |
![]() |
|||
WED-213 | The benefit of a local hepatitis B reactivation guideline to improve screening and prophylaxis for patients initiated on rituximab | Helen Boothman | ![]() |
![]() |
|||
WED-214 | The comparisons of clinical relapse timing and severity after cessation of prophylactic nucleos(t)ide analogue between chronic hepatitis B patients with lymphoma receiving chemotherapy with and without Rituximab | Yen-Chun Liu | ![]() |
![]() |
|||
THU-214 | Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 December 2022 | Tengiz Tsertsvadze | ![]() |
![]() |
|||
FRI-214 | New tools reaching hepatitis C elimination: automatic hepatitis C virus detection in presurgical evaluations | Marina Eliana Millan Lorenzo | ![]() |
![]() |
|||
WED-215 | Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast attenuates profibrogenic gene expression of myofibroblasts in human liver explant tissue with biliary fibrosis | Johanna Schaub | ![]() |
![]() |
|||
THU-215 | The most difficult to cure with pangenotypic regimens HCV infected population | Robert Flisiak | ![]() |
![]() |
|||
SAT-215 | Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism | Mikel Ruiz de Gauna | ![]() |
![]() |
|||
WED-216 | TLC-3595, a ive acetyl-CoA carboxylase 2 (ACC2) inhibitor, improves steatosis and fibrosis in murine models of NASH via pleiotropic mechanisms | Robert Myers | ![]() |
![]() |
|||
FRI-216 | Detection and functional analysis of HBV-specific stem cell memory T cells (Tscm) | Hiromi Chayama | ![]() |
![]() |
|||
THU-216 | Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir | Juan Carlos Ruiz-Cobo | ![]() |
![]() |
|||
SAT-216 | MAP17 promotes an epithelial-mesenchymal-amoeboid transition in hepatocellular carcinoma by switching one-carbon metabolism | Clŕudia Gil Pitarch | ![]() |
![]() |
|||
WED-217 | Spatial lipidomics reveal dysregulated sphingolipid metabolism in liver fibrosis | Aleksandra Gruevska | ![]() |
![]() |
|||
SAT-217 | Deciphering the cellular and molecular determinants of immunotherapy resistance in NASH-associated hepatocellular carcinoma by single-cell analysis | Lingyun Zhang | ![]() |
![]() |
|||
THU-217 | An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan | Ming-Lung Yu | ![]() |
![]() |
|||
FRI-217 | RBD1016 a novel anti-HBV GalNAc-siRNA drug resulted in sustained HBsAg reduction and seroconversion in mice models | Shu Quan Zheng | ![]() |
![]() |
|||
THU-218 | Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir | Stuart C Gordon | ![]() |
![]() |
|||
FRI-218 | HBV infection reshapes host chromatin accessibility and affects choline and iron metabolism | Vincenzo Alfano | ![]() |
![]() |
|||
SAT-218 | Differential hepatoprotective effects of semaglutide and lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC | Malte H. Nielsen | ![]() |
![]() |
|||
WED-218 | Cyclophilin inhibition exhibits preventive and curative antifibrotic effects via extracellular matrix remodelling | Una Rastovic | ![]() |
![]() |
|||
THU-219 | Concomitant use of proton pump inhibitors and Sofosbuvir/Velpatasvir: evidence from randomized clinical trials and real-world data | Maria Buti | ![]() |
![]() |
|||
WED-219 | Hepatic stellate cell-derived extracellular matrix to model aetiology-and patient-specific matrix remodelling and fibrosis progression | Sara Campinoti | ![]() |
![]() |
|||
SAT-219 | Capillarization of tumor endothelial cells within tumor associated with T cell exclusion in an autochthonous mouse HCC model | Pin-Hung Lin | ![]() |
![]() |
|||
FRI-219 | Identification of unique liver NK cells in HBV and a new perspective on exhaustion-related NK cell phenotypes by single-cell RNA sequencing | Andre Boonstra | ![]() |
![]() |
|||
SAT-220 | Anti-CD122 antibody restores specific CD8 T cell response in non-alcoholic steatohepatitis and prevents hepatocellular carcinoma growth | Stéphanie Lacotte | ![]() |
![]() |
|||
WED-220 | Selective RNF41 restoration in hepatic macrophages from thioacetamide-induced fibrotic mice reduces liver fibrosis and inflammation | Alazne Moreno-Lanceta | ![]() |
![]() |
|||
FRI-220 | Impact of pegylated interferon-alpha in combination with Bulevirtide in HBV/HDV infected humanized mice | Maura Dandri | ![]() |
![]() |
|||
THU-220 | Sofosbuvir/Velpatasvir plus Ribavirin for chronic hepatitis C virus genotype 3 infected cirrhotic patients with or without HIV or HBV coinfection: real-world experience from southwest China | Ti Wu | ![]() |
![]() |
|||
THU-221 | Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemia and monoclonal gammopathy | Sofiia Gavrisheva | ![]() |
![]() |
|||
WED-221 | Therapeutic effect of recombinant human Cytoglobin against mouse liver fibrosis and stellate cell activation via ROS scavenger function and activation of JAK-STAT1 pathway | Norifumi Kawada | ![]() |
![]() |
|||
SAT-221 | Metabolic rewiring by increased mitochondrial respiration drives immunosuppression in liver cancer | Naroa Goikoetxea-Usandizaga | ![]() |
![]() |
|||
FRI-221 | Automated high-throughput image-based screen discovers members of the Akt serine/threonine kinase family as potential targets for treatment of hepatitis E virus infection | Mara Klöhn | ![]() |
![]() |
|||
THU-222 | Resistance-associated substitutions described after failure of anti-NS5A direct-acting antiviral treatment in 58 hepatitis C virus (HCV) infected patients in cameroon | Serge Tchamgoue | ![]() |
![]() |
|||
FRI-222 | The hepatitis E virus ORF2 protein forms amyloid-like protein aggregates which may be pathogenic in human neurons | Jungen Hu | ![]() |
![]() |
|||
SAT-222 | Drug screening for hepatocellular carcinoma: automating and miniaturizing organoid assays for drug screening | Tijmen Booij | ![]() |
![]() |
|||
WED-222 | Hepatic proteomic analysis identifies proteins linked to hepatic sympathetic neuronal degeneration and disorganization which promotes liver fibrosis in bile duct ligation murine model | SADAM BHAT | ![]() |
![]() |
|||
WED-223 | Functional and mechanistic role of lncRNA-C1 in cholestatic liver diseases | Joan Blázquez Vicens | ![]() |
![]() |
|||
THU-223 | Retreatment of patients experiencing failure with Hepatitis C direct-acting antivirals | Nessa Quinn | ![]() |
![]() |
|||
FRI-223 | Hepatitis B virus infected hepatocytes are resistant to cell death induction by virus-specific T cells | Emely Springer | ![]() |
![]() |
|||
SAT-223 | Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma | Paula Olaizola | ![]() |
![]() |
|||
SAT-224 | Cytokine levels and circulating DNA profiling in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma | Elena Vargas Accarino | ![]() |
![]() |
|||
FRI-224 | A novel imaging approach to investigate hepatitis E virus entry | Rebecca Fu | ![]() |
![]() |
|||
THU-224 | Efficacy and safety of Sofosbuvir Plus Daclatasvir bilayer tablet with or without Ribavirin in patients with chronic hepatitis C genotype 4 Infection | Mohamed Hassany | ![]() |
![]() |
|||
WED-224 | Evaluation of anti-fibrotic compounds effect in 3D human NASH model using quantitative digital pathology | Radina Kostadinova | ![]() |
![]() |
|||
WED-225 | Bulk and single cell RNA sequencing profiling of human hepatic stellate cells and the potential biomarkers for liver cirrhosis | Xu Liu | ![]() |
![]() |
|||
SAT-225 | Fibroblast growth factor 19 cooperates with Myc to promote liver carcinogenesis | José Ursic Bedoya | ![]() |
![]() |
|||
FRI-225 | CTLA4 inhibits anti-HBs secretion by blocking BCR signaling pathway in chronic hepatitis B infection | Minxin Mao | ![]() |
![]() |
|||
THU-225 | Impact of human gut microbiota from PSC patients on a mouse model of biliary disease | Petra Hradicka | ![]() |
![]() |
|||
SAT-226 | KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor | Pedro Miguel Rodrigues | ![]() |
![]() |
|||
FRI-226 | Transcriptional analysis of HBV infected liver after treatment with selgantolimod reveals longitudinal changes in both inflammation-related pathways and B cell receptor repertoire | Nikita Kolhatkar | ![]() |
![]() |
|||
WED-226 | Novel natural killer cell immunotherapy through synthesized Neuroligin-4 peptides improved liver fibrosis | Johnny Amer | ![]() |
![]() |
|||
SAT-227 | NLRP3 and IL-1, but not IL-18, are drivers of hepatocellular carcinoma in two independent murine models | Mona Peltzer | ![]() |
![]() |
|||
THU-227 | Pasteurized Akkermansia muciniphila inhibits fibrosis progression in mouse cirrhosis model and induces changes in the gut microbiome | Sung-Min Won | ![]() |
![]() |
|||
FRI-227 | HBs-directed T cell engager antibodies foster efficient recruitment of T cells and lead to strong reduction of hepatitis B virus infection in livers of human liver chimeric mice | Annika Volmari | ![]() |
![]() |
|||
WED-227 | Multimodal decoding of the mesenchymal landscape of human biliary fibrosis | David Wilson | ![]() |
![]() |
|||
WED-228 | Composition of the bile salt pool critically modulates liver fibrosis towards humanization of murine models of liver disease | Jingguo Li | ![]() |
![]() |
|||
THU-228 | Investigating the correlation of a poly-metabolic risk score to clinical features in non-alcoholic fatty liver disease patients throughout a faecal microbiota transplant clinical trial | Nadeen Habboub | ![]() |
![]() |
|||
SAT-228 | Infiltrating suppressive myeloid cells dominate the pediatric hepatoblastoma tumor immune microenvironment | Yvonne Vercoulen | ![]() |
![]() |
|||
FRI-228 | HBV and HDV interaction and variability in a superinfection mouse model: role of type I interferon | Maria Francesca Cortese | ![]() |
![]() |
|||
SAT-229 | Fatty Acid Synthase expression promotes the malignant features of cholangiocarcinoma cells and predicts shorter survival in patients | Mirella Pastore | ![]() |
![]() |
|||
FRI-229 | Rapid functional secretome analysis of HBV-specific T cells to guide clinical management of CHB patients | Nina Le Bert | ![]() |
![]() |
|||
WED-229 | Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer | Qi Ruan | ![]() |
![]() |
|||
THU-229 | Identifying the role of intestinal blood-vessel associated macrophages in vascular barrier integrity in cirrhosis | Lena Smets | ![]() |
![]() |
|||
WED-230 | Hepatic stellate cells from zone 1 do not transform into myofibroblasts but engage in capillarization in preclinical models of liver fibrosis | Andreas Friebe | ![]() |
![]() |
|||
FRI-230 | Identification and functional analysis of miR-4461 associated with hepatitis B-derived hepatocellular carcinomas | Masaya Sugiyama | ![]() |
![]() |
|||
THU-230 | Altered gut microbiome and stool bile acids in sarcopenia in cirrhosis | Benard Aliwa | ![]() |
![]() |
|||
SAT-230 | Positive effects of PARP-1 inhibition in KRAS-mutated intrahepatic cholangiocarcinoma is mediated by CHK1 kinase | Darko Castven | ![]() |
![]() |
|||
WED-231 | Role of the hepatocyte Epidermal Growth Factor Receptor (EGFR) pathway on the cellular interactome within the liver fibrotic niche | Isabel Fabregat | ![]() |
![]() |
|||
FRI-231 | Reduced hepatic bile acid uptake and blocked hepatitis B viral infection after oral administration of novel small molecule inhibitors of the sodium taurocholate co-transporting polypeptide (NTCP) | Stan Van De Graaf | ![]() |
![]() |
|||
THU-231 | The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency | Francesco Annunziata | ![]() |
![]() |
|||
SAT-231 | Sortilin-driven cancer secretome enhances self-renewal and metastasis of hepatocellular carcinoma via de novo lipogenesis | Kwan Shuen Chan | ![]() |
![]() |
|||
FRI-232 | The divergent C-termini of L-HDAg regulates the dynamic life cycle of hepatitis D virus | Hongbo Guo | ![]() |
![]() |
|||
SAT-232 | Identification and experimental validation of druggable epigenetic targets in hepatoblastoma | Alex Claveria-Cabello | ![]() |
![]() |
|||
THU-233 | Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis | Jasmohan S Bajaj | ![]() |
![]() |
|||
WED-233 | MCPIP1 inhibits hepatic stellate cell activation in autocrine and paracrine manner | Jerzy Kotlinowski | ![]() |
![]() |
|||
SAT-233 | Tumor-extrinsic Axl expression shapes an inflammatory microenvironment independent of tumor-cell promoting Axl signaling | Kristina Breitenecker | ![]() |
![]() |
|||
FRI-233 | A novel recombinant HBV based ion system allows for a systematic genomic knock-out screening and the identification of host factors involved in HBV infection | Bo-Hung Liao | ![]() |
![]() |
|||
WED-234 | The proto-oncogene Bmi1 is a novel regulator of the activated hepatic stellate phenotype | Kim Su | ![]() |
![]() |
|||
THU-234 | Edible exosomes oral administration restores gut homeostasis and reduces systemic ammonia level in rodent model | P. Debishree Subudhi | ![]() |
![]() |
|||
FRI-234 | miR-26a targets USP15 to robustly suppress hepatitis E virus replication via the enhancement of RIG-I-mediated type I interferon response | Wenshi Wang | ![]() |
![]() |
|||
FRI-235 | Altered metabolic program initiates immune activation leading to hepatitis B surface antigen seroconversion in mild and severe hepatitis B reactivation patients | Jayesh Kumar Sevak | ![]() |
![]() |
|||
WED-235 | 3D engineered perihepatic endothelial cell implants reduce fibrosis and inflammation, boosting liver regeneration in fibrotic hepatectomized mice | Mireia Medrano-Bosch | ![]() |
![]() |
|||
THU-235 | Microbiota-targeted interventions in the gut-liver axis for chronic liver disease of DUAL etiology | Raquel Benedé | ![]() |
![]() |
|||
SAT-235 | PSMP inhibits HCC progression by regulating the polarization of tumor-associated macrophages via the PI3K/Akt pathway | Shaoping She | ![]() |
![]() |
|||
THU-236 | The novel class of microbially conjugated bile salts activate the main host bile salt receptors FXR and TGR5 | Ümran Ay | ![]() |
![]() |
|||
WED-236 | Artificial Intelligence analysis of liver biopsies in pre-cirrhotic NASH: qFibrosis explained | Pol Boudes | ![]() |
![]() |
|||
FRI-236 | HBsAg level defines different clinical phenotypes of chronic HBV infection eAg(-) related to the quality of the HBV-specific CD8 cell response | Henar Calvo Sánchez | ![]() |
![]() |
|||
THU-237 | The bile acid chenodeoxycholic acid increases muscle insulin sensitization via FOXO1 | Roshni Singaraja | ![]() |
![]() |
|||
SAT-237 | A patient-derived hepatocellular carcinoma multicellular spheroid system modeling the tumor microenvironment for drug development and precision medicine | Emilie Crouchet | ![]() |
![]() |
|||
WED-237 | Advancement of artificial intelligence in digital pathology: from exploratory endpoint to primary endpoint in non-alcoholic steatohepatitis clinical trials | Dean Tai | ![]() |
![]() |
|||
FRI-237 | Chimeric bio-nanoparticles induce targeted HBeAg seroclearance in a HBV hydrodynamic injection mouse model | Peter Revill | ![]() |
![]() |
|||
FRI-238 | Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver | Kusum Gupta | ![]() |
![]() |
|||
THU-238 | Characterization of pattern recognition receptor expression for regulating myeloid cell responses in the gut-liver axis in non alcoholic fatty liver disease and cholangiopathies | Alix Bruneau | ![]() |
![]() |
|||
WED-238 | Repeatability and reproducibility assessment and its acceptable standard error of means for qFibrosis system in multi-site NASH clinical trials | Jason Pik Eu Chang | ![]() |
![]() |
|||
SAT-238 | Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells | Ainhoa Lapitz | ![]() |
![]() |
|||
FRI-239 | A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice | Jin Hong | ![]() |
![]() |
|||
WED-239 | The anti-HIV drug Rilpivirine downregulates migration and proliferation of activated hepatic stellate cells: relevance for the purpose of drug repurposing in liver fibrosis | Nadezda Apostolova | ![]() |
![]() |
|||
THU-239 | Gut microbial proteomic changes from commensal bacteria are associated with development of first decompensation in cirrhosis | Jasmohan Bajaj | ![]() |
![]() |
|||
WED-240 | Is the fibrosis phenotype in pre- and post-menopausal F2/F3 women the same? | Isabel Fernández-Lizaranzu | ![]() |
![]() |
|||
SAT-240 | Carbohydrate restriction inhibits tumor progression in a hepatocellular carcinoma mouse model | Merve Erdem | ![]() |
![]() |
|||
THU-240 | Altered levels of secondary bile acids in enterohepatic circulation impairs liver regeneration in a rat model of partial hepatectomy | Impreet Kaur | ![]() |
![]() |
|||
FRI-240 | Impact of cirrhosis and long-term follow-up on the inflammatory milieu after HCV elimination | Moana Witte | ![]() |
![]() |
|||
FRI-241 | Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models | Tongfei Wu | ![]() |
![]() |
|||
THU-241 | Gut-liver crosstalk in hepatocellular carcinoma and non-ive beta-blockers: is there a link? | Yasmeen Attia | ![]() |
![]() |
|||
SAT-241 | Efficacy of HBV-TCR T cell therapy to eliminate circulating HBV-HCC cells in immunosuppressed whole blood | Anthony Tan | ![]() |
![]() |
|||
WED-241 | Amelioration of CCl4 induced hepatic fibrosis in-vitro and in-vivo by bone marrow derived mesenchymal stromal cells lysate loaded nanostructured lipid carriers | Sabeen Malik | ![]() |
![]() |
|||
THU-242 | Phascolarctobacterium as a predictor for survival in cirrhotic patients | Rosa Haller | ![]() |
![]() |
|||
WED-242 | The Long-Term Culture of Stem Cell-Derived Hepatic Stellate Cells and Liver Sinusoidal Endothelial Cells | Ingrid Wilhelmsen | ![]() |
![]() |
|||
SAT-242 | RBCK1 promotes cancer stemness and sorafenib resistance by restoring Numb/Notch1 axis independently of its ubiquitin ligase activity in hepatocellular carcinoma | Peng Chen | ![]() |
![]() |
|||
FRI-242 | The role of gamma delta T cells in chronic hepatitis B virus infection | Katja Steppich | ![]() |
![]() |
|||
FRI-243 | Recombinant hepatitis E viruses harboring a split luciferase tag in the ORF2 capsid protein | Maliki Ankavay | ![]() |
![]() |
|||
WED-243 | 3D Extracellular matrix human liver hydrogels for the investigation of genetic variants in hepatic stellate cells | Elisabetta Caon | ![]() |
![]() |
|||
SAT-243 | Pegozafermin inhibits NASH-induced hepatocellular carcinoma in the STAM mouse model | Maya Margalit | ![]() |
![]() |
|||
THU-243 | Long-term benefit of direct-acting antivirals on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection | NATTHAYA CHUAYPEN | ![]() |
![]() |
|||
FRI-244 | Identification of resistance-associated variants after sofosbuvir treatment in chronic hepatitis E patients | André Gömer | ![]() |
![]() |
|||
THU-244 | The intestinal immune barrier is associated with bile acid pool modifications in mice suffering from non-alcoholic steatohepatitis | Simon Peschard | ![]() |
![]() |
|||
WED-244 | Analysis of alpha adrenoblocker as antifibrotic and hepatoprotective agent in a Wistar rat model of cirrhosis | Mariana Yazmin Medina Pizańo | ![]() |
![]() |
|||
SAT-244 | Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis | Maria Mercado-Gómez | ![]() |
![]() |
|||
FRI-245 | HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg(-) predicts long-term HBV control | Henar Calvo Sánchez | ![]() |
![]() |
|||
SAT-245 | Exploiting RuvBL1 as a target to improve mTOR -driven hepatocarcinogenesis in mice | Alice Guida | ![]() |
![]() |
|||
WED-245 | MicroRNA-29b involves in the progression of NAFLD to liver fibrosis | qihua duan | ![]() |
![]() |
|||
THU-245 | Identification of gut microbiota signature for differentiating between viral- and non-viral related hepatocellular carcinoma | Pisit Tangkijvanich | ![]() |
![]() |
|||
FRI-246 | Nucleotide analogue therapy does not reverse the hyperexpression of innate-like markers on activated T cells consistent with immunopathology in chronic hepatitis B | Loey Mak | ![]() |
![]() |
|||
WED-246 | Novel Pathways implicated in the seladelpar-mediated reductions of established liver fibrosis are identified from RNA-SEQ data using plex search and two independent mouse pharmacology datasets | Edward Cable | ![]() |
![]() |
|||
SAT-246 | Determination of human polyploid hepatocellular carcinoma by pathological image diagnosis utilizing artificial intelligence | Tomonori Matsumoto | ![]() |
![]() |
|||
THU-246 | Pemafibrate modulates microbiota profile in a dietary model of fatty liver in rat | Roger Bentanachs | ![]() |
![]() |
|||
WED-247 | Cathepsin D expressed in hepatocytes does not participate in the development of liver fibrosis after chronic CCl4 administration | Paloma Ruiz-Blázquez | ![]() |
![]() |
|||
FRI-247 | Baseline plasma lipidome correlates with direct-acting antiviral therapy non-response for HCV in HIV-HCV coinfected patients | VASUNDHRA BINDAL | ![]() |
![]() |
|||
SAT-247 | Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification | Leidy Estefanía Zapata-Pavas | ![]() |
![]() |
|||
SAT-248 | Chromosome engineering and CRISPR-Cas9 viability screening reveals increased metastatic capacity targetable by patient-specific synthetic lethality | Stephanie Roessler | ![]() |
![]() |
|||
FRI-248 | Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study | Krishna Patel | ![]() |
![]() |
|||
WED-248 | Myeloperoxidase from neutrophile granulocytes accomplish destruction of Schistosoma mansoni eggs | Ricarda Nadja Soelter | ![]() |
![]() |
|||
THU-249 | Inhibition of the renal apical sodium-dependent bile acid transporter prevents cholemic nephropathy | Ahmed Ghallab | ![]() |
![]() |
|||
SAT-249 | Expression and role of the metabotropic glutamate receptor type 3 in hepatocarcinoma | Isabel Méndez | ![]() |
![]() |
|||
FRI-249 | Epigenetic modulation by DNA methyltransferase inhibition may enhance the effect of immune checkpoint inhibitors to restore HBV-specific T cell responses | Melanie Urbanek-Quaing | ![]() |
![]() |
|||
WED-249 | Identification of pseudo-immune tolerance for chronic hepatitis B patients : development and validation of a non-invasive prediction model | Shuo Li | ![]() |
![]() |
|||
WED-250 | The anti-fibrotic efficacy of Adelmidrol depends in the level of hepatic ppar gama | Huanyu Xiang | ![]() |
![]() |
|||
FRI-250 | Reduction in quantity and function of HBcAg-specific B cells indicates the response to anti-viral therapy in chronic HBV-infected patients receiving ETV or TDF treatment | Li Wang | ![]() |
![]() |
|||
SAT-250 | The rs72613567: TA polymorphism in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) is associated with survival benefit after development of hepatocellular carcinoma | Stephan Buch | ![]() |
![]() |
|||
THU-250 | Common, non-pathogenic variants in genes from monogenic disorders confer additional risk of liver injury later in life | Jake Mann | ![]() |
![]() |
|||
WED-251 | Predicting the current and future prevalence of primary sclerosing cholangitis with inflammatory bowel disease (PSC-IBD): a nationwide population-based study | Palak Trivedi | ![]() |
![]() |
|||
SAT-251 | Selective inhibition of human -catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma | Jin Hong | ![]() |
![]() |
|||
FRI-251 | Extracellular vesicle-derived microRNA signature in chronic hepatitis C patients with different stages of liver fibrosis | Amanda Fernández Rodríguez | ![]() |
![]() |
|||
FRI-252 | Prophylactic vaccine against hepatitis D virus (HDV) superinfection | Matti Sällberg | ![]() |
![]() |
|||
WED-252 | Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC | Richard Thompson | ![]() |
![]() |
|||
THU-252 | Human cytomegalovirus (HCMV) infection of macrophages induced abnormal development of cholangiocytes in an organoid co-culture model for biliary atresia | Syed Mushfiqur Rahaman | ![]() |
![]() |
|||
THU-253 | Bacterial vesicles associated virulence factors and epitope mimics in autoimmune hepatitis patients | Swati Thangariyal | ![]() |
![]() |
|||
WED-253 | Dominant strictures in patients with primary sclerosing cholangitis: comparison between old and new definition | Andrea Tenca | ![]() |
![]() |
|||
FRI-253 | Rat hepatitis E virus infection in a rat model has multiphasic viral replication kinetics | Harel Dahari | ![]() |
![]() |
|||
SAT-253 | Hepatitis B surface antigen impairs endoplasmic reticulum stress-related autophagic flux via down-regulation of LAMP2, thereby participating in hepatocarcinogenesis | Ruth Broering | ![]() |
![]() |
|||
SAT-254 | RuvBL1 is required for mitochondrial integrity and supports the metabolic reprogramming of HCC cells | Tommaso Mello | ![]() |
![]() |
|||
FRI-254 | (N)one size fits all: Genotype-matched analysis of different disease phases of chronic hepatitis B virus infection | Kai-Henrik Peiffer | ![]() |
![]() |
|||
WED-254 | Mitochondrial dysfunction and lipid alterations in primary sclerosing cholangitis | Mette Vesterhus | ![]() |
![]() |
|||
THU-254 | Transcriptomic analysis of biliary atresia finds ongoing hepatic hematopoiesis with elevated IGF2 | Jake Mann | ![]() |
![]() |
|||
THU-255 | Immune cell incompetence and hepatocyte differentiation defects explain mild fibrosis in a model of Alagille syndrome | Jan Maek | ![]() |
![]() |
|||
FRI-255 | A primary human hepatocyte system to evaluate antisense oligonucleotide activity against clinically identified hepatitis b virus variants that contain mismatches in the bepirovirsen binding site | Alexander Koenig | ![]() |
![]() |
|||
WED-255 | The socioeconomic status, epidemiology, and outcomes of people living with primary sclerosing cholangitis - inflammatory bowel disease in Ontario, Canada: a two-decade analysis | Kristel Leung | ![]() |
![]() |
|||
SAT-255 | Combining non-ive beta-blockers with sorafenib in HCC: targeting the culprits of metastasis | TASNIM Mahmoud MAHMOUD | ![]() |
![]() |
|||
WED-256 | Baseline characteristics and risk profiles of 1111 patients with primary biliary cholangitis (PBC) in need of second-line therapy | Gideon Hirschfield | ![]() |
![]() |
|||
THU-256 | SARS-CoV-2 productively infects human hepatocytes and induces cell death | Cho-Chin Cheng | ![]() |
![]() |
|||
FRI-256 | Application of magnetic nanoparticle on boosting HBV infection system effectiveness | Bo-Hung Liao | ![]() |
![]() |
|||
SAT-256 | Investigation of novel hepatoblastoma chemosensitizers based on the inhibition of ABC pumps-mediated drug efflux | Rocio IR Macias | ![]() |
![]() |
|||
WED-257 | Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome | Erica Walker | ![]() |
![]() |
|||
FRI-257 | A new glyco-biomarker for measuring infectious hepatitis B virus targeting surface antigen glycan isomer (HBsAgGi) | Kiyohiko Angata | ![]() |
![]() |
|||
THU-257 | Characterizing the role of human cytomegalovirus infection associated with biliary atresia | Allen KL Cheung | ![]() |
![]() |
|||
SAT-257 | Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver | Juan Gao | ![]() |
![]() |
|||
SAT-258 | Development of new personalized therapies targeting VDAC1 in intrahepatic cholangiocarcinoma using patient-derived liver organoids | SILVIA DE SIERVI | ![]() |
![]() |
|||
WED-258 | Non-adherence to standard pharmacotherapy in autoimmune hepatitis is associated with over-the-counter medication and steroid treatment. Results from the ERN online survey | Ewa Wunsch | ![]() |
![]() |
|||
THU-258 | Rescue of PKU disease phenotype using hepatic progenitor by cytosine base editor and prime editor in vitro | Myounghoi Kim | ![]() |
![]() |
|||
FRI-259 | Quadruple mutation GCAC1809-1812TTCT leads to a better prognosis by decreasing HBV-mediated fibrogenic activity | Esra Görgülü | ![]() |
![]() |
|||
THU-259 | ARBM-101 as an emerging potent therapeutic option for Wilson disease | Hans Zischka | ![]() |
![]() |
|||
WED-259 | Vibration-controlled transient elastography predicts clinical outcomes in patients with autoimmune hepatitis | Aldo Montano-Loza | ![]() |
![]() |
|||
SAT-260 | Capturing hepatocyte specific extracellular vesicles | Richell Booijink | ![]() |
![]() |
|||
FRI-260 | Growth factor stimulation enhances NTCP expression and improves in vitro HBV infection in hepatoma cells | Rodrigue Kamga Wouambo | ![]() |
![]() |
|||
THU-260 | Novel pathogenic ABCC2 variants identified in patients with Dubin-Johnson syndrome and functional evidence in abnormal bilirubin metabolism | Wenting Tan | ![]() |
![]() |
|||
WED-260 | RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease | Ciro Celsa | ![]() |
![]() |
|||
SAT-261 | Circular RNA hsa_circ_0062682 promotes oncogenesis in hepatocellular carcinoma and binds to YBX1 | Tadeja Rezen | ![]() |
![]() |
|||
THU-261 | Albumin levels are associated with portal hypertension in patients with porto sinusoidal vascular disorder | Lucia Lapenna | ![]() |
![]() |
|||
WED-261 | Clinical significance of F-actin IgA and gliadin IgA antibodies in primary sclerosing cholangitis | Ewa Wunsch | ![]() |
![]() |
|||
FRI-261 | Hepatitis B virus antigens induce a dramatic LPS-like activation of inflammasome dependent on viral variability | Eve Todesco | ![]() |
![]() |
|||
THU-262 | Genetic modifiers of liver phenotypes in pediatric Wilson disease: liver biopsy and transient elastography based study | Marcin Krawczyk | ![]() |
![]() |
|||
FRI-262 | Host Sequence snatching identified in-vivo enhances hepatitis E viral replication | Daniel Todt | ![]() |
![]() |
|||
WED-263 | A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors | Mar Riveiro | ![]() |
![]() |
|||
FRI-263 | Thiourea derivatives exhibit antiviral property by inhibiting hepatitis B virus DNA replication and HBx-induced gene transcription | Jitendra Kumar | ![]() |
![]() |
|||
SAT-263 | Relevance of hypoxia-inducible factor 1 alpha in hepatocellular carcinoma: clinical and pre-clinical analysis | Tania Payo-Serafín | ![]() |
![]() |
|||
THU-263 | In vivo adenine base editing reverts C282Y in an HFE- mouse model and improves iron metabolism | Simon Krooss | ![]() |
![]() |
|||
FRI-264 | Fas/Fas-ligand induced apoptosis of CD8() lymphocytes in the placenta of women with chronic hepatitis B plays a twofold role in the protection of fetus | Dionysia Mandilara | ![]() |
![]() |
|||
WED-264 | Impact of the metabolic profile on the response to ursodeoxycholic acid in patients with primary biliary cholangitis: results of the ColHai registry | Andrea González Pascual | ![]() |
![]() |
|||
SAT-264 | Therapeutic targets associated with conserved subtypes of hepatocellular carcinoma | Ju-Seog Lee | ![]() |
![]() |
|||
THU-264 | Alpha-1 antitrypsin inclusions sequester 78 kDa glucose-regulated protein in a bile-acid inducible manner | Igor Spivak | ![]() |
![]() |
|||
WED-265 | Chronic pruritus is associated with altered nerve fiber function and anatomy in patients with cholestatic hepatobiliary diseases | Miriam Düll | ![]() |
![]() |
|||
THU-265 | Human induced pluripotent stem cells-derived hepatocytes: a very effective tool for functional studies of rare liver diseases | Benedetta Blarasin | ![]() |
![]() |
|||
FRI-265 | Intrahepatic hepatitis B virus cccDNA amount and transcriptional activity in a well-characterized cohort of Gambian chronically infected patients: correlation with emerging serum viral markers | Barbara Testoni | ![]() |
![]() |
|||
SAT-266 | Prognostic and genomic portrait of hepatocellular carcinomas with bi-allelic inactivation of RB1 gene | Jihyun An | ![]() |
![]() |
|||
WED-266 | Vitamin D associates with clinical outcomes in patients with primary sclerosing cholangitis | Aldo Montano-Loza | ![]() |
![]() |
|||
FRI-266 | Hepatitis B pre-genomic RNA level has a prospective supporting role for predicting the outcomes of the hepatitis B virus inactive carrier phase | Prooksa Ananchuensook | ![]() |
![]() |
|||
THU-267 | Identification of correctors for traffic-defective ABCB4 variants by a high-throughput screening approach | Mounia Lakli | ![]() |
![]() |
|||
FRI-267 | Droplet digital PCR can quantify cccDNA in plasma of naive chronic HBV infected patients with low HBsAg levels | Ravinder Singh | ![]() |
![]() |
|||
WED-267 | Modulation of alkaline phosphatase levels by obeticholic acid in clinical trials and cultured human hepatocytes | Kris Kowdley | ![]() |
![]() |
|||
SAT-267 | Bacterial exosomes cargo vaccine with EpCAM aptamers for targeting hepatocellular carcinoma | Pushpa Yadav | ![]() |
![]() |
|||
WED-268 | Risk of death, liver transplant or hepatic decompensation in primary biliary cholangitis increases with increased duration and degree beyond established clinical thresholds for hepatic biomarkers and fibrosis scores | Kris Kowdley | ![]() |
![]() |
|||
SAT-268 | Poor sorafenib response in hepatocellular carcinoma patients is mediated by hypoxia-related 14-3-3 scaffolding proteins and induces a shift in tumor immune micromilieu | Jovana Castven | ![]() |
![]() |
|||
THU-268 | Schistosoma mansoni infection-associated oxidative stress triggers hepatocellular proliferation | Verena von Bülow | ![]() |
![]() |
|||
FRI-268 | COVID-19 vaccination alters NK cell dynamics and transiently reduces HBsAg titers among patients with chronic hepatitis B | Hyunjae Shin | ![]() |
![]() |
|||
WED-269 | Accuracy of controlled attenuation parameter (CAP) measurement for the detection of steatosis in autoimmune liver diseases | Silja Steinmann | ![]() |
![]() |
|||
SAT-269 | RBCK1 promotes the stabilization of HBx by linear ubiquitination to drive the progression of HBV-associated hepatocellular carcinoma | Zheyu Dong | ![]() |
![]() |
|||
FRI-269 | Serum metabolite revel mirochondrial dysfunction and energy metablism disruption in chronic hepatitis C virus infection | Amar Deep | ![]() |
![]() |
|||
WED-270 | Risk of decompensated cirrhosis in patients with primary biliary cholangitis under first, second and third-line therapies | Ana Lucena | ![]() |
![]() |
|||
FRI-270 | Characterization of biomarker kinetics in a novel in vitro HBV infection model with the cell line HepG2-hNTCP-sec revealed stable HBsAg composition during short- and long-term infection up to four weeks | Maria Pfefferkorn | ![]() |
![]() |
|||
SAT-270 | Molecular determinants of period-specific recurrences in patients with surgically resected hepatocellular carcinoma | Jihyun An | ![]() |
![]() |
|||
THU-270 | Clinical characteristics and pathogenic mechanism of five new ABCB4 missense mutations in progressive familial intrahepatic cholestasis type 3 | Yuhang Weng | ![]() |
![]() |
|||
SAT-271 | Monitoring the local HCC immune landscape by fine needle aspiration | Gloryanne Aidoo-Micah | ![]() |
![]() |
|||
FRI-271 | Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B | Magnus Illum Dalegaard | ![]() |
![]() |
|||
THU-271 | Immortalized patient-derived cell models for analysis of liver disease | Matthias Weiand | ![]() |
![]() |
|||
WED-271 | Improved survival with regular surveillance imaging in patients with primary sclerosing cholangitis | Natassia Tan | ![]() |
![]() |
|||
WED-272 | Relative enhancement and spleen volume predict clinical outcomes in primary sclerosing cholangitis | Laura Cristoferi | ![]() |
![]() |
|||
SAT-272 | Clinicopathological analysis of polyploidization in human hepatocellular carcinoma and the development of an evaluation methodology | Takanori Matsuura | ![]() |
![]() |
|||
THU-272 | CRISPR/Cas9-mediated gene correction of Wilson disease H1069Q mutation in an iPS cell model | Vanessa Sandfort | ![]() |
![]() |
|||
FRI-272 | An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients | Yannick Debing | ![]() |
![]() |
|||
SAT-273 | Epigenetic reprogramming synergizes with PD-1/PD-L1 inhibition for cell-targeted therapy in hepatocellular carcinoma | Loraine Kay Cabral | ![]() |
![]() |
|||
WED-273 | Hepatic steatosis in patients with autoimmune hepatitis: relationship with corticosteroid treatment and long-term outcome | Sarah Flatley | ![]() |
![]() |
|||
THU-273 | Liver transplantation for Wilson disease: single center experience | Amnah Alhanaee | ![]() |
![]() |
|||
FRI-273 | Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab | Bernhard Scheiner | ![]() |
![]() |
|||
WED-274 | Antibodies against multiple post-translationally modified proteins aid in diagnostic work-up of autoimmune hepatitis and associate with complete biochemical response to treatment | Anna Stoelinga | ![]() |
![]() |
|||
FRI-274 | Baveno VI and VII criteria are not suitable for screening of large size esophageal varices and clinically significant portal hypertension in patients with HCC | Manon Allaire | ![]() |
![]() |
|||
THU-274 | Effects of tetrathiomolybdate, trientine, and penicillamine on intestinal copper uptake: a randomized placebo-controlled 64Cu PET/CT study | Frederik Teicher Kirk | ![]() |
![]() |
|||
SAT-275 | Functional and mechanistic role of lncRNA-A1 in cholangiocarcinoma | Alberto Tinahones | ![]() |
![]() |
|||
THU-275 | Four-fold increased mortality rate in patients with Wilsons disease: a population-based cohort study of 151 patients | Hannes Hagström | ![]() |
![]() |
|||
FRI-275 | Multi-omic large scale risk prediction for hepatocellular carcinoma | Jan Clusmann | ![]() |
![]() |
|||
THU-276 | Risk of severe liver disease and hepatocellular carcinoma in hemochromatosis: a Swedish nationwide cohort study | Hanne ström | ![]() |
![]() |
|||
WED-276 | Collagen proportionate area is associated with adverse clinical outcomes and allows risk stratification of patients with autoimmune hepatitis | Neil Halliday | ![]() |
![]() |
|||
SAT-276 | TCR T cells to treat recurrent HCC after liver transplantation | Dave Sprengers | ![]() |
![]() |
|||
FRI-276 | Macrotrabecular-massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocellular carcinoma treated with liver resection | Ezequiel Mauro | ![]() |
![]() |
|||
WED-277 | Patient reported gaps between current practice and new practice guidelines for primary sclerosing cholangitis | Annika Bergquist | ![]() |
![]() |
|||
FRI-277 | GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction of hepatocellular carcinoma (HCC) development in patients with compensated advanced chronic liver disease (cACLD): a 12-year prospective study | Valentina Baldaccini | ![]() |
![]() |
|||
WED-278 | The changing clinical phenotype of autoimmune hepatitis across the millennium. A 40 year cohort study in Bologna, Italy | Marco Ferronato | ![]() |
![]() |
|||
THU-278 | Blood markers of immune activation help distinguish paediatric activated T-cell hepatitis from other causes | Tamir Diamond | ![]() |
![]() |
|||
SAT-278 | Nuclear translocation of YAP drives BMI1-associated hepatocarcinogenesis in hepatitis B virus infection | Ruth Broering | ![]() |
![]() |
|||
FRI-278 | Alternative surveillance using CT/MR improves clinical outcomes by detecting early-stage hepatocellular carcinoma in High-risk patients with chronic hepatitis B | Dong Ho Lee | ![]() |
![]() |
|||
THU-279 | Incidence of hemochromatosis in HFE p.H63D homozygote and p.C282Y/H63D compound heterozygote individuals | Lorenz Michael Pammer | ![]() |
![]() |
|||
FRI-279 | Presence of esophageal varices regardless their size is associated with overall survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab | Philippe Sultanik | ![]() |
![]() |
|||
WED-279 | Hospitalization Outcomes and Mortality of COVID-19 in Primary Sclerosing Cholangitis Liver Transplant Patients | Stela Celaj | ![]() |
![]() |
|||
WED-280 | INTEGRIS-PSC phase 2a study: evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitis | Gideon Hirschfield | ![]() |
![]() |
|||
FRI-280 | A machine learning-enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease (cACLD) | Sara Ascari | ![]() |
![]() |
|||
SAT-280 | Genetic variant in the hepatic sterol transporter is associated with increased gallstone risk in obese patients and with higher odds of developing gallbladder cancer in general | Marcin Krawczyk | ![]() |
![]() |
|||
THU-280 | Does earlier introduction of azathioprine result in a reduced cumulative dose of corticosteroid therapy in the treatment of autoimmune hepatitis (AIH) and does this result in the same degree of biochemical response? | Sital Shah | ![]() |
![]() |
|||
WED-281 | Peri-procedural complications in people with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography - evaluating a high-volume programme | Kristel Leung | ![]() |
![]() |
|||
SAT-281 | CRISPR-engineered cholangiocarcinoma tumoroids generation from chemically-derived hepatic progenitor organoid for disease modelling | Michael Adisasmita | ![]() |
![]() |
|||
THU-281 | Impact of alcohol consumption on the liver phenotype in alpha-1 antitrypsin deficiency | Malin Fromme | ![]() |
![]() |
|||
WED-282 | Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC | Erica Walker | ![]() |
![]() |
|||
FRI-282 | Validation of serum biomarker panels for early HCC detection: results from a large prospective European and Latin American multicenter study | Andre Boonstra | ![]() |
![]() |
|||
THU-282 | First nationwide genetic study on Wilson disease (spanish Wilson registry): high diversity in mutations and in use of genetic evaluation, association with clinical data and influence on diagnosis and health costs | Pablo Alonso Castellano | ![]() |
![]() |
|||
SAT-282 | The immunological impact of Axl/TGF-β signaling in HCC | Gregor Ortmayr | ![]() |
![]() |
|||
THU-283 | Myeloproliferative neoplasms and splanchnic vein thrombosis: results of a long-term UK prospective cohort study | Rupen Hargreaves | ![]() |
![]() |
|||
SAT-283 | Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma | Luca Fabris | ![]() |
![]() |
|||
FRI-283 | A novel AFP-M2BPGi score has better performance than CRAFITY score in predicting survival for patients with predominantly viral hepatocellular carcinoma undergoing immunotherapy | Pei-Chang Lee | ![]() |
![]() |
|||
WED-283 | Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD) | Richard Dean | ![]() |
![]() |
|||
FRI-284 | Implication of patients experience in the liver cancer multidisciplinary approach | Gemma Iserte | ![]() |
![]() |
|||
WED-284 | Spleen stiffness measurement predicts decompensation risk in primary biliary cholangitis | Giulia Francesca Manfredi | ![]() |
![]() |
|||
THU-284 | Efficacy and safety outcomes with odevixibat treatment: Pooled data from the phase 3 ASSERT and ASSERT-EXT studies in patients with Alagille syndrome | Madeleine Aumar | ![]() |
![]() |
|||
SAT-285 | Investigation of optimization model for predicting ICI treatment efficacy on contrast-enhanced CT images of hepatocellular carcinoma using AI | yasuhiko nakao | ![]() |
![]() |
|||
WED-285 | Rechallenge with anti-PD1 monotherapy after checkpoint inhibitor hepatitis is associated with low rates of recurrence: a single centre study | Lucy Walker | ![]() |
![]() |
|||
FRI-285 | Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion | Lorenz Balcar | ![]() |
![]() |
|||
FRI-286 | Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study | Alina Pascale | ![]() |
![]() |
|||
WED-286 | Transient elastography measurements of spleen stiffness are associated with treatment response to ursodeoxycholic acid in primary biliary cholangitis | ilkay ergen | ![]() |
![]() |
|||
SAT-286 | CD40 expression in liver cancer cells is upregulated by CD4T cells through IFN-gamma and ERK 1/2 pathway | Hanh Ngo Vinh | ![]() |
![]() |
|||
WED-287 | Associations between patient-reported outcomes, liver inflammation and fibrosis in patients with primary sclerosing cholangitis | Emilie Eifer Mller | ![]() |
![]() |
|||
SAT-287 | Potential biomarkers predicting ferroptosis sensitivity in hepatocellular carcinoma | Wan Seob Shim | ![]() |
![]() |
|||
THU-287 | High-dose oral thiamine was not superior to placebo in reducing fatigue in patients with primary biliary cholangitis: a randomised, double-blinded, placebo-controlled crossover trial | Palle Bager | ![]() |
![]() |
|||
FRI-288 | A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced NAFLD: first report | Serena Pelusi | ![]() |
![]() |
|||
SAT-288 | Genetic biomarkers for sorafenib response in patients with hepatocellular carcinoma | Lydia Giannitrapani | ![]() |
![]() |
|||
THU-288 | Cancer incidence and survival in HFE hemochromatosis A population-based cohort study | Lorenz Michael Pammer | ![]() |
![]() |
|||
WED-288 | Non-invasive evaluation of progression to primary biliary cholangitis in patients with positive antimitochondrial antibodies | Alvaro Diaz-Gonzalez | ![]() |
![]() |
|||
THU-289 | Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database | Bettina Hansen | ![]() |
![]() |
|||
SAT-289 | Association between gadoxetic acid-enhanced MR imaging, organic anion transporters, and farnesoid X receptor in benign focal liver lesions | Alicia Furumaya | ![]() |
![]() |
|||
WED-289 | Does fibrosis regression in autoimmune hepatitis require histological as well as biochemical remission? | Sarah Flatley | ![]() |
![]() |
|||
FRI-289 | Sex disparities in presentation and outcome of hepatocellular carcinoma: results of a nationwide study in France | Charlotte Costentin | ![]() |
![]() |
|||
FRI-290 | Artificial intelligence assisted qFibrosis as a pathological biomarker to evaluate disease severity in patients with hepatocellular carcinoma | Dean Tai | ![]() |
![]() |
|||
SAT-290 | Comprehensive analysis of single-cell and bulk RNA sequencing data identifies antioxidant-1 as a novel immune biomarker associated with immune cell infiltration in hepatocellular carcinoma metastasis | Ruijia Liu | ![]() |
![]() |
|||
THU-290 | Efficacy and safety of vaccination againts SARS-CoV-2 in patients with vascular liver disease | Valeria Perez-Campuzano | ![]() |
![]() |
|||
WED-290 | Predictive models of treatment benefit in patients with autoimmune hepatitis and decompensated cirrhosis at diagnosis | Pinelopi Arvaniti | ![]() |
![]() |
|||
SAT-291 | PD-L1 small molecule inhibitors and Paclitaxel orchestrating CD8 cell cytotoxicity via tumor-associated macrophages: a personalized HCC immunotherapeutic approach | Israa Helal | ![]() |
![]() |
|||
FRI-291 | Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology | Andre Boonstra | ![]() |
![]() |
|||
THU-291 | Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group | Carla Fiorella Murillo Perez | ![]() |
![]() |
|||
WED-291 | Anti-Saccharomyces cerevisiae antibodies predict severe liver disease and advanced fibrosis in patients with primary sclerosing cholangitis and inflammatory bowel disease | Lian Bannon | ![]() |
![]() |
|||
FRI-292 | Add-on benefits of AFP-L3, PIVKA-II and GALAD score to ultrasound plus AFP for surveillance of hepatocellular carcinoma | Supot Nimanong | ![]() |
![]() |
|||
THU-292 | Deep tissue exposure of antibiotics at the target site of infection in patients with cystic liver disease: a randomized pharmacokinetic trial | Marten A. Lantinga | ![]() |
![]() |
|||
WED-292 | Increased risk of osteoporotic fracture in patients with autoimmune hepatitis | Jihye Lim | ![]() |
![]() |
|||
SAT-292 | Intermittent fasting improves tumor-directed drug delivery by caveolar-mediated endocytosis | Svea Becker | ![]() |
![]() |
|||
WED-293 | Prognostic value of serum ALP levels during additional treatment in Japanese patients with primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate | Akihito Takeuchi | ![]() |
![]() |
|||
THU-293 | The non-invasive evaluation of vascular liver disease in patients with cystic fibrosis: a prospective cross-sectional study | Elton Dajti | ![]() |
![]() |
|||
FRI-293 | Addition of des-gamma-carboxy prothrombin to standard of care is effective for HCC surveillance among high-risk patients | Grishma Hirode | ![]() |
![]() |
|||
WED-294 | A novel web-based online nomogram to predict advanced liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome | Zhiyi Zhang | ![]() |
![]() |
|||
FRI-294 | A radiogenomics study for hepatocellular carcinoma: distinct transcriptome patterns underlying different radiomics phenotypes in early recurrence | Weijia Liao | ![]() |
![]() |
|||
WED-295 | Presence of metabolic associated liver disease in autoimmune hepatitis is associated with advanced liver fibrosis | ALVARO URZUA | ![]() |
![]() |
|||
THU-295 | Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection The VALDIG study | Pierre Deltenre | ![]() |
![]() |
|||
FRI-295 | Transversal psoas muscle thickness measurement is associated with response and survival in patients with hepatocellular carcinoma undergoing immunotherapy | Bernhard Scheiner | ![]() |
![]() |
|||
WED-296 | IMPACT OF IMMUNITY ON IMPROVING THE DIAGNOSTIC PERFORMANCE OF PRIMARY BILIARY CHOLANGITIS | Mario de Bonis Encinoso | ![]() |
![]() |
|||
FRI-296 | The efficacy of direct-acting antivirals for chronic hepatitis C in patients with the active oncological disease | Jerzy Jaroszewicz | ![]() |
![]() |
|||
THU-296 | Liver-related clinical events among adult patients with alpha-1 antitrypsin deficiency-associated liver disease: a longitudinal retrospective study using linked insurance claims data and electronic medical records in the United States | Ed G. Marins | ![]() |
![]() |
|||
THU-297 | Hepatobiliary malignancies in Wilson Disease: data from an Italian national reference centre | Lorenzo Canova | ![]() |
![]() |
|||
WED-297 | The devastating impact of severe pruritus in primary biliary cholangitis | Helen Smith | ![]() |
![]() |
|||
FRI-297 | Abbreviated magnetic resonance imaging for secondary surveillance of recurrent hepatocellular carcinoma after curative treatment | Sun Kyung Jeon | ![]() |
![]() |
|||
WED-298 | Variation in maintenance therapy practices in a large U.S. cohort of patients with autoimmune hepatitis | Therese Bittermann | ![]() |
![]() |
|||
FRI-298 | A new biomarker panel for differential diagnosis of cholangiocarcinoma: results from an exploratory analysis | Ashish Sharma | ![]() |
![]() |
|||
THU-298 | Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease | ALEXANDRA ALEXOPOULOU | ![]() |
![]() |
|||
THU-299 | Clinical, imaging and genetic findings of multiple biliary hamartomas | Juliana Gödiker | ![]() |
![]() |
|||
FRI-299 | CRAFITY score is associated with overall survival in patients with hepatocellular carcinoma treated with transarterial chemoembolisation | Rhea Veelken | ![]() |
![]() |
|||
WED-299 | Burden, impact and variability of pruritus in primary sclerosing cholangitis (PSC) over time: a prospective observational study | Nasir Hussain | ![]() |
![]() |
|||
FRI-300 | Development, clinical validation and implementation of a novel algorithmic score (GAAD) for the detection of early-stage hepatocellular carcinoma | Ashish Sharma | ![]() |
![]() |
|||
THU-300 | Performance of blood based non-invasive tests for liver fibrosis prediction by transient elastography in Alpha-1 antitrypsin deficiency | Hassaan Yousuf | ![]() |
![]() |
|||
WED-300 | Variation in the presentation pattern of primary biliary cholangitis (PBC) in Spain according to the diagnostic period: data from the Spanish registry of cholestatic and autoimmune liver diseases (COLHAI) | Sergio Rodriguez Taje | ![]() |
![]() |
|||
WED-301 | Health-related quality of life and medication adherence in adult patients after liver transplantation due to autoimmune hepatitis: a pilot, single centre study | Maciej K. Janik | ![]() |
![]() |
|||
THU-301 | Main clinical characteristics and evolutionary events among patients suffering Wilson disease in Spain: first results from the Spanish Wilson registry | Zoe Marińo | ![]() |
![]() |
|||
FRI-301 | Gadoxetic acid-enhanced MRI-based risk scoring system development and validation for the recurrence-free survival of a single hepatocellular carcinoma after curative surgery | Bohyun Kim | ![]() |
![]() |
|||
WED-302 | Autoimmune hepatitis (AIH) in Greece: first results from the Hellenic autoimmune liver diseases study group of the Hellenic association for the study of the liver (HASL) | Nikolaos Gatselis | ![]() |
![]() |
|||
THU-302 | Endoscopic ultrasound direct portal pressure measurement in patients with porto-sinusoidal vascular disorder and clinically significant portal hypertension: a comparison with hepatic venous pressure gradient measurement | Lucia Giuli | ![]() |
![]() |
|||
FRI-302 | The apparent diffusion coefficient values predict prognosis and Ki67 expression in intrahepatic cholangiocarcinoma on diffusion-weighted magnetic resonance imaging | Daiki Hokkoku | ![]() |
![]() |
|||
WED-303 | May symptom combinations at initial diagnosis of primary biliary cholangitis implicate distinct natural history? | Atsumasa Komori | ![]() |
![]() |
|||
FRI-303 | The Kupffer phase of Sonazoid-enhanced ultrasound as the major imaging feature for diagnosing hepatocellular carcinoma in at-risk individuals | Hyo-Jin Kang | ![]() |
![]() |
|||
THU-303 | Alpha-1 antitrypsin deficiency is underdiagnosed in cirrhotic liver transplant patients : a retrospective multicenter study | Manon EVAIN | ![]() |
![]() |
|||
WED-304 | Prevalence of celiac disease in adult patients with cryptogenic liver disease | Aditya Vikram Pachisia | ![]() |
![]() |
|||
THU-304 | The impact of a complete biochemical response on health-related quality of life in patients with autoimmune hepatitis: an international prospective cross-sectional study | Romée Snijders | ![]() |
![]() |
|||
FRI-304 | It takes a team for HCC: improvement of outcome with the multidisciplinary ambulatory for systemic therapy | Andrea Dalbeni | ![]() |
![]() |
|||
WED-305 | Budesonide is associated with less weight gain than Prednisolone amongst patients with autoimmune hepatitis: results from long term follow-up in routine clinical care | Josh Orpen-Palmer | ![]() |
![]() |
|||
THU-305 | Impact of extrahepatic portal vein obstruction on fertility and pregnancy outcomes- a tertiary center experience | Ankita Singh | ![]() |
![]() |
|||
FRI-305 | Aptamer biomarker models in hepatocellular carcinoma | Mikkel Breinholt Kjr | ![]() |
![]() |
|||
WED-306 | Unexpected high incidence of AMA positive primary biliary cholangitis in a northern Italian region | Davide Bitetto | ![]() |
![]() |
|||
FRI-306 | The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status: a nationwide population-based study | Su Jong Yu | ![]() |
![]() |
|||
THU-306 | Extrahepatic iron loading and disease complications in HFE haemochromatosis | John Olynyk | ![]() |
![]() |
|||
FRI-307 | Combined hepatocellular-cholangiocarcinoma : epidemiological, radiological and survival data from a retrospective single-center study | Guillaume HENIN | ![]() |
![]() |
|||
WED-307 | Norucholic acid for the treatment of primary sclerosing cholangitis: baseline data from a phase III trial | Michael Stie | ![]() |
![]() |
|||
FRI-308 | Predictors of extrahepatic recurrence after transarterial chemoembolization as first-line therapy for hepatocellular carcinoma | ELISA PINTO | ![]() |
![]() |
|||
WED-308 | Clinical, demographic, laboratory characteristics and disease progression of autoimmune hepatitis patients, asymptomatic at diagnosis, in a tertiary medical center in Israel | Ehud Zigmond | ![]() |
![]() |
|||
THU-308 | Chronic hepatitis B infection and porto-sinusoidal vascular disorder, a non-negligible coexistence | Pol Olivas Alberch | ![]() |
![]() |
|||
WED-309 | Prevalence and risk factors of osteoporosis in patients with primary biliary cholangitis in chinese population | Jialiang Chen | ![]() |
![]() |
|||
THU-309 | Effects of tetrathiomolybdate on copper distribution and biliary excretion: a controlled 64CuCl2 PET/MRI | Frederik Teicher Kirk | ![]() |
![]() |
|||
WED-310 | Symptom burden in people living with primary biliary cholangitis does not associate with transient elastography measures | Inbal Houri | ![]() |
![]() |
|||
THU-310 | Targeting CCL24 in primary sclerosing cholangitis with CM101: rationale and study design | Agnes Costello | ![]() |
![]() |
|||
FRI-310 | Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and MR imaging | Dong Ho Lee | ![]() |
![]() |
|||
FRI-311 | Liver function is a predictor of survival in patients with hepatocellular carcinoma in best supportive care | Fabio Marra | ![]() |
![]() |
|||
WED-311 | Drug-induced autoimmune hepatitis or drug-induced liver injury with autoimmune features: two faces of the same coin? | Pinelopi Arvaniti | ![]() |
![]() |
|||
THU-311 | Intrahepatic cholestasis of pregnancy: genetic testing and genotype-phenotype relations in a cohort from a Danish tertiary liver center | Henning Gronbaek | ![]() |
![]() |
|||
WED-312 | To assess response to steroids and validate SURFASA score in Indian autoimmune hepatitis patients | Harsh Gandhi | ![]() |
![]() |
|||
FRI-312 | Similar recurrence after curative treatment of HBV-related HCC regardless of HBV replication activity | Mi Na Kim | ![]() |
![]() |
|||
FRI-313 | Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a novel diagnostic biomarker for cholangiocarcinoma without underlying PSC | Marcin Krawczyk | ![]() |
![]() |
|||
WED-313 | The natural history and prognosis of primary sclerosing cholangitis: a multi-center, retrospective cohort study in China | Xiong Ma | ![]() |
![]() |
|||
THU-313 | Odevixibat therapy following liver transplantation in patients with FIC1-deficient progressive familial intrahepatic cholestasis: a retrospective case series | Georg-Friedrich Vogel | ![]() |
![]() |
|||
THU-314 | EPIDEMIOLOGY, TREATMENT AND BURDEN OF WILSON DISEASE IN FRANCE: A 10-YEAR ANALYSIS OF THE NATIONAL HEALTH INSURANCE DATABASE | Jean Philippe Combal | ![]() |
![]() |
|||
FRI-314 | Baseline cirrhosis in addition to the aMAP score increased the risk of developing hepatocellular carcinoma in patients with hepatitis B | Apichat Kaewdech | ![]() |
![]() |
|||
WED-314 | Elevated GGT levels as predictor of non-response to ursodeoxycholic acid in patients with primary biliary cholangitis | Flor María Fernández-Gordón Sánchez | ![]() |
![]() |
|||
FRI-315 | Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: a nationwide cohort study | Hae Lim Lee | ![]() |
![]() |
|||
WED-315 | Celiac disease in patients with autoimmune hepatitis is associated with a milder liver disease course and a better chance of immunosuppressive treatment withdrawal | Francesco Pezzato | ![]() |
![]() |
|||
THU-315 | Impact of suffering Wilson disease in Spain: an observational cross-sectional multicenter study | Zoe Marińo | ![]() |
![]() |
|||
WED-316 | Outcome and prognostic factors of primary biliary cholangitis in South Korea | Kyung-Ah Kim | ![]() |
![]() |
|||
THU-316 | Role of transient elastography to identify Fontan-associated liver disease (FALD) and novel risk-score to predict failing Fontan | Luisa Cavalletto | ![]() |
![]() |
|||
FRI-316 | Liver Frailty Index is associated with progression-free survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab | Philippe Sultanik | ![]() |
![]() |
|||
THU-317 | Real-world experience of Odevixibat in adults with genetic disorders of cholestasis | Palak Trivedi | ![]() |
![]() |
|||
FRI-317 | Characterization of the imaging signature of hepatocellular carcinoma with enhancement pattern mapping | Newsha Nikzad | ![]() |
![]() |
|||
WED-317 | The association between cholestatic biochemical markers and clinical symptoms non-end-stage primary sclerosing cholangitis | Tim Middelburg | ![]() |
![]() |
|||
FRI-318 | Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma | Chang Hun Lee | ![]() |
![]() |
|||
WED-318 | Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting | Christophe Corpechot | ![]() |
![]() |
|||
THU-318 | High diagnostic uptake of a targeted panel sequencing in adult patients with chronic hereditary liver disorders | Cristiana Bianco | ![]() |
![]() |
|||
FRI-319 | Effect of different radiologic modalities for surveillance of hepatocellular carcinoma on survival of high risk cirrhotic patients | Ahmed El Sabagh | ![]() |
![]() |
|||
THU-319 | Phytoestrogens as a possible hidden driver of cysts proliferation in polycystic liver disease in men and women after menopause | Miki Scaravaglio | ![]() |
![]() |
|||
WED-319 | Rifaximin plus lactulose is more effective than lactulose alone for the prevention of overt hepatic encephalopathy in patients with or without diabetes | Tobin Sharp | ![]() |
![]() |
|||
FRI-320 | Comparison of clinical manifestations and outcomes between non-viral-related and viral hepatitis-related hepatocellular carcinoma | Sih-Han Liao | ![]() |
![]() |
|||
THU-320 | Patient experience with acute hepatic porphyria before and after long-term givosiran treatment: a qualitative interview study | Stephen Lombardelli | ![]() |
![]() |
|||
WED-320 | Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study) | Giulia Iannone | ![]() |
![]() |
|||
WED-321 | Efficacy and safety of branched-chain amino acids supplementation on muscle cramps in patients with cirrhosis: a randomized double-blinded controlled trial | Thanapat Atthakitmongkol | ![]() |
![]() |
|||
FRI-321 | Impact of obesity on outcome of hepatocellular carcinoma in an Asian cohort: when should we consider obesity treatment? | Wei-Lun Liou | ![]() |
![]() |
|||
THU-322 | Surveillance of cystic echinococcosis in France: report of the first 103 cases from the French observatory OFREKYS | Solange Bresson-Hadni | ![]() |
![]() |
|||
FRI-322 | Collagen proportionate area (CPA) measurement of liver parenchyma and hepatocellular carcinoma (HCC) can predict HCC recurrence after liver resection | Chiara Sicuro | ![]() |
![]() |
|||
WED-322 | Effects of nutritional therapy on Sarcopenia in patient with liver cirrhosis a randomised controlled trial | Sudhir Maharshi | ![]() |
![]() |
|||
FRI-323 | Exploration of a holistic management procedure for liver cancer surveillance to improve the early diagnosis of liver cancer in Chinese population | Yong Li | ![]() |
![]() |
|||
WED-323 | Real-world treatment of decompensated liver cirrhosis in Italy: a propensity score-matched analysis of long-term versus acute albumin therapy | Lucy Harvey | ![]() |
![]() |
|||
THU-323 | Role of gut-derived endotoxins in porto-sinusoidal vascular disease | Stefania Gioia | ![]() |
![]() |
|||
THU-324 | Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis | Costello Medical | ![]() |
![]() |
|||
WED-324 | Potentially inappropriate medicine use and non-adherence in hepatic encephalopathy: a retrospective real-world cohort study | Zhen Howe Hong | ![]() |
![]() |
|||
FRI-324 | Chemerin protein in hepatocellular carcinomas is related to disease severity in European patients | Christa Buechler | ![]() |
![]() |
|||
THU-325 | Ultrasonographic liver characteristics among patients with Wilson disease | Zoe Marińo | ![]() |
![]() |
|||
FRI-325 | Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease | Amina Abdulle | ![]() |
![]() |
|||
SAT-325 | Outcome of sucralfate vs proton pump inhibitor vs sucralfate and proton pump inhibitor combination post endoscopic esophageal variceal band ligation - A randomized controlled trial | Arun Vaidya | ![]() |
![]() |
|||
WED-325 | Atorvastatin reduces inflammation markers TNF-a, CD62L and MMP2 in a randomised trial | Thit Mynster Kronborg | ![]() |
![]() |
|||
THU-326 | Exploring pregnancy, breastfeeding and contraception among women with Wilson disease in Spain: results from the Spanish Wilson registry | MARTA ROMERO-GUTIÉRREZ | ![]() |
![]() |
|||
FRI-326 | Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease | Theresa Hydes | ![]() |
![]() |
|||
SAT-326 | TIPS increases muscle mass in patients with decompensated cirrhosis | Theresa Bucsics | ![]() |
![]() |
|||
WED-326 | Impact of intrapulmonary vascular dilatations and hepatopulmonary syndrome on the clinical course of patients after transjugular intrahepatic portosystemic shunt insertion | Jim Benjamin Mauz | ![]() |
![]() |
|||
FRI-327 | Aetiology and outcomes of cirrhosis and hepatocellular carcinoma in Blantyre, Malawi | Alexander Stockdale | ![]() |
![]() |
|||
THU-327 | Hepatic alterations in COVID-19: a comparative autopsy study | Sigurd Lax | ![]() |
![]() |
|||
SAT-327 | Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with advanced chronic liver disease: an individual patient meta-analysis | Elton Dajti | ![]() |
![]() |
|||
THU-328 | Adequacy and safety of liver biopsy performed during cardiac catheterization in patients with Fontan and non-Fontan heart disease | Edward Cytryn | ![]() |
![]() |
|||
WED-328 | Safety and efficacy of continuous infusion terlipressin in Acute Kidney Injury-Hepatorenal Syndrome: The INFUSE Study | K. Rajender Reddy | ![]() |
![]() |
|||
FRI-328 | Survival outcomes of patients with non-alcoholic fatty liver disease-related HCC: a retrospective cohort study | Anders Mellemkjr | ![]() |
![]() |
|||
SAT-328 | Effects of renin angiotensin system inhibition on renal function and the clinical course of patients with decompensated liver cirrhosis and ascites | Tammo Lambert Tergast | ![]() |
![]() |
|||
FRI-329 | Targeted surveillance for hepatocellular carcinoma is cost effective in Australia: evidence from a microsimulation study | Barbara de Graaff | ![]() |
![]() |
|||
SAT-329 | Adoption of a clinical assessment service in hepatology | Sarah Clark | ![]() |
![]() |
|||
THU-329 | Deep learning quantification reveals fundamental prognostic role for ductular reaction in biliary atresia | Iiris Nyholm | ![]() |
![]() |
|||
WED-330 | The effects of alfapump on ascites control and quality of life in patients with cirrhosis and recurrent or refractory ascites: pivotal trial results | Florence Wong | ![]() |
![]() |
|||
SAT-330 | Diabetes impairs the hemodynamic response to non-ive betablockers in compensated cirrhosis and predisposes for hepatic decompensation | Rafael Paternostro | ![]() |
![]() |
|||
THU-330 | Long-term outcomes of patients with Wilson disease: a single center analysis of 361 Korean patients | Hyojin Nam | ![]() |
![]() |
|||
FRI-330 | Phenotypic diversity and regeneration in a model of Alagille syndrome recapitulate patient heterogeneity | Linde Sevenants | ![]() |
![]() |
|||
THU-331 | Lessons from population genomics for Wilson disease: Prevalence, penetrance of mutations, clinical implications and design of regional screening programmes | Pablo Alonso Castellano | ![]() |
![]() |
|||
WED-331 | Quickstroop, an App-based strategy that takes 1 minute, predicts time to overt hepatic encephalopathy development and hospitalizations | Jasmohan S Bajaj | ![]() |
![]() |
|||
SAT-331 | Preoperative transjugular intrahepatic portosystemic shunt and in-house mortality in patients with liver cirrhosis undergoing surgery | Felix Piecha | ![]() |
![]() |
|||
FRI-331 | Identification of potential targets amenable to novel therapeutics to treat symptoms in primary biliary cholangitis | Aaron Wetten | ![]() |
![]() |
|||
FRI-332 | Anti-nucleosome antibodies as an important marker to distinguish between autoimmune hepatitis and drug-induced liver injury | Nasser Semmo | ![]() |
![]() |
|||
WED-332 | On-treatment factors predict recompensation in entecavir-treated hepatitis B patients with decompensated cirrhosis | You Deng | ![]() |
![]() |
|||
SAT-332 | Indocyanine green clearance reflects various pathophysiological mechanisms and independently predicts liver-related events in ACLD | Mathias Jachs | ![]() |
![]() |
|||
SAT-333 | A multimodal deep learning network for non-invasive prediction of the hepatic decompensation risk in compensated cirrhotic people: a multicentre cohort study (CHESS1701) | Qian YU | ![]() |
![]() |
|||
FRI-333 | Combination of intestinal bile salt uptake inhibition with pharmacological repression of bile salt synthesis improves liver health in cholestatic mice | Stan Van De Graaf | ![]() |
![]() |
|||
THU-333 | Digital pathology using stain-free imaging indices as a tool for fibrosis quantification in patients with congestive hepatopathy | Matthew Yeh | ![]() |
![]() |
|||
WED-333 | Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis | Niv Zmora | ![]() |
![]() |
|||
THU-334 | Current transition management of adolescents and young adults with liver diseases: an European reference network rare liver survey | Joao Madaleno | ![]() |
![]() |
|||
SAT-334 | TIPS under-dilation strategy with new controlled expansion endoprosthesis: a hemodynamic and imaging confirmation of its feasibility | Dario Saltini | ![]() |
![]() |
|||
WED-334 | Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis | Benedikt Hofer | ![]() |
![]() |
|||
FRI-334 | Cholestatic liver disease is alleviated by colitis-induced inhibition of bile acid synthesis | Wenfang Gui | ![]() |
![]() |
|||
FRI-335 | Non-invasive imaging method demonstrates anti-fibrotic efficacy of a dual integrin alpha-v/beta-6 and alpha-v/beta-1 inhibitor in a rat model of biliary fibrosis | Johanna Schaub | ![]() |
![]() |
|||
WED-335 | Association of polymorphisms in genes of the innate immunity with transplant-free survival of patients with decompensated liver cirrhosis | Janett Fischer | ![]() |
![]() |
|||
THU-335 | Quality of life in patients with Wilson disease treated with Trientine dihydrochloride: a prospective study | Larissa Wijnberg | ![]() |
![]() |
|||
SAT-335 | Is elastography needed for diagnosing cACLD and stratifying CSPH risk? | Georg Semmler | ![]() |
![]() |
|||
THU-336 | Odevixibat therapy in patients with MYO5B mutations: a retrospective case series | Emmanuel Gonzalčs | ![]() |
![]() |
|||
WED-336 | Applicability of EASL clinical guidelines recommendations of empiric antibiotic treatment for spontaneous bacterial infections in patients with cirrhosis in south america | Melisa Dirchwolf | ![]() |
![]() |
|||
FRI-336 | Blockade of IL-18 via long-acting IL-18 binding protein attenuates experimental diet-induced cholestatic disease | Dong-Hyun Kim | ![]() |
![]() |
|||
SAT-336 | Systemic inflammation remains a critical determinant of the dynamic component of portal hypertension in abstinent patients with alcohol-related cirrhosis | Benedikt Hofer | ![]() |
![]() |
|||
THU-337 | Factor VIII synthesis by adipose tissue stromal cells contributes to coagulopathy in chronic liver disease | Sanal MG | ![]() |
![]() |
|||
WED-337 | Progression of cirrhosis is not associated with clinically significant alterations in hemostasis assessed by thromboelastography | Alina Buliarca | ![]() |
![]() |
|||
SAT-337 | Robust identification of patient subgroups in acute decompensated cirrhosis | Sara Palomino | ![]() |
![]() |
|||
WED-338 | Decreased platelet function is an independent predictor of liver-related and all-cause mortality in patients with advanced chronic liver disease | Benedikt Hofer | ![]() |
![]() |
|||
SAT-338 | Clinical profile and outcomes of porto-sinusoidal vascular disorder : Experience from tertiary referral hospital in India | Love Garg | ![]() |
![]() |
|||
THU-338 | e-Lysine-melittin reduces pathological bacterial translocation and enhances gut immunity in experimental decompensated cirrhosis | Deepika Jakhar | ![]() |
![]() |
|||
FRI-339 | Disparities in hospital outcomes among patients with end- stage liver disease with palliative care collaboration: a nationwide cohort analysis (2016-2020) | Sheza Malik | ![]() |
![]() |
|||
THU-339 | Combination of weekly albumin infusion, personalized nutrition and home-based exercise programme improves outcomes of patients with end stage liver disease (Al-Fit study) | Sasanka Vangara | ![]() |
![]() |
|||
WED-339 | Thromboelastography-guided coagulopathy correction in cirrhotic patients decreases blood product transfusion: a systematic review and analysis | Hamed Komeylian | ![]() |
![]() |
|||
SAT-339 | Impact of Rifaximin Use During the 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy (OHE) Hospitalization on the Annual Rates of Subsequent OHE Hospitalizations | Rebecca Bungay | ![]() |
![]() |
|||
SAT-340 | MELD-sarcopenia and clinically significant portal hypertension as independent risk factors in the evolution of liver cirrhosis | Elba Llop | ![]() |
![]() |
|||
FRI-340 | ACLF grade is not independently associated with 1-year mortality after hospital discharge in cirrhotic patients admitted to ICUs in the Netherlands | Jubi De Haan | ![]() |
![]() |
|||
WED-340 | An overview on microbial population in liver cirrhosis : changing paradigm in the known bacteriology of spontaneous bacterial peritonitis | Shirin Demma | ![]() |
![]() |
|||
THU-340 | Imperfect maturation in erythroid progenitors leads to severe anemia in cirrhotic patients | Deepika . | ![]() |
![]() |
|||
THU-341 | Study of epigenetic control of LSECtin in hepatic antigen presenting cells during experimental cirrhosis | Angel-Gomis Enrique | ![]() |
![]() |
|||
WED-341 | The combination of LACE index, MELD on discharge and a previous history of decompensation defines risk groups for early readmission in patients with liver cirrhosis | Yolanda Sanchez | ![]() |
![]() |
|||
SAT-341 | Spleen stiffness assessed by point shear-wave elastography predicts portal hypertension better than liver elastography | Vaclav Smid | ![]() |
![]() |
|||
FRI-341 | Outcomes, clinical trajectories and risk factors of acute kidney injury (AKI) in critically-ill patients with liver cirrhosis | Martin Schulz | ![]() |
![]() |
|||
WED-342 | Factors associated with inpatient albumin administration and center-level variation in a national cohort | Marina Serper | ![]() |
![]() |
|||
FRI-342 | VSIG4 as a biomarker for the diagnosis and prognosis of HBV-ACLF | Jun Li | ![]() |
![]() |
|||
SAT-342 | Suppression of the pituitary-adrenal axis in stable outpatients with advanced chronic liver disease increases with disease severity and may be linked to systemic inflammation and bile acids | Lukas Hartl | ![]() |
![]() |
|||
THU-342 | Nitazoxanide counteracts lipopolysaccharide-induced hepatic and renal transcriptomic profile changes to improve systemic inflammation and organ damage in a disease model of acute-on-chronic liver failure | Vanessa Legry | ![]() |
![]() |
|||
WED-343 | Serum PDL1 levels are associated with increased risk of bacterial infections in non-hospitalised patients with cirrhosis | Adria Juanola | ![]() |
![]() |
|||
FRI-343 | The prognostic impact of each organ failure is different than that of acute-on-chronic liver failure according to the major clinical presentation in acutely decompensated cirrhosis | Jung Hee Kim | ![]() |
![]() |
|||
THU-343 | Metabolic Derangements in Hematopoietic Stem and Progenitor Cells (HSPCs) underlie monocyte-macrophage dysfunction in cirrhosis | Deepanshu Maheshwari | ![]() |
![]() |
|||
SAT-343 | Role of non neoplastic portal vein thrombosis in natural history of patients with cirrhosis and hepatocellular carcinoma | Sarah Shalaby | ![]() |
![]() |
|||
WED-344 | Validation of automatic cell counting based on impendaciometry and flow cytometry in ascitic fluid | Aitor Odriozola Herrán | ![]() |
![]() |
|||
FRI-344 | Proteomics and metabolomics of bile reveal molecular insights and classify signatures predictive of carcinoma of gallbladder | Nupur Sharma | ![]() |
![]() |
|||
THU-344 | Constant alcohol consumption exacerbates hepatic encephalopathy and leads to neuronal loss in rats with chronic liver disease | Farzaneh Tamnanloo | ![]() |
![]() |
|||
SAT-345 | Bacterial translocation has an early onset in cirrhosis and induces a ive inflammatory response | Benedikt Simbrunner | ![]() |
![]() |
|||
FRI-345 | Serum proteomics reveals association of CCL24 with key aspects of primary sclerosing cholangitis | Raanan Greenman | ![]() |
![]() |
|||
WED-345 | Prevalence of minimal hepatic encephalopathy in patients with cirrhosis: a multicenter study | Simon Johannes Gairing | ![]() |
![]() |
|||
THU-345 | Targeting myeloid-derived suppressor cells in a carbon tetrachloride-induced murine model of chronic liver injury | Emilio Flint | ![]() |
![]() |
|||
WED-346 | Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis | Pei-Chang Lee | ![]() |
![]() |
|||
THU-346 | Cirrhosis alters receptor mediated clearance of therapeutic antibodies by hepatic sinusoidal endothelial cells | Bethany James | ![]() |
![]() |
|||
FRI-346 | Combination of Ileal bile acid transporter inhibitor and a non-steroidal Farnesoid X receptor agonist for reversal of cholestatic liver injury in Cyp2c70 KO mice with a humanized bile acid composition | Caroline Klindt-Morgan | ![]() |
![]() |
|||
SAT-346 | Efficacy of long term albumin therapy in treatment of decompensated cirrhosis | Deepanshu Khanna | ![]() |
![]() |
|||
SAT-347 | Recently validated non-invasive tests for liver fibrosis assessment have great performance in identifying NASH patients at risk for decompensation | Vlad Taru | ![]() |
![]() |
|||
WED-347 | Comparison of coagulation parameters as prognostic markers of decompensation and liver-related death in advanced chronic liver disease | Maria Pallozzi | ![]() |
![]() |
|||
THU-347 | Evaluation of the effect of glucocorticoids on cardiac chronotropic dysfunction in cirrhotic rats, do dopamine receptors also play a role? | Qamar Niaz | ![]() |
![]() |
|||
FRI-347 | Production of reactive oxidant species and fatty acid uptake is increased in regulatory T-cells in autoimmune hepatitis, and associated with down-regulation of markers linked to suppressor function | Scott Davies | ![]() |
![]() |
|||
FRI-348 | The cell cycle protein Cyclin E1 mediates pro-inflammatory signals in a mouse model of acute hepatitis and in primary macrophages | Christian Penners | ![]() |
![]() |
|||
WED-348 | Development and external validation of a model to predict multi-drug resistant bacterial infections in patients with cirrhosis | Sebastian Marciano | ![]() |
![]() |
|||
SAT-348 | Earlier diagnosis of hepatorenal syndrome-acute kidney injury with updated guidelines review of the Confirm trial | Vanessa Borkhoche | ![]() |
![]() |
|||
THU-348 | Distinct changes in the inflammatory profile of patients with EASL-CLIF- versus APASL-acute-on-chronic liver failure | Mona-May Langer | ![]() |
![]() |
|||
SAT-349 | Predicting esophageal varices and varices needing treatment in patients with compensated advanced chronic liver disease using Baveno VI Criteria, CHESS-ALARM score, FIB-4 score, and recently proposed FIB-5 score | Fares Mashal | ![]() |
![]() |
|||
FRI-349 | Depletion of excess liver copper ameliorates liver damage in a mouse model of chronic cholestatic liver disease | Dennis Koob | ![]() |
![]() |
|||
WED-349 | Factors related to a shorter survival in patients with liver disease and followed by a specialized palliative care clinic | Fernando Xavier de Almeida e Silva | ![]() |
![]() |
|||
THU-349 | Bacterial DNA translocation-induced systemic inflammation is associated with overt hepatic encephalopathy and predicts mortality in patients with cirrhosis | Kessarin Thanapirom | ![]() |
![]() |
|||
WED-350 | Validation of thigh ultrasound for measurement of sarcopenia and fat mass in patient with cirrhosis: correlation with body composition analysis. Higher fat mass, lower muscle mass and reduced functional muscle | Reza Saeidi | ![]() |
![]() |
|||
SAT-350 | Hepatic venous pressure gradient predicts further decompensation in cirrhosis patients with acute esophageal variceal bleeding | Manas Vaishnav | ![]() |
![]() |
|||
FRI-350 | Genetic predisposition for liver inflammation and response to anti-cholestatic therapy in experimental sclerosing cholangitis | Alexander Miethke | ![]() |
![]() |
|||
THU-350 | Platelets from patients with decompensated cirrhosis display pro-inflammatory features | Simone Di Cola | ![]() |
![]() |
|||
THU-351 | Single-cell RNA transcriptomics of peripheral blood mononuclear cells revealed altered gene expressions in monocyte and HLA variations in decompensated liver cirrhosis patients with sepsis | Nirupma Trehanpati | ![]() |
![]() |
|||
FRI-351 | In vitro modulation of fibrogenesis and inflammation in patient-derived cholangiocyte organoids | Anna Katharina Frank | ![]() |
![]() |
|||
WED-351 | Goals of care and end-of-life for patients with advanced liver disease followed by a specialized palliative care clinic | Fernando Xavier de Almeida e Silva | ![]() |
![]() |
|||
WED-352 | Gender differences in the patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites | Florence Wong | ![]() |
![]() |
|||
FRI-352 | Cholestatic liver disease enhances sociability and leads to significant adaptative changes in amygdala neural circuits regulating social behavior in mice | Wagdi Almishri | ![]() |
![]() |
|||
THU-352 | Role of extracellular vesicles in sarcopenia associated to chronic liver diseases | Simone Di Cola | ![]() |
![]() |
|||
THU-353 | Effects of -adrenergic hyperstimulation, liver cirrhosis and acute-on-chronic liver failure (ACLF) on the small intestinal gut-vascular barrier (GVB) | Marco Felber | ![]() |
![]() |
|||
WED-353 | The role of renal impairment on rotational thromboelastometry (ROTEM) parameters in hospitalised patients with cirrhosis a prospective cohort study | Louis Wang | ![]() |
![]() |
|||
FRI-353 | Oxazolone-mediated bile duct inflammation reveals specific natural killer T cell-dependent inflammatory pathways | Markus Jördens | ![]() |
![]() |
|||
SAT-353 | Liver innervation is dysregulated in a mouse model of Alagille syndrome | Elisabeth Verboven | ![]() |
![]() |
|||
SAT-354 | A novel organoid model of human liver bud development | Charlotte Grey-Wilson | ![]() |
![]() |
|||
THU-354 | Identification of complication- dependent gut microbial biomarkers for early detection of decompensated cirrhosis | Satya Priya Sharma | ![]() |
![]() |
|||
FRI-354 | The significance of patatin-like phospholipase domain-containing protein-3 I148M genetic variant in autoimmune hepatitis | Nikolaos Gatselis | ![]() |
![]() |
|||
WED-354 | Whole body clearance and production of ammonia quantified by constant ammonia infusion the effects of cirrhosis and ammonia targeting treatments | Peter Lykke Eriksen | ![]() |
![]() |
|||
WED-355 | Prognostic significance of individual decompensating events in stable decompensated outpatients with cirrhosis using a multi-center cohort | Jasmohan Bajaj | ![]() |
![]() |
|||
THU-355 | Pathophysiological biomarkers associated with resolution of ACLF in patients treated with the liver dialysis device, DIALIVE | Fausto Andreola | ![]() |
![]() |
|||
FRI-355 | Temporal characteristics of cell compartments in immune-mediated cholestatic disease | Markus Jördens | ![]() |
![]() |
|||
SAT-355 | Tunable host senescence determines the success of hepatocyte transplantation in a mouse model of liver injury | Victoria Gadd | ![]() |
![]() |
|||
THU-356 | Development and characterization of novel rodent ACLF models | Frank Erhard Uschner | ![]() |
![]() |
|||
WED-356 | Classification of bleeding risk from invasive procedures in patients with cirrhosis: an expert consensus | Alix Riescher-Tuczkiewicz | ![]() |
![]() |
|||
FRI-356 | HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis | Manuel Roqueta-Rivera | ![]() |
![]() |
|||
SAT-356 | Liver regeneration is regulated by intestinal sirtuin-1 | Sian Seaman | ![]() |
![]() |
|||
FRI-357 | Differential activation of regulatory CD4 T cells via the JAK-STAT-pathway in Primary sclerosing cholangitis | Leona Dold | ![]() |
![]() |
|||
WED-357 | The role of prolonged albumin replacement therapy in correction of its structure, functional properties and management of ascites | Anastasia Turkina | ![]() |
![]() |
|||
THU-357 | Distinct patterns of hepatic and systemic inflammation in different types/aetiologies of liver disease | Benedikt Hofer | ![]() |
![]() |
|||
SAT-357 | IGF1 specifically rescues peripheral intrahepatic biliary organoids from a mouse model of Alagille syndrome | Afshan Iqbal | ![]() |
![]() |
|||
WED-358 | A multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148 | Benjamin Bruno | ![]() |
![]() |
|||
THU-358 | Extracellular vesicles carrying oxidation-specific epitopes as effectors in acute hepatic decompensation and acute-on-chronic liver failure a pilot study | Benedikt Simbrunner | ![]() |
![]() |
|||
FRI-358 | scRNA transcriptomics reveal the role of cholangiocytes and neutrophils cross talk in PKHD1-KO mice | Mario Strazzabosco | ![]() |
![]() |
|||
SAT-358 | Endothelial autophagy is not required for liver regeneration after partial hepatectomy in mice with fatty liver | Adel HAMMOUTENE | ![]() |
![]() |
|||
FRI-359 | Golexanolone, a GABA receptor-modulating steroid antagonist, improves peripheral inflammation, fatigue, locomotor gait, motor incoordination and short-term memory in rats with cholestasis and hepatic encephalopathy due to bile duct ligation | Marta Llansola | ![]() |
![]() |
|||
THU-359 | Multi-omics reveals the regulation mechanism of the Chinese herbal AnLuoHuaXian formula on reversing liver cirrhosis in the rat | Ruijia Liu | ![]() |
![]() |
|||
WED-359 | Clinical effectiveness of human albumin in liver cirrhosis: a meta-analysis update | Yuhan Liu | ![]() |
![]() |
|||
SAT-359 | Transcriptomics confirm the establishment of a liver-immune dual-humanized mouse model after transplantation of a single type of human bone marrow mesenchymal stem cell | Jun Li | ![]() |
![]() |
|||
THU-360 | MCC950 reduces glial cell activation and neuroinflammation in an animal model of thioacetamide-induced hepatic encephalopathy | Syed Afroz Ali | ![]() |
![]() |
|||
FRI-360 | Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC | Michael Trauner | ![]() |
![]() |
|||
SAT-360 | Skin-decellularized matrix-derived microgels accelerate 3D cultures of functional primary hepatocyte spheroids in vitro | Ashwini Vasudevan | ![]() |
![]() |
|||
THU-361 | The pan-PPAR agonist lanifibranor decreases portal pressure in models of both hepatic and prehepatic portal hypertension | Anneleen Heldens | ![]() |
![]() |
|||
FRI-361 | Pyroptosis plays a key role in primary biliary cholangitis of humans and mice | Linxiang Huang | ![]() |
![]() |
|||
WED-361 | Clostridioides difficile infection in patients with liver cirrhosis | Olga Adriana Cakiman-Sturdza | ![]() |
![]() |
|||
SAT-361 | Autophagy regulates the generation and differentiation of chemically derived hepatic progenitors (CdHs) | Hayoon Kim | ![]() |
![]() |
|||
SAT-362 | Development of intrahepatic bile ducts during liver progenitor cell-driven liver regeneration is associated with epithelial cell adhesion molecule function | Eun Young Cho | ![]() |
![]() |
|||
FRI-362 | Molecular signatures of treatment response in autoimmune hepatitis | Bastian Engel | ![]() |
![]() |
|||
WED-362 | The prevalence and prognostic impact of myosteatosis with and without sarcopenia and its association with age and severity of liver cirrhosis | ALEXANDRA ALEXOPOULOU | ![]() |
![]() |
|||
FRI-363 | Loss of innate and adaptive effector lymphocytes is associated with diminished globe score prognosis in patients with primary biliary cholangitis | Hussain Syed | ![]() |
![]() |
|||
SAT-363 | Excessive proliferation and vascular damage after extended hepatectomy compromise liver function in mice | Maxime De Rudder | ![]() |
![]() |
|||
WED-363 | Comparison of prognostic value of sarcopenia and MELD score in assessing 28 days and 3 months mortality in patients with cirrhosis of liver | Shivam Gupta | ![]() |
![]() |
|||
WED-364 | Activation of the kynurenine pathway potentially underlies neurodegeneration in patients with covert hepatic encephalopathy | Georgia Zeng | ![]() |
![]() |
|||
SAT-364 | Conditioned medium from human allogeneic liver-derived progenitor cells protects against LPS-induced endothelial hyperpermeability via sphingosine-1 phosphate | Pauline De Berdt | ![]() |
![]() |
|||
THU-364 | Glial transcriptional changes in experimental HE arise early and show similarities with established neuroinflammatory disorders | Wouter Claeys | ![]() |
![]() |
|||
WED-365 | A virtual reality-driving test to predict car accidents in patients with cirrhosis | Simon Johannes Gairing | ![]() |
![]() |
|||
THU-365 | Ascites-resident innate-like CD8 T cells contribute to inflammation anddisease pathogenesis in patients with liver cirrhosis | Christian Niehaus | ![]() |
![]() |
|||
FRI-365 | Spatial transcriptomics reveals shared gene and cellular composition in recurrent and primary sclerosing cholangitis | Mikal Jacob Hole | ![]() |
![]() |
|||
SAT-365 | Lineage tracing of hepatic stellate cells with ultrasound-guided in utero nano-injection | Jingyan He | ![]() |
![]() |
|||
THU-366 | Evaluation of myocardial inflammation and fibrosis in an experimental model of liver cirrhosis by quantitative cardio-hepatic MRI | Franziska Schneider | ![]() |
![]() |
|||
WED-366 | The Association between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes | Roy Wang | ![]() |
![]() |
|||
SAT-366 | Autologous skeletal myoblast cell-sheet transplantation for liver regeneration | Keisuke Toya | ![]() |
![]() |
|||
FRI-366 | Cytotoxic activity of peripheral NK cells is decreased in primary sclerosing cholangitis | Leona Dold | ![]() |
![]() |
|||
WED-367 | Liver nutrition clinic improves nutritional outcomes in patients with advanced cirrhosis | Enoka Gonsalkorala | ![]() |
![]() |
|||
FRI-367 | The effect of the combination of metformin with propionic acid on the indicators of oxidative stress in liver tissue of rats with type 2 diabetes mellitus | Olena Khokhliuk | ![]() |
![]() |
|||
THU-367 | Peripheral blood metabolite associations with cardiac diastolic dysfunction in advanced chronic liver disease | Madeleine Gill | ![]() |
![]() |
|||
SAT-368 | Rescue mechanism of HIL-6 after partial hepatectomy | Julia Ettich | ![]() |
![]() |
|||
THU-368 | Biological differences between clinically different muscle wasting phenotypes in patients with decompensated ESLD undergoing assessment for liver transplantation: a UK prospective cohort study | Amritpal Dhaliwal | ![]() |
![]() |
|||
WED-368 | Impact of allelic HLA divergence on the risk of bacterial infections in cirrhotic patients awaiting liver transplantation | Clementine Roger | ![]() |
![]() |
|||
FRI-368 | Associations of fecal bile acids, diet, and intestinal microbes with markers of disease progression in primary sclerosing cholangitis disease | Christopher Bowlus | ![]() |
![]() |
|||
FRI-369 | CD44 reduces fibrosis development in chronic cholestatic liver injury in Mdr2 knock-out mice | Franziska Ihli | ![]() |
![]() |
|||
SAT-369 | Hepatic progenitor cell activation through the interaction of mesenchymal stem cells and liver sinusoidal endothelial cells | Seul Ki Han | ![]() |
![]() |
|||
WED-369 | The impact of a massive transfusion protocol on the outcomes of patients with acute variceal bleeding: propensity score-matched analysis | Aryoung Kim | ![]() |
![]() |
|||
THU-369 | Effect of fibrinogen substitution in hypofibrinogenaemic CTP class C patients on viscoelastic coagulation tests | Moritz Tobiasch | ![]() |
![]() |
|||
FRI-370 | Results of pharmacological treatment of Mcpip1 knock-out mice which develop symptoms of primary biliary cholangitis | Katarzyna Trzos | ![]() |
![]() |
|||
WED-370 | Acute kidney injury related to metamizole in advanced chronic liver disease patients undergoing major orthopedic surgery | Lidia Canillas Alavés | ![]() |
![]() |
|||
THU-370 | The gene expression profile of skeletal muscle in end-stage liver disease patients undergoing assessment for liver transplantation with muscle wasting | Sophie Allen | ![]() |
![]() |
|||
SAT-370 | Effect of kidney injury and hemodynamic effect after moderate abdominal paracentesis: a randomized control study | Sakkarin Chirapongsathorn | ![]() |
![]() |
|||
THU-371 | Placement of a trans-jugular intrahepatic portosystemic shunt (TIPS) modifies the expression of proinflammatory cytokines in circulating monocytes exposed to lipopolysaccaride | Mirella Pastore | ![]() |
![]() |
|||
FRI-371 | The role of Type II and III Interferons in primary biliary cholangitis | Yooyun Chung | ![]() |
![]() |
|||
SAT-371 | AAV-HBV mouse model replicates immune exhaustion patterns of chronic HBV patients at single-cell level | Oliver Lenz | ![]() |
![]() |
|||
WED-372 | Effectiveness and safety of anticoagulant treatment in patients with liver cirrhosis and non-tumoral splenic-portal thrombosis | Nelson Daniel Salazar Parada | ![]() |
![]() |
|||
SAT-372 | Developing highly pure, functional GMP grade Treg for the treatment of autoimmune liver disease | Naomi Richardson | ![]() |
![]() |
|||
THU-372 | Neurological dysfunction is improved after faecal microbiota transplantation in rats with bile duct ligated-induced chronic liver disease | Alexandre Bourgeois | ![]() |
![]() |
|||
SAT-373 | ILT2 as a biomarker of impaired natural killer cells expressing excess lipid peroxidation in patients with hepatocellular carcinoma | Toshihiro Sakata | ![]() |
![]() |
|||
WED-373 | Normalisation of the psychometric hepatic encephalopathy score in a Nigerian population | Mansur Mohammed | ![]() |
![]() |
|||
SAT-374 | Interplay between hepatitis B virus replication and intrahepatic expression of VISTA and TIM-3 immune checkpoint markers in chronic hepatitis B patients | Kim Thys | ![]() |
![]() |
|||
WED-374 | Nutritional status of patients with advanced chronic liver disease: descriptive baseline of a prospective study | Jose Miguel Rosales Zabal | ![]() |
![]() |
|||
SAT-375 | Kupffer cell activation enhances systemic anti-bacterial immunity | Christian Zwicker | ![]() |
![]() |
|||
WED-375 | Experiences from a palliative care clinic specialized in liver diseases utilization, clinical characteristics of patients and outcomes. | Fernando Xavier de Almeida e Silva | ![]() |
![]() |
|||
WED-376 | Booster SARS-CoV-2 vaccination elicits robust antibody response to wild-type but not Omicron subvariants BA.4/5 in patients with cirrhosis | Qian Zhu | ![]() |
![]() |
|||
SAT-376 | Osteopontin serves as a potential regulator of T cell immunity in patients with hepatocellular carcinoma | Tengfei Si | ![]() |
![]() |
|||
THU-377 | Alkaline phosphatase on admission to the intensive care unit as a new early prognostic biomarker for the development of COVID-19-associated secondary sclerosing cholangitis | Stephan Schmid | ![]() |
![]() |
|||
WED-377 | Poorer results in the clinical frailty scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis | Eva Maria Schleicher | ![]() |
![]() |
|||
SAT-377 | Comprehensive phenotypical and molecular characterization of B lymphocytes in patients affected by intrahepatic cholangiocarcinoma | Giulia Milardi | ![]() |
![]() |
|||
WED-378 | Anemia in cirrhotic patients is a risk factor for esophagogastric variceal bleeding and mortality | ELENA SANTOS | ![]() |
![]() |
|||
THU-378 | Outcomes in adult patients with progressive familial intrahepatic cholestasis treated with odevixibat: subgroup analysis from the PEDFIC 2 study | Janis M. Stoll | ![]() |
![]() |
|||
WED-379 | Prucalopride : a novel and safe usage for reducing incidence of hepatic encephalopathy in decompensated cirrhosis | MANASA ALLA | ![]() |
![]() |
|||
SAT-379 | The decrease of HCV-specific neutralising antibody responses after DAA therapy is associated with weak envelope-specific CD4 T cell immunity | Jill Werner | ![]() |
![]() |
|||
THU-379 | Association of liver injury and prognosis in patients with severe fever with thrombocytopenia syndrome | Rui Huang | ![]() |
![]() |
|||
SAT-380 | Epigenetic conversion of CD4 T cells to stable and functioning induced regulatory T cells via cyclin-dependent kinase inhibition and CD28 signal deprivation in patients with primary biliary cholangitis | Vincenzo Ronca | ![]() |
![]() |
|||
WED-380 | Surgical subtype predicts adverse outcomes and costs among nonalcoholic cirrhotic patients | Carolyn Catalano | ![]() |
![]() |
|||
THU-380 | State of knowledge of alpha 1 anti-trypsin deficiency among practitioners specialized in liver transplantation in France : a national survey | Manon EVAIN | ![]() |
![]() |
|||
THU-381 | Symptom severity measured by polycystic liver disease-specific questionnaire score partly correlates with both total number of liver cysts and the presence of dominant cysts | Avisnata Das | ![]() |
![]() |
|||
WED-381 | Analysis of surgical risk in patients with advanced chronic liver disease and major orthopedic surgery from a gender perspective | Lidia Canillas Alavés | ![]() |
![]() |
|||
FRI-381 | Insulin determines TGF- effects on HNF4a transcription in hepatocytes | Steven Dooley | ![]() |
![]() |
|||
SAT-381 | Intermediate monocytes and associated chemokines allow differentiation of idiosyncratic drug-induced liver injury (DILI) and autoimmune hepatitis (AIH) | Stuart Astbury | ![]() |
![]() |
|||
WED-382 | Availability and affordability of services affects outcome in hospitalized patients with cirrhosis-results from CLEARED consortium | Ashok Choudhury | ![]() |
![]() |
|||
THU-382 | Online education yields significant gains in gastroenterologists knowledge of clinical manifestations of Wilson disease | Adriana Stan | ![]() |
![]() |
|||
FRI-382 | 3D digital histopathology: a new methodology for morphological characterization of the human liver | Mathieu De Langlard | ![]() |
![]() |
|||
SAT-382 | TIGIT inhibits the cytotoxic effects of NK cells towards biliary epithelial cells in autoimmune hepatitis | Amber Bozward | ![]() |
![]() |
|||
WED-383 | Serum ammonia levels do not correlate with overt hepatic encephalopathy severity and time to resolution in hospitalized patients with cirrhosis | Tobin Sharp | ![]() |
![]() |
|||
SAT-383 | Liver sinusoidal scavenger cells eliminate betaherpesvirus from the blood stream | Anett Kristin Larsen | ![]() |
![]() |
|||
THU-383 | Progressive familial intrahepatic cholestasis: KFSH & RC | Muath Najmi | ![]() |
![]() |
|||
FRI-383 | Magnesium content decreases and transient receptor potential melastatin-subfamily member 7 expression increases in hepatocytes as liver inflammation and cirrhosis worsen in liver transplant candidates | simona parisse | ![]() |
![]() |
|||
FRI-384 | Three-dimensional single-cell digital atlas of liver tissue architecture | Fabián Segovia-Miranda | ![]() |
![]() |
|||
WED-384 | Six-fold increased rate of chronic kidney disease after acute kidney injury: a population-based cohort study of 46,946 patients with cirrhosis | Anna Cederborg | ![]() |
![]() |
|||
THU-384 | Clinical picture of acute hepatitis in children - single center observations | Anna Mania | ![]() |
![]() |
|||
SAT-384 | Immune characterization of the melanocortin-4-receptor mouse model for non-alcoholic steatohepatitis using mass cytometry and imaging mass cytometry | Fabienne Birrer | ![]() |
![]() |
|||
THU-385 | Differences in the rates of liver-related clinical events in paediatric patients with alpha-1 antitrypsin deficiency-associated liver disease in the United States | Ed G. Marins | ![]() |
![]() |
|||
WED-385 | Patients with liver cirrhosis and TIPS are prone to in-hospital falls | Nada Abedin | ![]() |
![]() |
|||
SAT-385 | The effect of testosterone on human T cells in health and autoimmune liver disease | Lara Henze | ![]() |
![]() |
|||
FRI-385 | Multiomic profiling associated with lipid remodeling in senescent primary human hepatocytes | Sin-Tian Wang | ![]() |
![]() |
|||
WED-386 | Correlation between mid-arm circumference and QRS alterations as markers of sarcopenia in patients with decompensated cirrhosis | Letitia Toma | ![]() |
![]() |
|||
THU-386 | Understanding the experience of patients with alpha-1 antitrypsin deficiency (AATD)-associated liver disease | Virginia Clark | ![]() |
![]() |
|||
FRI-386 | Tick-tock Uncovering new aspects of circadian-regulated liver metabolism by kinetic modeling | Christiane Körner | ![]() |
![]() |
|||
SAT-386 | CXCL9 does not ameliorate murine macrophage activation syndrome hepatitis | Tamir Diamond | ![]() |
![]() |
|||
FRI-387 | Dickkopf-1 inhibitor enhances the anti-tumor effects of sorafenib through inhibition of PI3K/Akt/Wnt signaling in hepatocellular carcinoma | Sang Hyun Seo | ![]() |
![]() |
|||
SAT-387 | Characterisation of invariant natural killer T cells in human hepatic biopsies | Elena Jiménez-Martí | ![]() |
![]() |
|||
WED-387 | Uromodulin serum levels are associated with poorer prognosis in patients with cirrhosis and hepatorenal syndrome | Eva Maria Schleicher | ![]() |
![]() |
|||
THU-387 | Acute liver failure due neonatal hemochromatosis: case with fatal outcome despite early diagnosis and treatment | Liudmyla Shostakovych-Koretska | ![]() |
![]() |
|||
SAT-388 | Mast cell activation index as a novel prognostic marker in a pan-analysis of gastrointestinal cancers | Nataliya Rohr-Udilova | ![]() |
![]() |
|||
FRI-388 | Liver spheroids engrafted in the anterior chamber of the eye - a novel platform to study hepatic physiology and pathology | Francesca Lazzeri-Barcelo | ![]() |
![]() |
|||
SAT-389 | The ascitic environment in cirrhosis upregulates the expression of the immune checkpoint CD155 on peritoneal macrophages | Joseph Delo | ![]() |
![]() |
|||
WED-389 | Rotational Thromboelastometry (ROTEM) reduces need for pre-emptive transfusion in low-moderate risk procedure in cirrhosis: a randomized controlled trial | Rahul Kumar | ![]() |
![]() |
|||
FRI-389 | With-in patient comparison of single-cell versus single-nucleus sequencing on human transjugular liver biopsies | Lukas Van Melkebeke | ![]() |
![]() |
|||
THU-389 | The ancestral haplotype HLA-A3 does not influence the likelihood of advanced hepatic fibrosis or cirrhosis in C282Y homozygous hemochromatosis | John Olynyk | ![]() |
![]() |
|||
THU-390 | Demographics, outcomes, and costs of Wilsons disease hospitalizations: a nationwide cohort study | Ankoor Patel | ![]() |
![]() |
|||
WED-390 | Long-term cellular immune response to COVID-19 vaccination in patients with chronic liver disease | Mariana Moura Henrique | ![]() |
![]() |
|||
SAT-390 | Distinct immunometabolic signatures in circulating immune cells define disease outcomes in acute-on-chronic liver failure | Schalk van der Merwe | ![]() |
![]() |
|||
FRI-390 | Accumulation of apical bulkheads and hepatocyte rosettes as adaptive responses upon impaired bile flow in liver diseases | Carlotta Mayer | ![]() |
![]() |
|||
WED-391 | The relation of serum nesfatin-1 levels with disease severity and complications in patients with liver cirrhosis | Hasan Eruzun | ![]() |
![]() |
|||
FRI-391 | Long-term effects in primary human hepatocytes (PHH) after exogenous exposure to human intestinal microbiome secretome peptides | Natalia Sanchez-Romero | ![]() |
![]() |
|||
SAT-391 | RIPK3-mediated XBP1-Foxo1 axis controls NOD1 function and Calcineurin/TRPM7-induced cell death in liver inflammatory injury | Bibo Ke | ![]() |
![]() |
|||
THU-391 | Proteomics for the study of biomarkers in Wilsons disease | LI LI | ![]() |
![]() |
|||
THU-392 | Emphysematous pancreatitis: a sporadic sequela of necrotizing pancreatic infections | Audrey Fonkam | ![]() |
![]() |
|||
SAT-392 | Phenotypical and functional sub-classification of Kupffer cells and liver monocyte-derived macrophages in mice | Hiroyuki Nakashima | ![]() |
![]() |
|||
FRI-392 | Integrated metabolomic and transcriptomic analyses implicate specific metabolic pathways in crocin-induced apoptosis of HCC cells | Amr Amin | ![]() |
![]() |
|||
WED-393 | A functional interaction between hepatic estrogen receptor-a and PNPLA3 p.I148M inherited variant drives fatty liver disease susceptibility in women | Alessandro Cherubini | ![]() |
![]() |
|||
SAT-393 | Early aminotransferase improvement in the phase 2b NATIVE study is predictive of response pattern of liver histology as well as hepatic and cardiometabolic health markers at the end of treatment in patients with non-cirrhotic NASH | Quentin Anstee | ![]() |
![]() |
|||
THU-393 | Noninvasive screening for histological features of autoimmune hepatitis and prognosis of patients with antinuclear antibody-positive drug-induced liver injury | Feiyu Zhang | ![]() |
![]() |
|||
FRI-393 | Serum proteomics in American adults with acute liver failure | Katharina Remih | ![]() |
![]() |
|||
SAT-394 | Novel artificial intelligence-assisted digital pathology quantitative image analysis predicts the occurrence of liver-related clinical events in the multicentric, European, hepatic outcomes and survival fatty liver registry (HOTSURFR) study | Vlad Ratziu | ![]() |
![]() |
|||
THU-394 | Outbreak of unexplained acute hepatitis in children: the role of viral infections | Yael Gozlan | ![]() |
![]() |
|||
FRI-394 | Inhibition of CCR-8 attenuates macrophage migration in vitro and intrahepatic monocyte recruitment in vivo | Eline Geervliet | ![]() |
![]() |
|||
FRI-395 | E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects | Xabier Buque | ![]() |
![]() |
|||
SAT-395 | Risk-stratification of patients with non-alcoholic fatty liver disease (NAFLD) in primary care: lessons from the Calgary NAFLD pathway | Abdel-Aziz Shaheen | ![]() |
![]() |
|||
WED-395 | Brain-derived neurotrophic factor knock-out mice develop nonalcoholic steatohepatitis | Mayuko Shimizu | ![]() |
![]() |
|||
FRI-396 | Mesenchymal stem cell-derived small extracellular vesicles ameliorate liver injury via attenuating macrophage extracellular traps | Zhihui Li | ![]() |
![]() |
|||
WED-396 | The PNPLA3 p.I148M risk variant was fixed in Neanderthals and segregates neutrally in humans | Andreas Geier | ![]() |
![]() |
|||
THU-396 | Determinants of steroid responsiveness in patients with severe acute hepatitis of indeterminate, autoimmune hepatitis and drug induced aetiologies | MohammadMahdi Saeidinejad | ![]() |
![]() |
|||
SAT-396 | Thrombospondin-2 as a new biomarker for at risk NASH and advanced fibrosis in a large multicentric European cohort | Vlad Ratziu | ![]() |
![]() |
|||
FRI-397 | SRT-015, best-in-class apoptosis signal-regulating kinase 1 inhibitor, demonstrates preclinical efficacy in acute models of liver injury | Kathleen Elias | ![]() |
![]() |
|||
THU-397 | Clinical and histological features of drug-induced liver injury: a retrospective study in biopsy-based cohort | Ting Zhang | ![]() |
![]() |
|||
SAT-397 | Predicting severe liver outcomes in NAFLD using repeated measurements of biomarkers---a cohort study in 1,260 patients | Ying Shang | ![]() |
![]() |
|||
WED-397 | Role of TGR5 in fat-to-liver communication during NAFLD | André L. Simăo | ![]() |
![]() |
|||
FRI-398 | Microbiome and metabolome analysis outlines circulatory predictors of poor outcomes in ALF | SUSHMITA PANDEY | ![]() |
![]() |
|||
THU-398 | Clinical characteristics of chronic drug-induced liver injury in China: a multicenter retrospective cross-sectional study | Hong Zhao | ![]() |
![]() |
|||
SAT-398 | Improvements in liver fibroinflammation (as assessed by corrected T1 cT1) with HTD1801 (berberine ursodeoxycholate) treatment in patients with nonalcoholic steatohepatitis and type 2 diabetes mellitus | Stephen Harrison | ![]() |
![]() |
|||
WED-398 | Hepatic lipid flux, and not lipid amount, damages the liver during starvation-induced steatosis | Sumeet Singh | ![]() |
![]() |
|||
THU-399 | Impact of plasma exchange and evolution of intensive care management in patients with acute liver failure in a liver transplant center over the past decade | Octavi Bassegoda | ![]() |
![]() |
|||
WED-399 | Targeting Apolipoprotein J restores autophagy and improves metabolic-associated fatty liver disease and diabetic nephropathy | Wang Hsin-Tzu | ![]() |
![]() |
|||
SAT-399 | Prevalence of NAFLD and advanced fibrosis in Stockholm, Sweden | Emilie Toresson Grip | ![]() |
![]() |
|||
FRI-399 | Neddylation inhibition recovers drug-induced liver injury through the stabilization of Tamm41 | CLŔUDIA GIL PITARCH | ![]() |
![]() |
|||
THU-400 | Reversibility and long-term outcomes of portal sinusoidal vascular disease in patients with drug-induced liver injury | Mengqi Li | ![]() |
![]() |
|||
WED-400 | mTORC1 response to glucose via dihydroxyacetone phosphate is regulated by MAT1A. Role in NAFLD | María De Los Reyes Luque Urbano | ![]() |
![]() |
|||
FRI-400 | Forward programming to produce hepatocytes organoids for cell based therapy | Fabian Bachinger | ![]() |
![]() |
|||
SAT-400 | Accuracy of 100 Hz transient elastography-based spleen stiffness for the identification of advanced fibrosis in biopsy-proven non alcoholic fatty liver disease | Angelo Armandi | ![]() |
![]() |
|||
SAT-401 | Performance of non-invasive tests as exclusion criteria for cirrhosis in trials targeting at-risk nonalcoholic steatohepatitis: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium) | Julie Dubourg | ![]() |
![]() |
|||
FRI-401 | Stress-driven suppression of the hippo pathway accelerates liver injury | Na Young Lee | ![]() |
![]() |
|||
WED-401 | Development of a target engagement biomarker for HSD17B13: preclinical pharmacodynamic studies of small molecule inhibition of HSD17B13 by INI-822 | Chuhan Chung | ![]() |
![]() |
|||
THU-401 | Stanozolol-induced liver injury: a peculiar biochemical profile in a series of thirteen cases | Vinicius Nunes | ![]() |
![]() |
|||
WED-402 | Modelling the biological mechanisms of a PNPLA3 polymorphism in a 3D human liver spheroid for NASH progression and drug efficacy | Francisco Verdeguer | ![]() |
![]() |
|||
THU-402 | Systematic review: patients with pre-existing chronic liver disease are more vulnerable to the severe sequelae of drug induced liver injury | Georgia Zeng | ![]() |
![]() |
|||
FRI-402 | Irinotecan dysregulates lipolysis in chemotherapy-associated steatohepatitis | Martina Derler | ![]() |
![]() |
|||
SAT-402 | FIB-4 predicts the risk of hepatocellular carcinoma in patients with type 2 diabetes: a longitudinal multicentre study | Vincent Mallet | ![]() |
![]() |
|||
THU-403 | Autoimmune hepatitis (AIH) or drug-Induced liver injury (DILI) a diagnostic challenge | Yaakov Maor | ![]() |
![]() |
|||
SAT-403 | FIB-4 as a screening tool for significant liver fibrosis in a cohort of overweight subjects involved in a weight loss program conducted in a primary care setting | Charlotte Costentin | ![]() |
![]() |
|||
FRI-403 | Control compounds used to validate in vitro models of idiosyncratic drug-induced liver injury: a systematic review | Marina Villanueva Paz | ![]() |
![]() |
|||
WED-403 | Perivascular macrophages contribute to adipose tissue angiogenesis in patients with advanced non-alcoholic fatty liver disease | Celia Sánchez | ![]() |
![]() |
|||
THU-404 | Gender differences in liver transplantation (LT) for acute liver failure (ALF) in a multicentre ALF-LT Spanish cohort | Victoria Aguilera Sancho | ![]() |
![]() |
|||
FRI-404 | A systems medicine approach for the identification of potential prognostic biomarkers in patients with acute decompensation of cirrhosis | Estefania Huergo Iglesias | ![]() |
![]() |
|||
SAT-404 | Soluble TREM2 and PRO-C3 as efficacy of intervention markers in NASH | Charlotte Wernberg | ![]() |
![]() |
|||
WED-404 | The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH | Maider Apodaka Biguri | ![]() |
![]() |
|||
SAT-405 | Dynamic changes in liver stiffness assessed by transient elastography as a prognostic factor in NAFLD patients with prediabetes and type 2 diabetes | Elias Maleh | ![]() |
![]() |
|||
FRI-405 | Kelch-like ECH-associated protein-1 deletion rescues cell death associated with glutathione-glutathione peroxidase 4 knockdown in hepatocytes in acute models of liver injury | Leticia Colyn | ![]() |
![]() |
|||
WED-405 | The PNPLA3 I148M variant initiates metabolic reprogramming in macrophages | Emmanuel Dixon | ![]() |
![]() |
|||
THU-405 | CDK 4/6 inhibitors induced liver injury: 7 cases from REFHEPS registry | Lucy Meunier | ![]() |
![]() |
|||
THU-406 | Exponential increase of paracetamol liver injury over the last decade in a Spanish referral center | Anna Pocurull | ![]() |
![]() |
|||
WED-406 | Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH) | Wenhao Li | ![]() |
![]() |
|||
FRI-406 | Altered intestinal permeability in patients with drug-induced liver injury and other forms of acute liver injury: a sequential analysis of serum levels of LBP, CD14 and CD163 | Daniel E. Di Zeo-Sánchez | ![]() |
![]() |
|||
SAT-406 | Fibrosis-4 score and liver stiffness measurement by vibration-controlled transient elastography predict risk of liver-related events in non-alcoholic fatty liver disease | Esteban Urias | ![]() |
![]() |
|||
THU-407 | Liver transplantation in acute liver failure in Slovenia | Marjana Turk Jerovek | ![]() |
![]() |
|||
SAT-407 | A stepwise screening approach using noninvasive tests to identify phenotypic nonalcoholic steatohepatitis (NASH) patients with fibrosis for clinical trials | Swapna Shenvi | ![]() |
![]() |
|||
FRI-407 | Platelets proteome dynamics and its association with liver severity in severe alcoholic hepatitis | Rupinder Kalra | ![]() |
![]() |
|||
WED-407 | Characterization of extracellular vesicles derived from human precision-cut liver slices in non-alcoholic fatty liver disease | Ke Luo | ![]() |
![]() |
|||
FRI-408 | Characterization of fibrogenesis in severe alcohol-related hepatitis using a 3D model of coculture of organoids and fibroblasts from patients | Line Carolle Ntandja Wandji | ![]() |
![]() |
|||
THU-408 | Chemotherapy-induced hepatotoxic reactions in patients with acute myeloid leukemia: the overweight and obesity role in the pathogenesis | Igor Skrypnyk | ![]() |
![]() |
|||
WED-408 | E2F2-promoted DNA damage in NASH worsens the metabolic scenario | Beatriz Gomez-Santos | ![]() |
![]() |
|||
WED-409 | Uncovering a novel potential target in non-alcoholic fatty liver disease | Stine Marie Praestholm | ![]() |
![]() |
|||
FRI-409 | An increase in the number of activated regulatory T cells is associated with an improvement in liver function of patients with severe alcoholic hepatitis after steroid therapy | Soon Kyu Lee | ![]() |
![]() |
|||
SAT-409 | Validation of elastography criteria and cACLD risk model for diagnosis of compensated advanced chronic liver disease (cACLD) in NAFLD patients | Antonio Liguori | ![]() |
![]() |
|||
WED-410 | mir-22 inhibition as glp1 agonist orthogonal mechanism for nafl and nash treatment | Riccardo Panella | ![]() |
![]() |
|||
THU-410 | Systematic screening for NAFLD-related advanced fibrosis in high-risk population in diabetology using transient elastography: a prospective study | Cyrielle Caussy | ![]() |
![]() |
|||
FRI-410 | Plasma lipidomics and meta-proteomics analysis classifies lipid species and microbial peptides associated with poor outcome in SAH patients | jaswinder singh maras | ![]() |
![]() |
|||
SAT-410 | Predictors of liver stiffness changes in consecutive cohorts of patients with non-alcoholic fatty liver disease and longitudinal follow up | Mirko Zoncapč | ![]() |
![]() |
|||
THU-411 | Low-quality muscle mass predicts fibrosis progression in a prospective biopsy-proven nonalcoholic fatty liver disease cohort | Sae Kyung Joo | ![]() |
![]() |
|||
SAT-411 | Association of non-high-density lipoprotein cholesterol trajectories with the development of non-alcoholic fatty liver disease | Hyo Young Lee | ![]() |
![]() |
|||
WED-411 | Biomarkers identifying hepatic inflammation in non-alcoholic fatty liver disease (NAFLD) | Elisabeth Galsgaard | ![]() |
![]() |
|||
SAT-412 | A gut-mycobiome-derived signature predicts advanced fibrosis in people with diabetes | Rohit Loomba | ![]() |
![]() |
|||
THU-412 | Natural history & long-term outcomes of the Newcastle non-alcoholic fatty liver disease cohort | Jenny Gallacher | ![]() |
![]() |
|||
WED-412 | Peroxisome proliferator-activated receptor alpha and estrogen related receptor alpha ligand combinations ameliorate nonalcoholic fatty liver disease | Milton Antwi | ![]() |
![]() |
|||
FRI-412 | The beneficial effects of the diet withdrawal and physical exercise on steatohepatitis of DUAL etiology | Olga Estévez Vázquez | ![]() |
![]() |
|||
FRI-413 | When is the optimal time to collect baseline data for calculating the Lille score in severe alcoholic hepatitis? | Mina Ignat | ![]() |
![]() |
|||
THU-413 | Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium) | Julie Dubourg | ![]() |
![]() |
|||
SAT-413 | Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease | Guanlin LI | ![]() |
![]() |
|||
WED-413 | PNPLA3, MBOAT7 and TM6SF2 modify mitochondrial dynamics in NAFLD patients: dissecting the role of cell-free circulating mtDNA and copy number | Miriam Longo | ![]() |
![]() |
|||
WED-414 | NAT10-mediated N4-acetylcytidine of hepatic lipogenesis-associated mRNA contributes to maternal high-fat diet-induced non-alcoholic fatty liver disease in juvenile offspring | Qianren Zhang | ![]() |
![]() |
|||
THU-414 | Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients | Ying Shang | ![]() |
![]() |
|||
SAT-414 | Standardized non-invasive screening for non-alcoholic fatty liver disease in people with type 2 diabetes identifies a substantial number of individuals with advanced liver disease | Naomi Lange | ![]() |
![]() |
|||
FRI-414 | Low doses of different hepatotoxins induce alcohol-related liver disease and drive hepatocellular carcinoma | Brisa Rodope Alarcón-Sánchez | ![]() |
![]() |
|||
WED-415 | Type I NKT cells are involved in exacerbation of steatohepatitis in aged mice | Kazuyoshi Kon | ![]() |
![]() |
|||
THU-415 | Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism | Chiara Rosso | ![]() |
![]() |
|||
FRI-415 | Systemic dyslipidemia in Ldlr mice accelerates hepatic fibrosis after chronic-binge ethanol feeding | Constanze Hoebinger | ![]() |
![]() |
|||
THU-416 | Patatin-like phospholipase domain-containing 3 (PNPLA3) risk allele increases rate of progression to end-stage liver disease outcomes and decreases survival rate over time irrespective of degree of fibrosis | Javier Armisen | ![]() |
![]() |
|||
WED-416 | Depicting metabolic and immune landscape of bariatric surgery intervened NAFL | Hanyang Liu | ![]() |
![]() |
|||
SAT-416 | Performance of non-invasive fibrosis tests for long-term liver and heart outcomes in Europeans with metabolic risk factors from the UK Biobank | Federica Tavaglione | ![]() |
![]() |
|||
THU-417 | A risk prediction model for hepatocellular carcinoma for non-alcoholic fatty liver disease without cirrhosis | Gi-Ae Kim | ![]() |
![]() |
|||
FRI-417 | Multi-omics analysis reveals the therapeutic effect and mechanism of the Chinese herbal JiGuCao capsule on acute alcoholic hepatitis in mice | Yue Chen | ![]() |
![]() |
|||
WED-417 | Efficacy and reproducibility of AI-assisted Gubra Histopathological Objective Scoring Technique (GHOST) in preclinical rodent models of NASH | Susanne Pors | ![]() |
![]() |
|||
SAT-417 | Impact of age as a confounding factor on non-invasive blood-based tests for the evaluation of non-alcoholic fatty liver disease: comparing NIS2TM to established tests | Quentin Anstee | ![]() |
![]() |
|||
THU-418 | Histological classifications versus liver-related events: results from the multicentric, European, hepatic outcomes and survival fatty liver registry (HOTSURFR) study | Vlad Ratziu | ![]() |
![]() |
|||
SAT-418 | Cost effectiveness analysis of screening for advanced hepatic fibrosis in patients with various at-risk population in guidelines | Hye-Lin Kim | ![]() |
![]() |
|||
WED-418 | The PNPLA3 I148M variant aggravates inflammation through dysfunctional LXR and PPAR gamma signalling in macrophages | Emmanuel Dixon | ![]() |
![]() |
|||
FRI-418 | Strategies are needed to support people with alcohol use disorder and alcohol-related liver disease to take part in randomised clinical trials: results from the MIRAGE pilot trial of functional imagery training | Ashwin Dhanda | ![]() |
![]() |
|||
FRI-419 | Supplementation of choline attenuates the onset of alcohol-related liver disease | Victor Manuel Sanchez Juarez | ![]() |
![]() |
|||
WED-419 | The disturbance of intracellular chloride induces the development and progression of nonalcoholic fatty liver disease | Biguang Tuo | ![]() |
![]() |
|||
THU-419 | GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals | Rajamannar Thennati | ![]() |
![]() |
|||
SAT-419 | Which screening of advanced liver fibrosis in NAFLD? | PAUL CALES | ![]() |
![]() |
|||
FRI-420 | Increased concentration of 4-hydroxyphenyllactic acid in patients with alcohol-related liver disease could promote the growth of Lactobacillus spp | Jin-Ju Jeong | ![]() |
![]() |
|||
WED-420 | Mice lacking Cyclophilin B, but not Cyclophilin A, are significantly protected from the development of major features of NAFLD/NASH in a diet and chemical-induced model | Winston Stauffer | ![]() |
![]() |
|||
THU-420 | Association between consumption of ultra-processed foods and nonalcoholic fatty liver disease in the Framingham heart study | Natalie Sun | ![]() |
![]() |
|||
SAT-420 | Glomerular hyperfiltration: a new marker of fibrosis severity in non-cirrhotic non-alcoholic fatty liver disease | Marta Garbin | ![]() |
![]() |
|||
FRI-421 | Granulocyte monocyte/macrophage apheresis for corticosteroid-nonresponsive or -intolerant severe alcohol-associated hepatitis: a nonrandomized controlled study | Ryosuke Kasuga | ![]() |
![]() |
|||
SAT-421 | NIS2 as a screening tool for optimizing patient ion in non-alcoholic steatohepatitis therapeutic trials | Yacine HAJJI | ![]() |
![]() |
|||
WED-421 | Growth differentiation factor 15 in plasma and liver is associated with hepatic oxidative stress in non-alcoholic fatty liver disease | Mikkel Werge | ![]() |
![]() |
|||
THU-421 | Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease | Grazia Pennisi | ![]() |
![]() |
|||
WED-422 | Decoding hepatocyte transcriptional responses in murine non-alcoholic steatohepatitis using single-nucleus RNA-sequencing | Juliet Luft | ![]() |
![]() |
|||
SAT-422 | Abdominal adiposity and insulin resistance are the main predictors of CAP values in individuals with metabolic dysfunction: the liver-bible cohort | Cristiana Bianco | ![]() |
![]() |
|||
FRI-422 | Diabetes increases risk of mortality in alcohol-related liver disease | Richard Parker | ![]() |
![]() |
|||
THU-422 | PNPLA3 GG genotype is associated with higher incidence of cirrhosis and liver-related events among patients with nonalcoholic fatty liver disease | Vincent Chen | ![]() |
![]() |
|||
THU-423 | Long-term prognosis of patients with non-alcoholic fatty liver disease: a retrospective cohort study to understand the impact of surrogate disease endpoints on long-term outcomes in South Korea | Sung Won Chung | ![]() |
![]() |
|||
SAT-423 | A mass-spectrometry serum test for identifying liver fibrosis and at-risk NASH enabling cost-effective population screening | Shira Shaham-Niv | ![]() |
![]() |
|||
FRI-423 | Pharmacological therapy for alcohol use disorder is effective and safe in patients with cirrhosis. Systematic review and meta-analysis | Jordi Gratacos | ![]() |
![]() |
|||
WED-424 | Peculiar monocyte bioenergetic profile in nonalcoholic steatohepatitis (NASH) | Moris Sangineto | ![]() |
![]() |
|||
SAT-424 | Comparison between EASL and AGA algorithms for hepatology referral in 1572 outpatients with type 2 diabetes and suspected NAFLD seen in a diabetes clinic | laurent Castera | ![]() |
![]() |
|||
THU-424 | Prevalence of extrahepatic manifestations in nonalcoholic fatty liver disease in lean individuals compared to non-lean individuals | Majd Aboona | ![]() |
![]() |
|||
FRI-424 | Binge drinking acutely induces fatty liver with increased liver stiffness which is readily reversed | Kristoffer Kjrgaard | ![]() |
![]() |
|||
THU-425 | De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease | Chiara Rosso | ![]() |
![]() |
|||
SAT-425 | Non-Alcoholic Steatohepatitis impacts on visceral adipose tissue proteomic signature | Cristian Martinez Navidad | ![]() |
![]() |
|||
FRI-425 | Disentangling the contributions of alcohol and alcohol-related liver disease towards dementia | Sixian Zhao | ![]() |
![]() |
|||
WED-425 | Co-stimulatory signals mediated by inducible T-cell co-stimulator (ICOS) influence the hepatic expansion auto-aggressive CD8T-cells in non-alcoholic steatohepatitis (NASH) | Alessia Provera | ![]() |
![]() |
|||
THU-426 | A social media listening study of patients experiences toward NAFLD (LISTEN-NAFLD) | Abhinab Bhanja | ![]() |
![]() |
|||
WED-426 | Uncovering the role of ISOC1 in non-alcoholic fatty liver disease | Nicolas Goossens | ![]() |
![]() |
|||
SAT-426 | AI-enabled virtual hematoxylin & eosin and Massons trichrome staining for nonalcoholic fatty liver disease activity scoring from single unstained slide | Shamira Sridharan | ![]() |
![]() |
|||
FRI-426 | Nucleoredoxin-dependent functioning is dysregulated by chronic alcohol consumption and is associated with the establishment of cellular senescence in the liver of aged mice | Osiris German Idelfonso García | ![]() |
![]() |
|||
THU-427 | Genetic risk factors for NAFLD and clinically significant fibrosis in persons living with HIV | Eduardo Vilar Gomez | ![]() |
![]() |
|||
FRI-427 | Risk of alcohol-related liver disease in offspring of individuals with alcohol-related liver disease: a nationwide cohort study in Denmark | Gro Askgaard | ![]() |
![]() |
|||
SAT-427 | Practical diagnosis of cirrhosis by liver specialists in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests | Jérme Boursier | ![]() |
![]() |
|||
WED-427 | APB-R3, a novel long-acting IL-18 binding protein, inhibits IL-18 activity, and thereby ameliorates NASH progress with reduced liver fibrosis | Yong-Hyun Han | ![]() |
![]() |
|||
SAT-428 | Associations of genetic risk panel with enhanced liver fibrosis scores among patients with non-alcoholic fatty liver disease | Carey Escheik | ![]() |
![]() |
|||
THU-428 | Digital pathology with artificial intelligence analyses provides deeper insights into lifestyle intervention-induced fibrosis regression in NASH | Ren Ya-Yun | ![]() |
![]() |
|||
WED-428 | In vitro investigation of the role of adipocyte-derived exosomes in the development of non-alcoholic steatohepatitis | Robim M Rodrigues | ![]() |
![]() |
|||
FRI-428 | US trends and contribution of metabolic syndrome in alcohol-associated liver disease from 1999-2018 | Brian Lee | ![]() |
![]() |
|||
FRI-429 | Alcohol rehabilitation after alcoholic hepatitis is associated with reduced mortality: results of a 2012-2021 National retrospective study | Vincent Mallet | ![]() |
![]() |
|||
THU-429 | Societal costs and labor market affiliation of histologically confirmed non-alcoholic steatohepatitis a Danish register-based study | Peter Bo Poulsen | ![]() |
![]() |
|||
SAT-429 | Morphometric analysis of sonic hedgehog in non-alcoholic fatty liver and steatohepatitis patients by MorphoQuant: a potential biomarker of disease severity | Cindy Serdjebi | ![]() |
![]() |
|||
SAT-430 | Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study | Gian Paolo Caviglia | ![]() |
![]() |
|||
THU-430 | Prevalence and mortality of non-alcoholic fatty liver disease (NAFLD) in non-diabetics, pre-diabetics, and diabetics in the United States | Carey Escheik | ![]() |
![]() |
|||
FRI-430 | The role of HSD17B13 and MBOAT7 during alcohol detoxification: different effects on fibrosis and inflammation | Sebastian Mueller | ![]() |
![]() |
|||
WED-430 | Adipose tissue macrophage dysfunction and depletion are associated with a breach of vascular integrity in non-alcoholic steatohepatitis | Schalk Van Der Merwe | ![]() |
![]() |
|||
WED-431 | Circadian sleep-wake rhythms in non-alcoholic fatty liver disease | Emilio Flint | ![]() |
![]() |
|||
SAT-431 | LIVERFASt GP (LiverSTAT), first-line screening tool in at-risk MAFLD patients outperforms the standard-of-care (SOC) FIB-4 | Mona Munteanu | ![]() |
![]() |
|||
FRI-431 | Patients with alcohol-related cirrhosis who recompensate on follow-up have a characteristic metabolomic profile with differential concentrations of lipid and amino-acid metabolites | Helena Hernandez Evole | ![]() |
![]() |
|||
THU-431 | Genetic and metabolic characteristics of lean non-alcoholic fatty liver disease in Asian | Dae Won Jun | ![]() |
![]() |
|||
THU-432 | PNPLA3 protein levels are increased in liver and decreased in adipose tissue from patients with obesity-associated nonalcoholic steatohepatitis | Helena Castańé | ![]() |
![]() |
|||
FRI-432 | A cost-comparison of the LiverPRO score with FIB-4, ELF, and FibroScan in 6,032 study participants | Katrine Lindvig | ![]() |
![]() |
|||
SAT-432 | Velacur ACE outperforms CAP for liver fat quantification using MRI PDFF as the gold standard | Rohit Loomba | ![]() |
![]() |
|||
WED-432 | TLR-X (IOA-359) attenuates steatosis and fibrosis in a preclinical NASH model | Marit Ten Hove | ![]() |
![]() |
|||
FRI-433 | HAZARDOUS ALCOHOL CONSUMPTION IS ASSOCIATED WITH A WORSE PROGNOSIS IN PATIENTS UNDERGOING BARIATRIC SURGERY | Edilmar Alvarado-Tapias | ![]() |
![]() |
|||
THU-433 | Impact of PNPLA3 polymorphism on non-alcoholic fatty liver disease in Japan: a multicenter cohort study | YUYA SEKO | ![]() |
![]() |
|||
SAT-433 | Assessing the role of organokines as biomarkers for diagnosing non-alcohol related liver disease | Andrea Jiménez Franco | ![]() |
![]() |
|||
WED-434 | Statins regulate PNPLA3 through a mechanism that requires SREBF2 in human liver cells | Osman Ahmed | ![]() |
![]() |
|||
SAT-434 | Evaluating the prevalence of liver fibrosis in children with non-alcoholic fatty liver disease using transient elastography, Dutch Fibrokids cohort | Bart Koot | ![]() |
![]() |
|||
FRI-434 | Low sphingolipid levels indicate poor survival in patients with alcohol-related liver disease | Thit Mynster Kronborg | ![]() |
![]() |
|||
THU-434 | Pilot results for a multidisciplinary community metabolic liver clinic | Theresa Hydes | ![]() |
![]() |
|||
FRI-435 | Cause-specific mortality in patients with alcohol-related liver disease: a nationwide Danish cohort study | Anna Emilie Kann | ![]() |
![]() |
|||
WED-435 | Deletion of mixed lineage kinase domain like pseudokinase aggravate chronic alcohol induced liver injury via increasing apoptosis | Dae Won Jun | ![]() |
![]() |
|||
THU-435 | Influence of chronotype and adherence to the mediterranean diet on the risk of liver fibrosis in patients with non-alcoholic fatty liver disease | Gabriele Castelnuovo | ![]() |
![]() |
|||
FRI-436 | Risk of primary liver cancer in alcohol-related cirrhosis - Danish and English cohort studies | Morten Daniel Jensen | ![]() |
![]() |
|||
SAT-436 | The impact of projected increases in obesity prevalence on incident liver disease in the UK: insights from bayesian-network modelling | Tom Waddell | ![]() |
![]() |
|||
THU-436 | Relationship of hepcidin levels to metabolic factors, anthropometric indicators of adiposity and disease severity in NAFLD patients | Claudia Cravo | ![]() |
![]() |
|||
WED-436 | Validation and utility of artificial intelligence-based zonal annotations as an additional assessment tool for the histopathologic review of fibrosis in non-alcoholic steatohepatitis patients | Gwyneth Soon | ![]() |
![]() |
|||
FRI-437 | Beneficial effects of a screening programme for alcohol-related liver fibrosis with transient elastography in people with alcohol use disorder promoting alcohol abstinence | Emma Avitabile | ![]() |
![]() |
|||
WED-437 | Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis | Jung Kuk Kim | ![]() |
![]() |
|||
THU-437 | Impairment of health-related quality of life among people with type 2 diabetes and advanced fibrosis | Maurice Michel | ![]() |
![]() |
|||
WED-438 | Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models | Xiaoxiao Wang | ![]() |
![]() |
|||
THU-438 | The impact of glycemic control on progressive forms of nonalcoholic fatty liver disease: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium) | Julie Dubourg | ![]() |
![]() |
|||
SAT-438 | Utility of SomaSignalTM panels for drug response and monitoring disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis | Kris Kowdley | ![]() |
![]() |
|||
FRI-438 | Epidemic within pandemic: alcohol-related hepatitis and COVID-19 | Natalie Marlowe | ![]() |
![]() |
|||
WED-439 | A heterozygous N559Y mutation in Semaphorin 7A promotes nonalcoholic fatty liver disease progression through induction of hepatic ROS production and inflammation | Yao Tong | ![]() |
![]() |
|||
FRI-439 | Alcohol use disorder among patients admitted with non-alcohol related conditions: a retrospective cohort study in secondary care | Mohsan Subhani | ![]() |
![]() |
|||
SAT-439 | Wearable technology utilizing an electrical impedance tomography (EIT) system for hepatic steatosis quantification and the role in ambulatory monitoring | Loey Mak | ![]() |
![]() |
|||
THU-439 | Glycated hemoglobin as an independent predictor of hepatocyte ballooning in nonalcoholic steatohepatitis: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium) | Julie Dubourg | ![]() |
![]() |
|||
FRI-440 | Histological inflammation in severe alcohol-related hepatitis is the main pre-treatment factor associated to glucocorticoid response | Antonio Saviano | ![]() |
![]() |
|||
THU-440 | Liver fibrosis is associated with cardiovascular disease burden amongst patients with non-alcoholic steatohepatitis: the unCoVer-NASH longitudinal cohort study | Kathleen Corey | ![]() |
![]() |
|||
SAT-440 | Head-to-head comparison of Agile 3, LSM-VCTE, NFS, and FIB-4 scores for detecting advanced fibrosis in patients with type 2 diabetes seen in diabetes clinic | Laurent Castéra | ![]() |
![]() |
|||
WED-440 | Endothelial and platelet-derived microvesicles as a biomarker of cardiovascular risk in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) | Sheila Gato Zambrano | ![]() |
![]() |
|||
THU-441 | Low rates of fibrosis scoring in the primary care records of 5,987 people living with type 2 diabetes | James Hallimond Brindley | ![]() |
![]() |
|||
SAT-441 | Screening for advanced fibrosis due to NAFLD in patients with type 2 diabetes in a retina scanning facility | Andrea Lindfors | ![]() |
![]() |
|||
FRI-441 | The synergistic impact of food insecurity and alcohol use on mortality in adults with significant liver fibrosis | Ani Kardashian | ![]() |
![]() |
|||
WED-441 | IOA-289, an orally available type IV autotaxin inhibitor, ameliorates steatosis and fibrosis in a progressive preclinical murine NASH model | Marit Ten Hove | ![]() |
![]() |
|||
SAT-442 | MRI-PDFF captures the whole spectrum of lipid composition beyond traditional histological evaluation of macrosteatosis | David Marti-Aguado | ![]() |
![]() |
|||
THU-442 | A machine learning-based classification of adult-onset diabetes identifies patients at risk for liver-related complications | Lukas Otero Sanchez | ![]() |
![]() |
|||
WED-442 | Cannabidiolic acid (CBDA) regulates energy homeostasis and protects against non-alcoholic fatty liver disease (NAFLD) | Albert Giralt | ![]() |
![]() |
|||
THU-443 | NAFLD prevalence in the elderly declines with age and is associated with increased frailty, reduced physical function and social disadvantage status: results from the ASPREE study | Daniel Clayton-Chubb | ![]() |
![]() |
|||
FRI-443 | Hemoglobin is a short-term prognostic factor in decompensated alcohol-associated cirrhosis | José Ursic Bedoya | ![]() |
![]() |
|||
WED-443 | Quantification of vessel and bile duct parameters using Second Harmonic Generation in patients with NAFLD across fibrosis stages | Jörn Schattenberg | ![]() |
![]() |
|||
SAT-443 | Two steps algorithm for the diagnosis of advanced liver fibrosis in general population. Real-life data | Ana Pérez | ![]() |
![]() |
|||
THU-444 | Ascites is the most frequent decompensating event in stable And strictly compensated NAFLD with advanced fibrosis | Zouhir Gadi | ![]() |
![]() |
|||
FRI-444 | Impact of heavy alcohol consumption on mitochondrial metabolism | Scott Minchenberg | ![]() |
![]() |
|||
WED-444 | Liver-associated dysmetabolism is related to brain structure and perfusion changes in obesity: the BARICO study | Florine Seidel | ![]() |
![]() |
|||
SAT-444 | Imaging and biomarker thresholds to accurately diagnose NASH cirrhosis in a 180 patient biopsy confirmed cohort | Rohit Loomba | ![]() |
![]() |
|||
WED-445 | Combination therapy of TERN-501, a ive agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves nonalcoholic steatohepatitis (NASH) in a GAN diet-induced and biopsy-confirmed mouse model | Swapna Shenvi | ![]() |
![]() |
|||
THU-445 | The impact of Clostridium difficile on mortality and outcomes in patients with NAFLD vs. NASH | Ankoor Patel | ![]() |
![]() |
|||
FRI-445 | Recompensation following an episode of alcohol-associated hepatitis mostly occurs in the first year of follow-up and is related to Child-Pugh score, levels of GGT and platelets, and alcohol abstinence | Jordi Gratacos | ![]() |
![]() |
|||
SAT-445 | Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test | denis ouzan | ![]() |
![]() |
|||
THU-446 | Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients | Giordano Sigon | ![]() |
![]() |
|||
WED-446 | Unravelling the role of iron-catalysed ferroptotic cell death in non-alcoholic steatohepatitis | Cédric Peleman | ![]() |
![]() |
|||
FRI-446 | A prospective study of hepatic fibrosis evaluation in an alcohol withdrawal unit of an university hospital center : role of FIB-4 and elastometry. Fibraddict study | Armand Abergel | ![]() |
![]() |
|||
FRI-447 | The prevalence and prognostic impact of bariatric surgery in patients hospitalized with alcoholic liver disease | Louis Onghena | ![]() |
![]() |
|||
SAT-447 | Low risk FIB-4 results in patients under 50 years accurately risk assessed patients for adverse liver outcomes over a follow-up of up to 35 years | Jenny Gallacher | ![]() |
![]() |
|||
THU-447 | The national audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK | Wenhao Li | ![]() |
![]() |
|||
WED-447 | CCR-2 antagonizing peptide attenuates macrophage infiltration in NASH | Eline Geervliet | ![]() |
![]() |
|||
WED-448 | Longitudinal ultrasound imaging assessment of murine liver fibrosis in a high fat, fructose, cholesterol (FFC) model and its response to therapy | Ryan Gessner | ![]() |
![]() |
|||
FRI-448 | Prognostic role of serum alpha-1 antitrypsin levels for waitlist mortality in patients with alcohol-associated liver disease | Ronald Samuel | ![]() |
![]() |
|||
SAT-448 | Serum levels of type IV collagen 7S can predict liver-related mortality and events as well as advanced fibrosis: a multi-center study | Hiroshi Ishiba | ![]() |
![]() |
|||
SAT-449 | The genetic background of NAFLD patients markedly affects their metabolomic and lipidomic signatures | Lina Jegodzinski | ![]() |
![]() |
|||
FRI-449 | Type VII collagen degradation biomarker (C7M): a new marker of alcohol-induced gut injury and bacterial translocation in steatotic liver disease | Emil Deleuran Hansen | ![]() |
![]() |
|||
THU-449 | Nutritional behavior and food pattern are sex-specific with higher salt intake and consumption of ultra-processed foods in a large cohort of NAFLD patients | Monika Rau | ![]() |
![]() |
|||
WED-449 | Inhibition of CCAT/enhancer-binding protein beta - serpinB3 axis by 1-piperidin propionic acid: a new targeted therapy for non-alcoholic steatohepatitis | Francesca Protopapa | ![]() |
![]() |
|||
FRI-450 | Implementation and outcomes of liver health check clinics in community alcohol services | Michael Griffiths | ![]() |
![]() |
|||
SAT-450 | Prevalence of diagnosed advanced liver fibrosis in high-risk population with metabolic-dysfunction associated fatty liver disease screened in diabetology using transient elastography | Cyrielle Caussy | ![]() |
![]() |
|||
THU-450 | Prevalence of dysmetabolic iron overload syndrome in non-alcoholic fatty liver disease | Noel Ravindranayagam | ![]() |
![]() |
|||
WED-450 | Senescence sensitizes hepatocytes for fatty acid-induced cytotoxicity by compromising the mitochondrial function | Lilli Rausch | ![]() |
![]() |
|||
THU-451 | Effect of PNPLA3 (rs738409 CG) and TM6SF2 (rs58542926 CT) polymorphisms on the prognosis of non-alcoholic fatty liver disease (NAFLD) in patients with type-2 Diabetes Mellitus | Cristiane Villela-Nogueira | ![]() |
![]() |
|||
WED-451 | Ageing rates and oxidative stress in patients with non-alcoholic fatty liver disease and profound insulin resistance | Anastasiia Radchenko | ![]() |
![]() |
|||
SAT-451 | Serological biomarkers of extracellular matrix related disease activity are elevated in patients at risk of NASH with significant liver stiffness | Thomas Mller | ![]() |
![]() |
|||
FRI-451 | Detrimental association between COVID-19 pandemic stages and alcoholic hepatitis admissions: a Canadian population-based study | Abdel-Aziz Shaheen | ![]() |
![]() |
|||
SAT-452 | Prognostic value of the Enhanced Liver Fibrosis (ELF) test to predict long-term outcomes in a NAFLD cohort with up to 35 years follow-up | Jenny Gallacher | ![]() |
![]() |
|||
FRI-452 | PRO-C6 Predicts Cardiovascular events in patients with Alcohol-related liver disease. | Ida Ziegler Spedtsberg | ![]() |
![]() |
|||
WED-452 | The potential role of Omentin-1 in metabolic associated fatty liver disease (MAFLD): evidence from translational studies | Noel Salvoza | ![]() |
![]() |
|||
THU-452 | IP-10 levels increase across the spectrum of liver disease and are associated with insuline resistant components in subjects with NAFLD | Marta Guariglia | ![]() |
![]() |
|||
WED-453 | Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements | Baptiste Heriard-Dubreuil | ![]() |
![]() |
|||
THU-453 | Stigma in NAFLD and NASH: a global survey of patients and providers | Carey Escheik | ![]() |
![]() |
|||
SAT-453 | Utilization of fibroscan-AST scoring system to risk-stratify non-alcoholic steatohepatitis patients for clinical trials and novel therapies | Naim Alkhouri | ![]() |
![]() |
|||
THU-454 | Effects of a one-month consumption of different non-alcoholic beers on metabolic and liver health in young men | Henriette Kreimeyer | ![]() |
![]() |
|||
FRI-454 | Risk factors for acute myocardial infarction in patients with alcohol-related liver cirrhosis - a nationwide register-based nested case-control study | Emma Celia Herting | ![]() |
![]() |
|||
WED-454 | Zebrafish larvae as a model system to characterize effects of metabolic, drug and genetic perturbations on liver fat accumulation | Endrina Mujica | ![]() |
![]() |
|||
SAT-454 | A screening strategy of hidden compensated advanced chronic liver disease in diabetic outpatients using sequential and automatic fibrosis-4 and enhanced liver fibrosis scores | Clara Amiama Roig | ![]() |
![]() |
|||
WED-455 | Cyclophilin inhibition with rencofilstat shifts the liver transcriptome and lipidome in preclinical models toward resolution of nonalcoholic steatohepatitis | Daren Ure | ![]() |
![]() |
|||
THU-455 | Cognitive impairment in obesity and NAFLD | Charlotte Wernberg | ![]() |
![]() |
|||
SAT-455 | Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease: multicenter cohort study | SE YOUNG JANG | ![]() |
![]() |
|||
FRI-455 | Opportunistic cirrhosis casefinding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high risk group | Ann Archer | ![]() |
![]() |
|||
SAT-456 | Shortcomings of FIB-4 First strategy in screening for non alcoholic fatty liver disease (NAFLD) patients at risk for disease progression in a real life setting: will we be detracting therapeutic opportunities from patients? | Simone Cappelli | ![]() |
![]() |
|||
THU-456 | Longitudinal Outcomes Associated With Non-Alcoholic Fatty Liver Disease: A Meta-analysis of 129 Studies | Margaret Teng | ![]() |
![]() |
|||
WED-456 | Tyrosol reduces steatosis, fibrosis and inflammation in a murine model of NASH by modulating the immune hepatic phenotype | Daniela Gabbia | ![]() |
![]() |
|||
FRI-456 | Potential gut microbial biomarkers for detection of sarcopenia in alcohol-related liver disease patients | Haripriya Gupta | ![]() |
![]() |
|||
SAT-457 | Analysis of correlation and predictive ability of oral glucose tolerance tests with insulin assays for liver stiffness measurement in non-cirrhotic overweight and obese patients | Valentino Osti | ![]() |
![]() |
|||
THU-457 | Metabolic dysfunctionassociated fatty liver disease is associated with increased risk of extrahepatic malignancies: a nationwide cohort study | Min Kyung Park | ![]() |
![]() |
|||
WED-457 | Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD) | Rocío Montero-Vallejo | ![]() |
![]() |
|||
FRI-457 | Validation of the Lille 4 score on a cohort of romanian severe alcoholic hepatitis patients | Andreea Livia Bumbu | ![]() |
![]() |
|||
WED-458 | Increasing gut microbiota produced secondary bile acids to protect against non-alcoholic steatohepatitis | Justine Gillard | ![]() |
![]() |
|||
FRI-458 | Evaluation of histological differences between cirrhosis due to alcoholic-related liver disease and non-alcoholic steatohepatitis using automated fibrosis phenotyping of liver histology | Masanori Fukushima | ![]() |
![]() |
|||
SAT-459 | ABDA score: a non-invasive model to identify subjects with fibrotic non-alcoholic steatohepatitis in the community | Shalimar Shalimar | ![]() |
![]() |
|||
WED-459 | Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers | Marica Meroni | ![]() |
![]() |
|||
THU-459 | Metabolic dysfunction associated fatty liver disease and the risk of hepatocellular carcinoma | BYEONGGEUN SONG | ![]() |
![]() |
|||
FRI-459 | Radiomic data can define phenotypes of acute alcoholic hepatitis | Nawaz Safdar | ![]() |
![]() |
|||
FRI-460 | New patient referrals and alcohol consumption data in an Irish hepatology outpatient setting | Aoife Moriarty | ![]() |
![]() |
|||
THU-460 | Assessing treatment outcomes in an AIH/NAFLD overlap cohort | Nancy Reau | ![]() |
![]() |
|||
WED-460 | Thermoacoustic assessment of fatty liver disease - an early clinical feasibility study | Michael Thornton | ![]() |
![]() |
|||
SAT-460 | Evaluation of serum biomarkers for the diagnosis of nonalcoholic fatty liver disease in the general population: a cross-sectional Spanish population-based study | Jesús Rivera-Esteban | ![]() |
![]() |
|||
FRI-461 | Carbohydrate-deficient transferrin is a suitable drinking marker for patients with metabolic dysfunction-associated fatty liver disease | Kazuyoshi Kon | ![]() |
![]() |
|||
THU-461 | Metabolic associated fatty liver disease: different impact of the three defining criteria on the hepatic and cardiovascular complications | Jaqueline Currŕ | ![]() |
![]() |
|||
SAT-461 | MorphoQuant, the first fully-automated morphometric software for the assessment of liver biopsy, identified significant differences between non-alcoholic fatty liver disease and steatohepatitis biopsies | Cindy Serdjebi | ![]() |
![]() |
|||
WED-462 | Hepatocyte depletion of ERK5 impairs the response to lipotoxic oxidative stress resulting in defective insulin receptor signaling | Elisabetta Rovida | ![]() |
![]() |
|||
FRI-462 | Early liver transplantation for acute alcoholic hepatitis In a spanish liver transplant center | Victoria Aguilera | ![]() |
![]() |
|||
SAT-462 | Diagnostic performance of fibrosis-4 index and NAFLD fibrosis score in at-risk group from low prevalence population | Eileen Yoon | ![]() |
![]() |
|||
THU-462 | Histological and biopsychosocial predictors of quality of life in Spanish and UK cohorts of patients with non-alcoholic fatty liver disease | Jesús Funuyet-Salas | ![]() |
![]() |
|||
THU-463 | Clinical features of non-obese NAFLD: analysis of health check-up cohort | Shunsuke Sato | ![]() |
![]() |
|||
SAT-463 | A diagnostic non-invasive model for liver advanced fibrosis and cirrhosis in chronic hepatitis B (CHB) concurrent with nonalcoholic fatty liver disease (NAFLD) based on machine learning (ML) | Jie Li | ![]() |
![]() |
|||
FRI-463 | Identification of risk factors for alcohol relapse in liver transplant patients with alcohol-related liver disease | Dilara Turan Göke | ![]() |
![]() |
|||
WED-463 | Hepatic Apolipoprotein J facilitates metabolic disease progression by promoting mTOR-mediated suppression of autophagy | Duan Shuangdi | ![]() |
![]() |
|||
THU-464 | Sarcopenia is an independent risk factor for non-alcoholic fatty liver disease regardless of fat mass in men: 1:1 propensity score matching analysis | Hyo Young Lee | ![]() |
![]() |
|||
FRI-464 | Estimating the cost of acute alcoholic hepatitis to the health service in England | Lucy Turner | ![]() |
![]() |
|||
FRI-465 | Adverse childhood experiences as a background for alcoholic liver disease cohort analysis of risk score in ALD and non-ALD cirrhosis patients in comparison with the control group | Karolina Kristina Sulejova | ![]() |
![]() |
|||
SAT-465 | High performance of serological indexes in the non-invasive assessment of liver steatosis | BEATRIZ PILLADO | ![]() |
![]() |
|||
WED-465 | Human skin stem cell-derived hepatic cells with genetic predisposition for liver fat accumulation mimic susceptibility to develop MAFLD | Alexandra Gatzios | ![]() |
![]() |
|||
SAT-466 | Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective | Mimi Kim | ![]() |
![]() |
|||
THU-466 | The risk of liver-related long term outcomes is altered by dynamic changes in metabolic dysfunctionassociated fatty liver disease status: a nationwide cohort study | Min Kyung Park | ![]() |
![]() |
|||
WED-466 | The pan-PPAR agonist lanifibranor improves increased portal pressure, endothelial dysfunction and liver histology in a rat model of early NAFLD | Shivani Chotkoe | ![]() |
![]() |
|||
FRI-466 | Efficacy and safety of LPCN 1144 in hypogonadal and eugonadal subjects for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis | Ben Bruno | ![]() |
![]() |
|||
FRI-467 | Incidence and risk of dyslipidemia and hyperglycemia in a phase 3 study of obeticholic acid for the treatment of nonalcoholic steatohepatitis | Manal Abdelmalek | ![]() |
![]() |
|||
THU-467 | Dietary patterns associated with metabolic associated fatty liver disease protection | Carolin Schneider | ![]() |
![]() |
|||
SAT-467 | Performance of non-invasive markers in evaluating presence and severity of liver fibrosis in non-alcoholic fatty liver disease: results from a multi-ethnic Asian cohort of biopsy-proven non-alcoholic fatty liver disease patients | EN YING TAN | ![]() |
![]() |
|||
WED-467 | A new nuclear-erythroid-2-related factor 2 activator for the treatment of nonalcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices | Adel Hammoutene | ![]() |
![]() |
|||
THU-468 | Rheological properties of bile in patients with nonalcoholic steatohepatitis with and without obesity | Olena Barabanchyk | ![]() |
![]() |
|||
WED-468 | The NRF2/b-TrCP axis: new therapeutic target in non-alcoholic steatohepatitis (NASH) | Raquel Fernández-Ginés | ![]() |
![]() |
|||
FRI-468 | Prospective, multi-center, open-label, randomized, omega-3-acid ethyl ester-controlled trial to assess the impact of the pemafibrate on liver function in hypertriglyceridemia patients with non-alcoholic fatty liver disease (Portrait study) | Yoshio Sumida | ![]() |
![]() |
|||
SAT-468 | Impact of obesity on transient elastography accuracy among patients with non-alcoholic fatty liver disease | María Del Barrio Azaceta | ![]() |
![]() |
|||
FRI-469 | Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis using SomaSignaltests in patients with obesity with/without type 2 diabetes, and correlation of SomaSignal tests with histology in patients with non-alcoholic steatohepatitis: analysis of data from three randomised trials | Jörn Schattenberg | ![]() |
![]() |
|||
SAT-469 | A sequential use of transient elastography followed by Agile 3 score significantly improves the screening of advanced fibrosis in patients with NAFLD with or without severe obesity | Cyrielle Caussy | ![]() |
![]() |
|||
THU-469 | Risk factors for significant fibrosis in non-obese Asian patients with NAFLD | Jae Yoon Jeong | ![]() |
![]() |
|||
WED-469 | Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters | Baptiste Heriard-Dubreuil | ![]() |
![]() |
|||
SAT-470 | Cost-effectiveness of screening for advanced hepatic fibrosis by noninvasive test in general population | Bo-Kyeong Kang | ![]() |
![]() |
|||
THU-470 | Impact of PNPLA3 rs738409 single nucleotide polymorphism and carbohydrate intake for the personalized management of patients with non-alcoholic fatty liver disease | Nuria Pérez Diaz del Campo | ![]() |
![]() |
|||
FRI-470 | HPG1860 in patients with NASH: a phase II double-blind, placebo-controlled, dose-ranging study | Naim Alkhouri | ![]() |
![]() |
|||
WED-471 | A novel autophagy inducer attenuated nonalcoholic steatohepatitis by regulating the adneylate cyclase 6 in hepatocytes | Se Yong Park | ![]() |
![]() |
|||
SAT-471 | Using elevated plasma alanine transaminase to screen for non-alcoholic fatty liver disease in overweight and obese individuals from the Danish general population | Elias Rashu | ![]() |
![]() |
|||
FRI-471 | The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease | Dominic Crocombe | ![]() |
![]() |
|||
THU-471 | Diabetes mellitus (DM) is the strongest risk factor of significant inflammation or fibrosis in chronic hepatitis B (CHB) combined with nonalcoholic fatty liver disease (NAFLD) | Jie Li | ![]() |
![]() |
|||
WED-472 | Effect of vitamin D receptor signaling on endoplasmic reticulum stress in non-alcohol related steatohepatitis: exploring potential autophagy dependence | Basma Alaa | ![]() |
![]() |
|||
FRI-472 | Resmetirom improves the lipid/lipoprotein profile in patients with nonalcoholic fatty liver disease | Naim Alkhouri | ![]() |
![]() |
|||
SAT-472 | Analysis of the diagnostic accuracy of the non-invasive fibrosis indices NFS, HFS, and FIB-4 in the staging of advanced fibrosis in patients with metabolic fatty liver: meta-analysis of comparative studies | Carmen Lara Romero | ![]() |
![]() |
|||
THU-472 | PNPLA3 I148M polymorphism does not promote liver disease progression in severe alpha1-antitrypsin deficiency | Ines Volkert | ![]() |
![]() |
|||
THU-473 | Frailty in metabolic dysfunction-associated fatty liver disease is related to the presence of diabetes and the severity of liver fibrosis | Guillaume HENIN | ![]() |
![]() |
|||
WED-473 | Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis | Jung Kuk Kim | ![]() |
![]() |
|||
FRI-473 | Different class effects of oral hypoglycemic agents on nonalcoholic fatty liver disease regression and clinical outcomes: a nationwide cohort study | Heejoon Jang | ![]() |
![]() |
|||
SAT-473 | Correlation between serial Fibrosis-4 scores and liver stiffness measurements in patients with low-risk non-alcoholic fatty liver disease | Tanvi Goyal | ![]() |
![]() |
|||
SAT-474 | AGILE 3 and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease | Kamela Gjini | ![]() |
![]() |
|||
THU-474 | Significant fibrosis is a risk factor for worse health perception and impaired mental health in people living with HIV | Jesús Funuyet-Salas | ![]() |
![]() |
|||
FRI-474 | SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study | Rosa Lombardi | ![]() |
![]() |
|||
WED-474 | A translational rat model to study metabolic associated fatty liver disease with fibrosis and portal hypertension | María Martell | ![]() |
![]() |
|||
THU-475 | Caloric input is inadequate in predicting the presence of liver steatosis and fibrosis in a population adhering to a screening program for metabolic syndrome | Lucia Brodosi | ![]() |
![]() |
|||
SAT-475 | Diagnostic performance of NAFLD fibrosis score in lean NAFLD | Mimi Kim | ![]() |
![]() |
|||
WED-475 | Secretomics identifies IGFBP1 as a stress signaling marker in human models for NAFLD | Ruth Walker | ![]() |
![]() |
|||
FRI-475 | Semaglutide improves non-alcoholic steatohepatitis: a 10-year retrospective study | Parth Shah | ![]() |
![]() |
|||
FRI-476 | Resmetirom helps regulate thyroid hormone levels within the liver in patients with nonalcoholic fatty liver disease | Stephen Harrison | ![]() |
![]() |
|||
WED-476 | Serum exosomal mir-4668-5p in Non-alcoholic Fatty liver Disease (NAFLD) patients with significant liver fibrosis | JONG EUN YEON | ![]() |
![]() |
|||
SAT-476 | Fatty liver score: a novel fatty liver index based on magnetic resonance imaging-proton density fat fraction | Eileen Yoon | ![]() |
![]() |
|||
SAT-477 | The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients | Young Youn Cho | ![]() |
![]() |
|||
FRI-477 | Dynamics of liver stiffness measurements provide incremental prognostic information in advanced chronic liver disease | David JM Bauer | ![]() |
![]() |
|||
WED-477 | Effectiveness of vaccine education on vaccine awareness and vaccine uptake in patients with cirrhosis of liver of a tertiary care center in South India | Lt Col (Dr) Ajee K L | ![]() |
![]() |
|||
THU-478 | C105SR, a novel non-peptidic small-molecule cyclophilin inhibitor with potent mitoprotective and hepatoprotective properties in the context of hepatic ischemia/reperfusion injury | Fatima Teixeira-Clerc | ![]() |
![]() |
|||
FRI-478 | Liver stiffness measurement Baveno VII rule of 5 and risk of hepatocellular carcinoma after HCV eradication in patients with cirrhosis | Binu John | ![]() |
![]() |
|||
SAT-478 | One-step diagnosis: detection and stratification of incidental hepatic steatosis by multiparametric abdominal ultrasound | Clara Amiama Roig | ![]() |
![]() |
|||
WED-478 | Better strategies are needed to increase engagement of patients with cirrhosis with allied health and community services | Patricia Valery | ![]() |
![]() |
|||
THU-479 | Application of human chemically-derived hepatic progenitors organoids (hCdHO) in regenerative medicine, hepatotoxic and disease modeling | Elsy Soraya Salas Silva | ![]() |
![]() |
|||
WED-479 | Whos testing who? Healthcare professional and patient knowledge of hepatitis delta virus and appropriate testing in an East Midlands hospital | Rachel Ryder | ![]() |
![]() |
|||
SAT-479 | High performance of new multiparametric ultrasound in the non-invasive assessment of liver disease | Gloria Ruiz-Fernandez | ![]() |
![]() |
|||
FRI-479 | Liver stiffness can monitor disease severity and changes predict decompensation in alcohol-related liver disease | Katrine Holtz Thorhauge | ![]() |
![]() |
|||
FRI-480 | Transient elastography efficiently detects severe fibrosis in patients with chronic hepatitis D | Dominique Roulot | ![]() |
![]() |
|||
SAT-480 | Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years experience in a tertiary referral center with genotyping facility | Marcin Krawczyk | ![]() |
![]() |
|||
THU-480 | In vitro model of liver ischemia/reperfusion injury identifies iRhom2 as new target of disease | Giovanni Zito | ![]() |
![]() |
|||
WED-480 | First hepatitis C mass-testing in a category A prison in the United Kingdom | Alison MacElhinney-West | ![]() |
![]() |
|||
SAT-481 | Performance of novel collagen turnover biomarkers in relation to FIB-4 to detect advanced fibrosis in NAFLD | Hannes Hegmar | ![]() |
![]() |
|||
THU-481 | HBV re-infection or de-novo infection in the course of liver transplantation in patients chronically infected with HBV, HBV/HDV, or HCV | Teresa Pollicino | ![]() |
![]() |
|||
WED-481 | A prospective study to assess medication adherence to systemic therapy among patients with hepatocellular carcinoma | Suja Kumari | ![]() |
![]() |
|||
FRI-481 | Screening for hepatic fibrosis in primary care by FIB-4 score, followed in second line f the ELF (enhanced liver fibrosis) test: what are the best thresholds? | Denis Ouzan | ![]() |
![]() |
|||
SAT-482 | Evaluating the role of novel magnetic resonance imaging-based biomarkers in non-invasive assessment of hepatic fibrosis and activity in non-alcoholic fatty liver disease | EN YING TAN | ![]() |
![]() |
|||
WED-482 | Advanced practice nurses scope of practice in liver care: evaluation of two different Swiss settings | Patrizia Kuenzler | ![]() |
![]() |
|||
FRI-482 | Validation of cut-off values proposed by the society of radiologists in ultrasound liver elastography for diagnosis of compensated advanced chronic liver disease using 2D shear wave elastography | Ji Hun Kang | ![]() |
![]() |
|||
THU-482 | The impact of statin utilization on mortality in liver transplant recipients independent of underlying cardiovascular risk | Megan Ghai | ![]() |
![]() |
|||
SAT-483 | Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review | Hamish Miller | ![]() |
![]() |
|||
WED-483 | Value based healthcare: patient perception of the liver cancer advanced practice nurse care at the Barcelona clinic liver cancer | Neus Llarch | ![]() |
![]() |
|||
FRI-483 | Hospital discharge after percutaneous liver biopsy less is more? | Isabel Garrido | ![]() |
![]() |
|||
WED-484 | Hepatitis C education and training for community pharmacists in Ireland | Miriam Coghlan | ![]() |
![]() |
|||
SAT-484 | Diagnostic performance of non-invasive fibrosis markers in patients with immune-mediated disease and hepatic steatosis | María Del Barrio Azaceta | ![]() |
![]() |
|||
FRI-484 | Non-invasive assessment of adult bilirubin based on multispectral reconstruction technology and a smartphone platform | Wenqian Geng | ![]() |
![]() |
|||
FRI-485 | Diagnosis and treatment of patients with suspected mucinous cystic neoplasms according to the EASL-guidelines: a retrospective cohort study | Alicia Furumaya | ![]() |
![]() |
|||
WED-485 | Quality improvement project: improving early identification of liver disease in diabetic patients in a district general hospital with opportunistic FibroScan | Amy Thatcher | ![]() |
![]() |
|||
THU-485 | Polycystic disease: a cumbersome benign indication for transplantation | Alberto Calleri | ![]() |
![]() |
|||
SAT-485 | The liver worsens in non-alcoholic fatty liver disease patients as diabetes mellitus worsens and lasts longer | Zülal Istemihan | ![]() |
![]() |
|||
THU-486 | De novo cancers after liver transplantation: a French nationwide cohort | Ilias Kounis | ![]() |
![]() |
|||
WED-486 | Changes in frailty as a predictor of readmission risk in patients with liver cirrhosis. Preliminary results | Martina Pérez Guasch | ![]() |
![]() |
|||
SAT-486 | Implementing a clinical care algorithm for screening of liver fibrosis in specialist diabetes care | Hannes Hagström | ![]() |
![]() |
|||
WED-487 | Mental health, quality of life, and stigmatization in Danish patients with liver disease | Nadja stberg | ![]() |
![]() |
|||
SAT-487 | The use of non-invasive tests compared with histological fibrosis stage in predicting liver-related events in metabolic dysfunction-associated fatty liver disease | Wah Loong Chan | ![]() |
![]() |
|||
FRI-487 | Fibrosis-4 index is associated with cardiovascular risk in people living with HIV | Giulia Morsica | ![]() |
![]() |
|||
THU-487 | Assessment of silent coronary artery disease with functional and anatomic tests in liver transplantation: analysis of the diagnostic and prognostic capacity of a risk-adapted protocol | Giulia Pagano | ![]() |
![]() |
|||
FRI-488 | Diagnostic accuracy of magnetic resonance elastography, transient elastographyand predictive scores in cystic fibrosis related liver steatosis and fibrosis | Carmen Lara Romero | ![]() |
![]() |
|||
WED-488 | Clinical interdisciplinary development of a home-based enteral nutrition initiation and refeeding monitoring model of care for patients with chronic liver disease | Erin Russell | ![]() |
![]() |
|||
THU-488 | Sex-based differences and comparative predictive value of MELD 3.0 in simultaneous liver-kidney transplantation waitlist outcomes after standardization of listing criteria in the United States | Emily Leven | ![]() |
![]() |
|||
SAT-488 | LIVERFASt GP (GP), a non-invasive blood testing for NAFLD staging, improves risk stratification of patients with indeterminate FIB-4 results | Naim Alkhouri | ![]() |
![]() |
|||
SAT-489 | Assessing the feasibility of AI-based Hamaguchi score estimation for NAFLD diagnosis using ultrasound images | Alessia Visintin | ![]() |
![]() |
|||
FRI-489 | Negative and positive predictive values of utilizing a two-stage approach to non-invasive fibrosis testing in patients with hepatitis C virus infection | Rachel Epstein | ![]() |
![]() |
|||
WED-489 | Hepatology nursing consultation in a tertiary hospital without liver transplantation: initial experience | Francisco Jorquera | ![]() |
![]() |
|||
THU-489 | Increased left ventricular dimensions are the new risk factor for acute kidney injury after living donor liver transplantation (cardio-renal interaction) | Dheapak V | ![]() |
![]() |
|||
WED-490 | Development of a web-based mobile health application (ReLiver-N App) for patient activation, self-efficacy, and quality of life in patients with liver cirrhosis | Ferya Celik | ![]() |
![]() |
|||
SAT-490 | Metabolic and adipocytokine disorders as a background cause of the progression of nonalcoholic steatohepatitis in obese patients depending on comorbidity with chronic obstructive pulmonary disease | Ivanna Rachynska | ![]() |
![]() |
|||
THU-490 | Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on post-liver transplant mortality and major adverse cardiovascular events | Kelli Kosako Yost | ![]() |
![]() |
|||
FRI-491 | Pattern of transient elastography in Egyptian people living with HIV: predictors of hepatic steatosis and fibrosis | Ahmed Cordie | ![]() |
![]() |
|||
THU-491 | Deep learning prediction modeling of major adverse cardiovascular events following liver transplantation | Ahmed Abdelhameed | ![]() |
![]() |
|||
WED-491 | Analysis of health-related quality of life in the liver transplant patient conducted more than 10 years ago, statewide study | Fernando García Pérez | ![]() |
![]() |
|||
WED-492 | Fellowship for hepathology nurses a new exchange program at Karolinska university hospital | Pia Loqvist | ![]() |
![]() |
|||
SAT-492 | Development of a novel non-invasive test for prediction of liver fibrosis in patients with clinically severe obesity defined by a BMI over 50 kg/m | Maximilian Joseph Brol | ![]() |
![]() |
|||
THU-492 | The growing prevalence and impact of type 2 diabetes among liver transplant candidates in the United States | Carey Escheik | ![]() |
![]() |
|||
FRI-492 | Enhanced detection of cirrhosis and risk of advanced fibrosis with dynamic breath analysis | Giuseppe Ferrandino | ![]() |
![]() |
|||
SAT-493 | Detecting early improvements in a NAFLD patient population during diet-induced weight loss | Pietro Torre | ![]() |
![]() |
|||
THU-493 | The evolution of the muscle compartment from the listing to six-month post-transplantation: a longitudinal monocentric study | Delorme Alicia | ![]() |
![]() |
|||
THU-494 | Endothelial glycocalyx damage marker Syndecan-1 measured during hypothermic oxygenated machine perfusion can predict early allograft dysfunction after liver transplantation | Laurin Rauter | ![]() |
![]() |
|||
FRI-494 | Soluble CD163 as a biomarker of liver fibrosis in liver transplant recipients | Emilie Hegholm Ernst Lauridsen | ![]() |
![]() |
|||
SAT-494 | Echocardiography-based markers for subclinical cardiac dysfunction in patients with non-alcoholic fatty liver disease and significant fibrosis with preserved ejection fraction: preliminary data from a prospective monocentric Italian cohort | Daphne DAmato | ![]() |
![]() |
|||
FRI-495 | Does methotrexate therapy harm the liver in psoriatic patients? | Isabel Bessa | ![]() |
![]() |
|||
THU-495 | Use of von Willebrand factor antigen for surgical decision making in patients with hepatocellular carcinoma | David Pereyra | ![]() |
![]() |
|||
SAT-495 | Comparison of performance of non-invasive indices in assessing degree of steatosis in non-alcoholic fatty liver disease | EN YING TAN | ![]() |
![]() |
|||
THU-496 | Incidence and risk factors for de-novo NAFLD after liver transplantation: real-world data | Katharina Hupa-Breier | ![]() |
![]() |
|||
SAT-496 | Evaluation of the performance of a novel single-nuclei digital pathology method for the continuous quantification of steatosis and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH | Mathieu Petitjean | ![]() |
![]() |
|||
FRI-496 | Performance of the scores diagnosis of autoimmune hepatitis in Moroccan patients | Sara Chbourk | ![]() |
![]() |
|||
SAT-497 | Development of ultra-sensitivity enzyme-linked immunosorbent assay for hepatitis delta virus antibody detection | Nomin Ariungerel | ![]() |
![]() |
|||
THU-497 | Long-term outcomes following donation after cardiac death (DCD) liver transplantation in primary sclerosing cholangitis (PSC) | Palak TRIVEDI | ![]() |
![]() |
|||
FRI-497 | Assessment of international normalized ratio to albumin ratio in predicting mortality in decompensated liver disease at a resource limited medical centre | Marium Fatima Waqar | ![]() |
![]() |
|||
THU-498 | Evaluation of a delayed liver transplant strategy for patients listed for hepatocellular carcinoma treated with resection or thermo-ablation as a bridge to liver transplantation; the DELTAS-HCC study | Catherine Lamarque | ![]() |
![]() |
|||
FRI-498 | Moving toward a more perfect liver function test: the next generation of HepQuant tests | Michael McRae | ![]() |
![]() |
|||
SAT-498 | Biomarkers of hepatocyte basement membrane turnover reflect disease activity in patients with early-stage non-alcoholic fatty liver disease | Ida Lnsmann | ![]() |
![]() |
|||
FRI-499 | Liver elastography is a useful technique to assess the severity of liver congestion in patients with Budd-Chiari syndrome | Marcos Andres Thompson | ![]() |
![]() |
|||
SAT-499 | Development of loop-mediated isothermal amplification assay for detection of hepatitis delta virus | Saruul Enkhjargal | ![]() |
![]() |
|||
THU-500 | Donor outcomes incidence after living-donor liver transplantation: meta-analysis and systematic review | Mark Muthiah | ![]() |
![]() |
|||
FRI-500 | Fibrosis-4 score less than 2.67 and normal gamma-glutamyl transferase levels are associated with high negative predictive value for high-risk of liver stiffness in patients with primary biliary cholangitis | Alan Bonder | ![]() |
![]() |
|||
THU-501 | Access to liver transplant for women in Spain: a national registry analysis | Marta TEJEDOR | ![]() |
![]() |
|||
FRI-501 | Suitability of FibroScan, APRI and FIB-4 indexes compared with liver biopsy in the evaluation of liver fibrosis: a single-centre retrospective study | Alvaro Yagüe | ![]() |
![]() |
|||
SAT-501 | Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease | Roberta Forlano | ![]() |
![]() |
|||
THU-502 | Body composition and MAFLD are associated with prognosis after resection of intrahepatic cholangiocarcinoma | Isabella Lurje | ![]() |
![]() |
|||
THU-503 | Cytomegalovirus reactivation is associated with lower hepatocelullar carcinoma recurrence rates after liver transplantation | Victoria Aguilera | ![]() |
![]() |
|||
SAT-503 | SAFE score yielded a better performance than FIB-4 and NFS in predicting significant fibrosis among Asian NAFLD patients | Pimsiri Sripongpun | ![]() |
![]() |
|||
THU-504 | The influence of immunosuppression and recipient geography on non-melanoma skin cancer risk after liver transplantation | Therese Bittermann | ![]() |
![]() |
|||
SAT-504 | A descriptive analysis of transient elastography results and metabolic co-morbidities in people living with HIV mono-infection in an urban clinic in the UK | Claire Mullender | ![]() |
![]() |
|||
WED-505 | Rilpivirine as an anti-inflammatory agent in non-alcoholic fatty liver disease: evidence from human hepatocytes, hepatic stellate cells and blood cells | Ana Blas-García | ![]() |
![]() |
|||
THU-505 | Perfusate composition of transplanted and not transplanted livers during normothermic machine perfusion | Jule Dingfelder | ![]() |
![]() |
|||
SAT-505 | Liver stiffness measurements with a new point-of-care device, hepatoscope, using two-dimensional transient elastography showed both very good reproducibility and correlation to fibroscan | Joel Gay | ![]() |
![]() |
|||
FRI-505 | CVI-301, a potent and ive thyroid hormone receptor beta full agonist, demonstrates profound total cholesterol and LDL-cholesterol reductions in a hyperlipidemic mouse efficacy model | Jingwen Liu | ![]() |
![]() |
|||
SAT-506 | Are non-invasive tests of fibrosis effective in patients with metabolic associated fatty liver disease? Comparative study between liver biopsy and non-invasive scores or fibroscan | Annalisa Cespiati | ![]() |
![]() |
|||
FRI-506 | Effects of a novel tetra-specific drug (OGB21502) in the obese mice model of liver disease | Yunki Kim | ![]() |
![]() |
|||
THU-506 | Risk factors associated with surgical morbidities of laparoscopic living liver donors | Jinsoo Rhu | ![]() |
![]() |
|||
WED-506 | Characterization of portal inflammation and hepatic fibrosis in non-alcoholic fatty liver disease | Carey Escheik | ![]() |
![]() |
|||
WED-507 | b-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype | Giada Tria | ![]() |
![]() |
|||
SAT-507 | A biomarker of fibrosis resolution, CTX-III, increases after bariatric surgery in early NAFLD patients with histological liver improvements | Ida Lnsmann Sorribes | ![]() |
![]() |
|||
FRI-507 | Treatment monitoring with the Agile 3 score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutide | Laurent Castéra | ![]() |
![]() |
|||
THU-507 | Clinical impact and treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after liver transplant (LT): the role of transjugular intrahepatic porto-systemic shunt (TIPS) | TRIOLO MICHELA | ![]() |
![]() |
|||
SAT-508 | Free light chains: novel serum biomarkers for NASH stratification, an update | Antonio Liguori | ![]() |
![]() |
|||
WED-509 | Effect of housing temperature on nonalcoholic fatty liver disease development in C57BL/6N mice | Olga Horakova | ![]() |
![]() |
|||
FRI-509 | Lessons for the setting of an international integrated research platform to conduct adaptive trials in non-alcoholic steatohepatitis: results of the EU-PEARL project | Elena De Sena | ![]() |
![]() |
|||
THU-509 | Outcomes in patients with new-onset atrial fibrillation after liver transplantation using the national readmission database | Induja Nimma | ![]() |
![]() |
|||
SAT-509 | Non-alcoholic fatty liver disease made easy for diabetologists: the automated fibrosis-4 index | Mona Ismail | ![]() |
![]() |
|||
SAT-510 | Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with nonalcoholic fatty liver disease (NAFLD) based on machine learning (ML) | Jie Li | ![]() |
![]() |
|||
FRI-510 | The influence of probiotics on biologic and imagistic alterations in non-alcoholic steato-hepatitis | Elena Laura Iliescu | ![]() |
![]() |
|||
WED-510 | Preclinical characterization of HPG7233, a potent, liver-targeted and highly selective thyroid hormone receptor beta (THR-beta) agonist for nonalcoholic steatohepatitis (NASH) | Xinpeng Zhao | ![]() |
![]() |
|||
FRI-511 | Efficacy of pemafibrate in patients with non-alcoholic fatty liver disease complicated by dyslipidemia: a single-arm prospective study | Hiroki Ono | ![]() |
![]() |
|||
THU-511 | Long-term outcome following liver transplantation for chronic liver disease in intensive care unit: the French nationwide experience | magdalena meszaros | ![]() |
![]() |
|||
WED-511 | Plasma short chain fatty acids are associated with non-alcoholic fatty liver disease and fibrosis severity | Mira Thing | ![]() |
![]() |
|||
SAT-511 | Economic modelling of clinical management options of unexplained hyperferritinaemia in the adult general population: a proposed new model of care | John Olynyk | ![]() |
![]() |
|||
WED-512 | Artificial neural networks predict via label-free imaging analysis cellular injury in a human steatohepatitis model | Julian Weihs | ![]() |
![]() |
|||
FRI-512 | Characterization of the patterns of resolution of histopathology after efruxifermin treatment of patients with NASH fibrosis (F2/3) for 24 weeks | Cynthia Behling | ![]() |
![]() |
|||
THU-512 | Validation of MELD3.0 in two centres from different continents | Marta TEJEDOR | ![]() |
![]() |
|||
SAT-512 | A systematic review and meta-analysis of the prevalence and cross-sectional severity of South Asian patients with non-alcoholic fatty liver disease | Michael James | ![]() |
![]() |
|||
WED-513 | IFI16 expression and its genotype variant are associated with NAFLD progression | Hyun Goo Woo | ![]() |
![]() |
|||
FRI-513 | Fat versus lean tissue loss in short term versus long term weight loss: a dynamic effect with implications for NASH trials | Lars Johansson | ![]() |
![]() |
|||
SAT-513 | Serum glycochenodeoxycholic acid-3-sulfate can discriminate non-alcoholic steatohepatitis from steatosis | Barbora Nováková | ![]() |
![]() |
|||
THU-513 | Pre-transplant mycophenolate mofetil may be associated with reduced intrahepatic cholangiopathy in ABO-incompatible liver transplantation | Jinsoo Rhu | ![]() |
![]() |
|||
SAT-514 | ALT/AST ratio: the useful predictive marker for insulin resistance | Seul Ki Han | ![]() |
![]() |
|||
WED-514 | Knockdown of a novel target gene enhances liver regeneration and attenuates chronic liver damage related liver fibrosis | Shainan Hora | ![]() |
![]() |
|||
FRI-514 | Efficacy of digital health-supported lifestyle modification on patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis | JOO HYUN OH | ![]() |
![]() |
|||
THU-514 | Prevalence of renal dysfunction is higher in patients that receive a liver transplant for non-alcoholic steatohepatitis | Ruben Sanchez-Aldehuelo | ![]() |
![]() |
|||
WED-515 | Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr-/-.Leiden mice | Eveline Gart | ![]() |
![]() |
|||
SAT-515 | Validation of Baveno VII criteria in NAFLD patients according to body mass index | María Del Barrio Azaceta | ![]() |
![]() |
|||
FRI-515 | A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study | Katherine Edwards | ![]() |
![]() |
|||
WED-516 | Novel bariatric surgery models in mice differential effects on body weight loss and fatty liver disease | Louis Onghena | ![]() |
![]() |
|||
FRI-516 | Incidence and median times to onset and resolution of pruritus adverse events in a phase 3 study of obeticholic acid in patients with nonalcoholic steatohepatitis | Zobair Younossi | ![]() |
![]() |
|||
WED-517 | Oxysterols and Hepatic Stellate Cell Activation | Ingrid Wilhelmsen | ![]() |
![]() |
|||
SAT-517 | The sequential use of liver stiffness measurement and direct biomarkers of fibrosis is able to identify patients with severe non-alcoholic steatohepatitis | Filippo Gabrielli | ![]() |
![]() |
|||
THU-517 | CMV reactivation after liver transplantation (LT) in HIV infected is similar to non-HIV patients: a single center comparative study | Sonia García García | ![]() |
![]() |
|||
FRI-517 | Correlation between severity of hepatic steatosis and markers of cardiometabolic health, and effect of lanifibranor therapy in patients with non-cirrhotic NASH | Michael Cooreman | ![]() |
![]() |
|||
FRI-518 | Hepatic fat and liver volume reductions impact on non-alcoholic steatohepatitis trials and potential solutions using concomitant fibrosis with ballooning with fibrosis | Stephen A. Harrison | ![]() |
![]() |
|||
WED-518 | Opposite correlations between hepatic -oxidation activity and triglyceride levels in male and female rats after a high-fat diet supplemented with liquid fructose | Roger Bentanachs | ![]() |
![]() |
|||
THU-518 | Development of metabolic disorders in transplant recipients | HALE GOKCAN | ![]() |
![]() |
|||
SAT-518 | The clinical significance of transient elastografy and cap in the diagnosis and surveillance of non alcoholic fatty liver disease | Eleni Gigi | ![]() |
![]() |
|||
WED-519 | Prophylactic and therapeutic hepatoprotective effects of lanifibranor in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis | Jacob Nhr-Meldgaard | ![]() |
![]() |
|||
SAT-519 | Ultrasound predictors of hemodynamic TIPS dysfunction: friends or foes? | Andreea Fodor | ![]() |
![]() |
|||
THU-519 | Tailored immunosuppression with LCPT extended release Tacrolimus based on NFAT-regulated gene expression | Judith Kahn | ![]() |
![]() |
|||
FRI-519 | Effectiveness of prebiotic treatment in patients with non-alcoholic fatty liver disease (NAFLD) a randomized trial | Yaakov Maor | ![]() |
![]() |
|||
FRI-520 | B-cell activating factor in non-alcoholic steatohepatitis | Iris Gines | ![]() |
![]() |
|||
THU-520 | Long-term survival after liver transplantation in patients with common variable immunodeficiency | Ina Marie Andersen | ![]() |
![]() |
|||
WED-520 | Light cytokine-deficiency effects in inmune cells subpopulations in a murine non alcohol-related steatohepatitis model | María Aguilar Ballester | ![]() |
![]() |
|||
SAT-520 | Efficacy of Simvastatin plus non-ive beta blocker in improving survival of cirrhotic patients with variceal bleed: a systematic review and meta analysis | Jemimah Andrea Fajardo | ![]() |
![]() |
|||
FRI-521 | SNP-630, a novel compound with multiple mechanisms, reverses liver inflammation and fibrosis in preclinical models and NASH phase 2 clinical trial | Shin-Wei Chen | ![]() |
![]() |
|||
WED-521 | Evaluation of genetic risk score of a dysmetabolic and obese population of southern Italy | Benedetta Maria Motta | ![]() |
![]() |
|||
THU-521 | Porto-pulmonary hypertension in patients considered for liver transplantation: a cohort study | Declan Lewis | ![]() |
![]() |
|||
SAT-521 | Validation of the Baveno VII criteria for risk stratification in compensated advanced chronic liver disease after HCV-cure | Georg Semmler | ![]() |
![]() |
|||
WED-522 | Characterizing the histologic implications of resmetirom-induced liver volume reduction using artificial intelligence-powered digital pathology | Adam Stanford-Moore | ![]() |
![]() |
|||
SAT-522 | Real-world practice of pre-emptive tipps: an Asia perspective based on Singapore nationwide variceal bleeding audit | Yu Jun Wong | ![]() |
![]() |
|||
THU-522 | Liver transplantation in patients with cystic fibrosis: 30 years of experience in Australia and New Zealand | Thomas Wilson | ![]() |
![]() |
|||
FRI-522 | Serological biomarkers PRO-C3 and PRO-C6 reveal the anti-fibrotic and pro-metabolic effects of MSDC-0602K, an insulin sensitizer, in non-alcoholic steatohepatitis patients during the EMMINENCE phase IIb study | Alejandro Mayorca Guiliani | ![]() |
![]() |
|||
FRI-523 | Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with non-alcoholic fatty liver disease | Matthew Armstrong | ![]() |
![]() |
|||
WED-523 | Unraveling the individual contributions of the PPAR isotypes to the pan-PPAR agonist Lanifibranor-induced improvements of the vascular alterations and liver histology in a rat model of early NAFLD | Shivani Chotkoe | ![]() |
![]() |
|||
FRI-524 | Safety and efficacy of oral semaglutide in overweight diabetic patients with non-alcoholic fatty liver disease: an interim analysis | Gauri Unnithan | ![]() |
![]() |
|||
WED-524 | GTX-011 improves fibrosis and hepatic stellate cells phenotype in human precision cut liver slices | Jordi Gracia-Sancho | ![]() |
![]() |
|||
THU-524 | Management in hepatology: cost analysis of two oppposite options for pretransplantation evaluation | Irene Peńas Herrero | ![]() |
![]() |
|||
SAT-524 | Sequential BAVENO VI plus dedicated spleen stiffness measurement or a novel spleen-centered algorithm significantly enlarges non-invasive ruling out of high risk varices: results from an international derivation-validation cohort study | Emma Vanderschueren | ![]() |
![]() |
|||
THU-525 | Primary sclerosing cholangitis as an indication for liver transplantation. Results and conditioning factors: relationship with associated intestinal pathology | Ainhoa Fernández Yunquera | ![]() |
![]() |
|||
WED-525 | Beneficial effect of extravirgin olive oil on hepatic fatty acid accumulation and fibrogenesis: oleocanthalic acid as a promising compound for the treatment of NAFLD and NASH | Martina Colognesi | ![]() |
![]() |
|||
SAT-525 | Detection of candida species in hospitalized patients with decompensated liver cirrhosis and ascites indicates an unfavorable clinical course and outcome | Marie Griemsmann | ![]() |
![]() |
|||
FRI-525 | The effects of a novel online app (Noom Weight) on weight loss and liver biomarkers in patients with NAFLD: a single arm proof-of-concept study | Naim Alkhouri | ![]() |
![]() |
|||
WED-526 | Novel image analysis and immunohistochemistry advances to accompany pathologist driven non-alcoholic fatty liver disease diagnosis | Maroua Tliba | ![]() |
![]() |
|||
THU-526 | Liver transplant recipients with autoimmune hepatitis in the Swiss transplant cohort study have a higher risk of graft loss and vascular complications | Aurélie Rosat | ![]() |
![]() |
|||
SAT-526 | Clinical utility of liver and spleen elastography in the management of patients living with liver disease | Carmen Lara Romero | ![]() |
![]() |
|||
FRI-526 | The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients | Leen Heyens | ![]() |
![]() |
|||
WED-527 | Evaluating the hepatic efficacy and cardiometabolic profile of PNPLA3, TM6SF2, and other therapeutic targets for NALFD: a drug-target Mendelian randomization analysis | Daniel Rosoff | ![]() |
![]() |
|||
SAT-527 | Secondary prevention of variceal bleeding is often imperfect: a national, population-based cohort study of 3,592 patients | Hannes Hagström | ![]() |
![]() |
|||
THU-527 | Primary sclerosing cholangitis recurrence after liver transplantation: a nationwide survey in Italy | Maria Cristina Morelli | ![]() |
![]() |
|||
FRI-528 | Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1 | Artur Plonowski | ![]() |
![]() |
|||
WED-528 | High-fat diet exacerbates lipopolysaccharide-induced liver injury in obese KK-Ay mice | Satoshi Sakuma | ![]() |
![]() |
|||
SAT-528 | Terlipressin has acute effects on systemic inflammation markers in patients with cirrhosis and ascites | Nikolaj Torp | ![]() |
![]() |
|||
THU-529 | The GALAD score allows early detection of recurrent hepatocellular carcinoma after orthotopic liver transplantation | Magdalena Hahn | ![]() |
![]() |
|||
FRI-529 | Barriers for regular exercise in people with non-alcoholic fatty liver disease | Kedar Deshpande | ![]() |
![]() |
|||
WED-529 | Exploring transcriptome profiles to combat non-alcoholic fatty liver disease | Eva Kocar | ![]() |
![]() |
|||
FRI-530 | A randomized controlled trial of kalmegh supplementation on non-alcoholic fatty liver disease | Sanket Nandekar | ![]() |
![]() |
|||
SAT-530 | Individualized portal pressure gradient threshold based on liver function categories in preventing rebleeding after TIPS | Guangchuan Wang | ![]() |
![]() |
|||
THU-530 | Post reperfusion syndrome in liver transplant after normothermic perfusion: reference center experience | Luciano Beltrăo Pereira | ![]() |
![]() |
|||
WED-530 | Effects of HSD17B13-targeting siRNA - R0737072 on Liver Fibrosis and Steatosis in a mouse model of NASH | Shu Quan Zheng | ![]() |
![]() |
|||
SAT-531 | Elevated serum inflammatory markers predict acute-on-chronic liver failure following transjugular intrahepatic portosystemic shunt implantation | Lukas Sturm | ![]() |
![]() |
|||
WED-531 | Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease | Eileen Yoon | ![]() |
![]() |
|||
THU-531 | Comorbidities and complications of patients hospitalized for liver transplantation evaluation, transplant and post-LT: a fourteen-year nationwide study in Germany | Wenyi Gu | ![]() |
![]() |
|||
SAT-532 | Refractory hepatic hydrothorax is associated with Increased mortality compared to cirrhosis and refractory ascites | Binu John | ![]() |
![]() |
|||
THU-532 | Long-term benefit of mTOR inhibitors for dropping calcineurin inhibitors in liver transplant recipients | Yael Milgrom | ![]() |
![]() |
|||
WED-532 | Unravelling an autophagy-dependent role of vitamin D in preserving gut integrity in experimental NASH | Andrew Hakeem | ![]() |
![]() |
|||
FRI-533 | Incidence, risk factors and outcomes of acute kidney disease in cirrhosis patients with sepsis-related acute kidney injury | MD DM | ![]() |
![]() |
|||
THU-533 | Sarcopenia at listing for liver transplantation is a negative predictor for post-transplant survival, but not for graft survival | Guido Stirnimann | ![]() |
![]() |
|||
WED-533 | Selective modulation of mitochondrial complex I ameliorates steatosis and hepatic inflammation in MCD-diet fed rats | Laura Giuseppina Di Pasqua | ![]() |
![]() |
|||
SAT-533 | Validation of Baveno-VII criteria regarding non-invasive diagnosis of clinically significant portal hypertension | BYEONGGEUN SONG | ![]() |
![]() |
|||
THU-534 | Safety of coronary angiography and stent placement in patients with cirrhosis as part of an evaluation for liver transplantation. | Jassin Rashidi-Alavijeh | ![]() |
![]() |
|||
SAT-534 | Pressure response to TIPS does not depend on stent diameter | Michael Schultheiss | ![]() |
![]() |
|||
WED-534 | Inhibition of NLRP3 inflammasome activation by MK571, a multidrug resistance-associated protein (MRP) inhibitor | Oh Seungseok | ![]() |
![]() |
|||
FRI-534 | Machine learning model is superior to CLIF-C ACLF score for predicting ICU mortality in patients with ACLF | Maike Pollmanns | ![]() |
![]() |
|||
FRI-535 | Albumin use in acute-on-chronic liver failure in a large national cohort | Nadim Mahmud | ![]() |
![]() |
|||
WED-535 | A formulation of palmitoylethanolamide and phenolic compounds improves NAFLD-associated hepatic lipid dysmetabolism and oxidative stress in obese mice | Stefania Melini | ![]() |
![]() |
|||
THU-535 | Incidence of de novo tumors after liver transplantation (LT) in HIV infected is similar to non-HIV patients: a single center comparative study | Isabel Terol Cháfer | ![]() |
![]() |
|||
SAT-535 | Single-centre experience of spleen stiffness measurement across the spectrum of chronic liver disease | Jacinta Holmes | ![]() |
![]() |
|||
FRI-536 | Microbial cell-free DNA next-generation sequencing of ascites in acutely decompensated cirrhosis patients: a proof-of-concept study | Beiling Li | ![]() |
![]() |
|||
WED-536 | Mice lacking the NO receptor develop primary sclerosing cholangitis | Muhammad Ashfaq Khan | ![]() |
![]() |
|||
THU-536 | Biliary strictures in liver transplant recipients: novel strategies for identifying therapeutic targets of biliary fibrosis. | Alex Bofill | ![]() |
![]() |
|||
SAT-536 | Adverse outcomes following transjugular intrahepatic portosystemic shunt placement in relation to the underlying cause of portal hypertension | Sarwa Darwish Murad | ![]() |
![]() |
|||
FRI-537 | Performances of the CLIF-consortium acute-on-chronic liver failure (ACLF) score are sex specific | Sophie-Caroline Sacleux | ![]() |
![]() |
|||
SAT-537 | Validation of a discrete event simulation model evaluating the cost-effectiveness of long-term albumin administration in real-world UK patients with recurrent ascites | Kris Bennett | ![]() |
![]() |
|||
THU-537 | Coronary computed tomography angiography in pre-liver transplant cardiac work-up | Chiara Manuli | ![]() |
![]() |
|||
WED-537 | Empagliflozin improves non-alcoholic fatty liver disease in a new translational mice model even without impact on weight loss | Katharina Hupa-Breier | ![]() |
![]() |
|||
FRI-538 | The risk factors for poor prognosis according to the clinical course after first acute decompensation in cirrhotic patients | Sung-Eun Kim | ![]() |
![]() |
|||
THU-538 | Safety and efficacy of glucagon-like peptide-1 receptor agonists and sodium- glucose co-transporter-2 inhibitors compared with the standard of care in a cohort of liver transplanted patients: a retrospective study | Aida Rebiha | ![]() |
![]() |
|||
WED-538 | The effects of lipopolysaccharides on inducing nonalcoholic fatty liver disease in human precision-cut liver slices | Mei Li | ![]() |
![]() |
|||
SAT-538 | Application of updated diagnostic criteria for cirrhotic cardiomyopathy: evaluation of its clinical impact in liver transplantation candidates | Sarah Raevens | ![]() |
![]() |
|||
THU-539 | Influence of marginal organs on the drug metabolism in liver transplantation | Laura Bütow | ![]() |
![]() |
|||
WED-539 | Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction | Katja Csarmann | ![]() |
![]() |
|||
FRI-539 | Prediction of sepsis in patient of acute on chronic liver failure (ACLF) - a machine learning approach | Ashok Choudhury | ![]() |
![]() |
|||
SAT-539 | Baveno VII algorithm can avoid endoscopic surveillance in patients with cirrhosis | Haiyu Wang | ![]() |
![]() |
|||
SAT-540 | Symptoms from refractory ascites: contributions from both abdominal pressure and the patient | Nikhilesh Mazumder | ![]() |
![]() |
|||
WED-540 | MicroRNA as novel biomarker for disease severity evaluation and therapeutic target in NAFLD | Yoonseok Lee | ![]() |
![]() |
|||
THU-540 | A multi-center, stratification-randomized, double-blind, placebo-controlled, phase III clinical trial of topical recombinant human thrombin for intraoperative hemostasis | Jun Yu | ![]() |
![]() |
|||
FRI-540 | Predictors of clinical courses in patients wih acutely decompensated cirrhosis. An external validation of the PREDICT study | Enrico Pompili | ![]() |
![]() |
|||
FRI-541 | Increased serum IL-6 and IL-8 are associated with echocardiographic signs of diastolic dysfunction in patients admitted for acutely decompensated cirrhosis | Victor Dragan | ![]() |
![]() |
|||
SAT-541 | A retrospective evaluation of the effectiveness and safety of palliative long-term abdominal drains for the management of refractory ascites in patients with end-stage liver disease, in comparison with large volume paracentesis | Rodrigo Motta | ![]() |
![]() |
|||
WED-542 | A N-acylethanolamines mixture counteracts hepatic dysmetabolism induced in high-fat diet-fed obese mice | Claudio Pirozzi | ![]() |
![]() |
|||
SAT-542 | Coagulation profile in adult patients with porto-sinusoidal vascular disease | Sidharth Harindranath | ![]() |
![]() |
|||
FRI-542 | Different risk factors of clinical outcomes between variceal bleeding and non-variceal gastrointestinal bleeding in acutely decompensated cirrhosis | Sung-Eun Kim | ![]() |
![]() |
|||
SAT-543 | Continuous terlipressin infusion improves muscle function but not muscle mass in patients with cirrhosis and portal hypertension | Ryma Terbah | ![]() |
![]() |
|||
FRI-543 | Trajectory of outcome from acute-on-chronic liver failure is determined beyond 48 hours of admission to intensive care | Thomas Dixon | ![]() |
![]() |
|||
WED-543 | Preclinical efficacy and clinical translatability of resmetirom and semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH | Michael Feigh | ![]() |
![]() |
|||
WED-544 | Loss of gut barrier integrity in nonalcoholic fatty liver disease is associated with severe vibriosis | Punnag Saha | ![]() |
![]() |
|||
SAT-544 | Predicting the efficacy of splenic embolization on refractory ascites using a computational model of portal hypertension | Nikhilesh Mazumder | ![]() |
![]() |
|||
FRI-545 | Impaired pituitary-thyroid signaling and low free triiodothyronine indicate increased risk for ACLF and mortality in cirrhosis | Lukas Hartl | ![]() |
![]() |
|||
WED-545 | A guinea pig model of pediatric NASH | Kamilla Pedersen | ![]() |
![]() |
|||
SAT-545 | Administration of Lactulose, Rifaximin, or combination therapy for hepatic encephalopathy is associated with a reduction in gastrointestinal cancers | Ankoor Patel | ![]() |
![]() |
|||
THU-545 | Liver transplantation as treatment option for cholangiocellular carcinoma | Gabriela Berlakovich | ![]() |
![]() |
|||
FRI-546 | Nosocomial infections in cirrhosis are unpredictable and vary based on region of the world: CLEARED study | Jasmohan S Bajaj | ![]() |
![]() |
|||
SAT-546 | Use and impact of transjugular intrahepatic portosystemic shunt: a twelve-year nationwide study in Germany | Wenyi Gu | ![]() |
![]() |
|||
WED-546 | Pemafibrate abrogates lipid liver accretion in a dietary model of fatty liver in rat | Roger Bentanachs | ![]() |
![]() |
|||
THU-546 | PREVALENCE STUDY IN LIVER TRANSPLANT IN PATIENTS WITH SQUISTOSOMIASIS MANSONI IN A THIRD LEVEL REFERENCE HOSPITAL IN SAO PAULO, BRAZIL | martina zannini | ![]() |
![]() |
|||
FRI-547 | Metabolic biomarkers significantly enhance the prediction of HBV-related acute-on-chronic liver failure prognosis | Yan Zhang | ![]() |
![]() |
|||
WED-547 | The overexpression of TM6SF2 and/or MBOAT7 wild-type genes restores the mitochondrial lifecycle and activity in an in vitro NAFLD model | erika paolini | ![]() |
![]() |
|||
SAT-547 | Spontaneous portosystemic shunts (SPSS) regress after transjugular intrahepatic portosystemic shunt (TIPS) implantation | Theresa Bucsics | ![]() |
![]() |
|||
WED-548 | Development of a 2D nonalcohol-related steatohepatitis (NASH) model | Esther Arnaiz Gonzalez | ![]() |
![]() |
|||
SAT-548 | Predicting post-TIPSS mortality: external validation of the FIPS score in a Canadian cohort | Shamir Malik | ![]() |
![]() |
|||
FRI-548 | Combination of CLIF-C ACLF and ammonia levels as a predictor of in-hospital outcomes in patients with acute-on-chronic liver failure | Sagnik Biswas | ![]() |
![]() |
|||
FRI-549 | Soluble urokinase plasminogen activator receptor is a biomarker for outcome in decompensated liver cirrhosis and acute-on-chronic liver failure | Sven Lamatsch | ![]() |
![]() |
|||
SAT-549 | Clinical practice results of the use of intrahepatic portosystemic shunt for the treatment of refractory hepatic hydrothorax | Elena Tenorio González | ![]() |
![]() |
|||
WED-549 | Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease | Grazia Pennisi | ![]() |
![]() |
|||
SAT-550 | Detection of minimal hepatic encephalopathy: standardization of psychometric hepatic encephalopathy scale for Israeli population | Helena Katchman | ![]() |
![]() |
|||
THU-550 | Differential risk of 23 specific incident cancers and cancer-related mortality in patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects | Su Jong Yu | ![]() |
![]() |
|||
WED-550 | Obeticholic acid administration increases hepatic eNOS levels counteracting lipid accumulation and fibrosis in a diet-induced ob/ob mouse model of NASH | Laura Giuseppina Di Pasqua | ![]() |
![]() |
|||
FRI-550 | ACLF course profiles over screening period in the phase IIb DHELIVER study | Noelia Gordillo | ![]() |
![]() |
|||
FRI-551 | Lower free and total serum cortisol levels are associated with higher risk of bacterial infection and acute-on-chronic liver failure in stable outpatients with advanced chronic liver disease | Lukas Hartl | ![]() |
![]() |
|||
THU-551 | The rising burden of non-alcoholic fatty liver disease (NAFLD) related HCC: is time running out to contain this silent epidemic? | Saima Ajaz | ![]() |
![]() |
|||
WED-551 | Cholesterol-free ketogenic diet feeding improves experimental non-alcoholic fatty liver disease (NAFLD) | Alessia Provera | ![]() |
![]() |
|||
SAT-551 | Impact of non-selective beta-blockers on hepatic decompensation and survival after transjugular intrahepatic portosystemic shunt insertion | Anja Tiede | ![]() |
![]() |
|||
THU-552 | Comparison of nonalcoholic steatohepatitis severity between Hispanics and non-Hispanics: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium) | Julie Dubourg | ![]() |
![]() |
|||
WED-552 | Metabolic effects of n-3 fatty acids administered as Calanus oil to transgenic mice lacking functional peroxisome proliferator-activated receptor alpha | Martin Rossmeisl | ![]() |
![]() |
|||
FRI-552 | Acute on chronic liver failure is associated with prolonged clot initiation in rotational thromboelastometry as compared to acute decompensation, but clot formation time and firmness are similar | Tian Yu Qiu | ![]() |
![]() |
|||
SAT-552 | Audit assessing real-world incidence of adverse events and mortality rate in patients receiving Terlipressin for hepatorenal syndrome at Royal free hospital | Naz Kanani Alviri | ![]() |
![]() |
|||
SAT-553 | Collagen-proportionate area determined by semiautomated histomorphometry correlates with HVPG across different liver disease etiologies | Thomas Sorz | ![]() |
![]() |
|||
FRI-553 | Even small amounts of alcohol consumption can worsen the prognosis in acutely decompensated patients with viral hepatitis | Jung Hee Kim | ![]() |
![]() |
|||
THU-553 | Study of an association of the serum iron markers, hepatic iron deposition and severity of nonalcoholic fatty liver disease: a single-centered prospective study | Shubham Jain | ![]() |
![]() |
|||
WED-553 | Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice | José Inia | ![]() |
![]() |
|||
THU-554 | The importance of regular screening for HCC in non-alcoholic steatohepatitis/ non-alcoholic fatty liver disease | Taisei Keitoku | ![]() |
![]() |
|||
WED-554 | The road to a fatty liver-on-chip system to study metabolic syndrome associated fatty liver disease | Victoria Palasantzas | ![]() |
![]() |
|||
SAT-554 | Impact of new ESC/ERS diagnostic criteria for pulmonary hypertension in cirrhotic patients with portal hypertension on the frequency of portopulmonary hypertension | Hiroki Ono | ![]() |
![]() |
|||
FRI-554 | High histamine levels associate with acute-on-chronic liver failure and liver-related death in patients with advanced chronic liver disease | Michael Schwarz | ![]() |
![]() |
|||
WED-555 | Improvement of NAFLD by Totum-448: effects in the liver, adipose tissue and gut in western-diet fed hamsters | Vivien Chavanelle | ![]() |
![]() |
|||
THU-555 | Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy | Wah Loong Chan | ![]() |
![]() |
|||
FRI-555 | Detection of 1,3-beta-D-glucan increases with the severity of decompensation stages in liver cirrhosis and is associated with lower survival in patients with acute on chronic liver failure | Adam Herber | ![]() |
![]() |
|||
SAT-555 | Correlation of lymphangiogenesis and inflammation in patients with ACLD | Florian Offensperger | ![]() |
![]() |
|||
SAT-556 | Current prognosis of gastric variceal bleeding in France: preliminary results from a multicenter prospective cohort of 102 cirrhotic patients | Delphine Weil-Verhoeven | ![]() |
![]() |
|||
FRI-556 | Parvovirus B19 infection associated with adverse outcomes in decompensated cirrhosis patients | Changze Hong | ![]() |
![]() |
|||
THU-556 | Serum vitamin D is strongly associated with liver steatosis but not with liver and spleen stiffness assessed by transient elastography in patients at risk | Gediz Dogay Us | ![]() |
![]() |
|||
FRI-557 | Real-world evidence of reversibility in patients with acute-on-chronic liver failure that survive hospitalization | Alexandra Phillips | ![]() |
![]() |
|||
THU-557 | Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease | FLORIANA SANTOMENNA | ![]() |
![]() |
|||
SAT-557 | MELD 3.0 score in prediction of varices and comparison with its previous versions in patients undergoing esophago-gastro-duodenoscopy for variceal screening or band ligation | Faiza Sadaqat Ali | ![]() |
![]() |
|||
SAT-558 | Study the effect of serum YKL-40 as a risk of variceal bleeding in Egyptian cirrhotic patients | Prof.Abdelfattah Hanno | ![]() |
![]() |
|||
THU-558 | Impact of visceral adiposity for coronary artery calcification progression in patients with metabolic dysfunction-associated fatty liver disease; multicenter cohort study | Jung Gil Park | ![]() |
![]() |
|||
FRI-559 | Plasma thrombomodulin as a candidate biomarker for the diagnosis and prognosis of HBV-related acute-on-chronic liver failure | Jun Li | ![]() |
![]() |
|||
SAT-559 | Progression of portal hypertension in PBC: doppler ultrasound velocity as a non-invasive assessment | Aiymkul Ashimkhanova | ![]() |
![]() |
|||
SAT-560 | Clinical features and analysis of serum BMP9 levels in patients with portal pulmonary hypertension | Ruihua Zhang | ![]() |
![]() |
|||
FRI-560 | Frequency of ACLF and predictors of in-hospital mortality in cirrhotic patients in a tertiary care hospital of Pakistan | Sulhera Khan | ![]() |
![]() |
21-24 June Vienna
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|